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1. Summary 
 
Nuclear factor kappa B (NF-κB) had been suggested to play important roles in 
inflammatory and neurodegenerative disorders as well as carcinogenesis. NF-κB 
encompasses a family of inducible and widely expressed transcription factors which 
played a crucial role in the regulation of genes involved in immune and inflammatory 
responses. Over 500 target genes depending on NF-κB had been identified so far. 
PARP-1, an abundant nuclear chromatin associated protein belongs to a large 
family of enzymes that catalyze the transfer of ADP-ribose units from its substrate β-
nicotinamide adenine dinucleotide covalently to itself and other chromatin associated 
proteins. PARP-1 deficient mice were protected against experimentally induced 
septic shock, diabetes type I and Parkinsonism. This phenotype indicated that PARP-
1 is important for the pathogenesis of these events. Indeed, PARP-1 was shown to 
be an important coactivator of NF-κB. Interestingly, recent studies had shown that the 
cleavage of PARP-1 by caspases could be important for the activity of PARP-1 in 
NF-κB-dependent disease processes.  
In addition to PARP-1, many other coactivators such as the coactivator-
associated arginine methyltransferase-1 (CARM-1) are also required for NF-κB-
dependent gene expression. 
Aim of this thesis was to investigate NF-κB-dependent gene expression in regard 
to their PARP-1 or CARM-1 dependency and furthermore to the caspase-mediated 
cleavage of PARP-1. For this purpose, gene expression levels of wild-type mouse 
lung fibroblasts, mouse embryonic fibroblasts and Raw264 cells were compared with 
the corresponding knock-out or knock-in cells upon stimulation. From over 500 target 
genes of NF-κB, 16 selected genes were analyzed. The results indicated that only a 
subset of the target genes were activated by the certain investigated coactivators. 
Moreover, PARP inhibitors did not influence NF-κB-dependent gene expression 
under the tested conditions. On the other hand, a small subset of NF-κB-dependent 
genes seemed to be regulated by caspase activities, potentially through the cleavage 
of PARP-1.   
Together these results provide strong evidence for a crucial role of PARP-1 and 
CARM-1 in NF-κB gene expression. 
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1. Zusammenfassung 
 
Der Nukleare Faktor kappa B (NF-κB) spielt eine zentrale Rolle in vielen 
Entzündungs- und Nerven-zerstörenden Krankheiten, aber auch in der Entstehung 
von Krebs. NF-κB gehört zu einer Familie von induzierbaren Transkriptionsfaktoren, 
welche hauptverantwortlich sind für die Regulation von Genen, die in der 
Immunabwehr und in Entzündungsprozessen eine wichtige Rolle spielen. Mehr als 
500 verschiedene NF-κB abhängige Gene konnten bis jetzt identifiziert werden.  
PARP-1 ist ein Chromatin-assoziiertes Protein, welches in hohen Mengen im 
Zellkern vorkommt und zu einer grossen Familie von Enzymen gehört, welche ADP-
Ribose Einheiten von NAD als Substrat auf sich selber oder andere Chromatin-
assoziierte Proteine übertragen. PARP-1 Knockout-Mäuse zeigen eine 
ausgesprochen hohe Resistenz gegenüber experimentell induziertem Septischem 
Schock, Diabetes Typ 1 und Parkinson Krankheit. Dieser Phänotyp ist ein klares 
Indiz dafür, dass PARP-1 in die Pathogenese dieser Prozesse involviert ist. In der 
Tat fungiert PARP-1 als wichtiger Koaktivator von NF-κB. Darüber hinaus wurde 
kürzlich in einer Studie gezeigt, dass die proteolytische Spaltung von PARP-1 durch 
Caspasen möglicherweise wichtig ist für die PARP-1 Aktivität in NF-κB abhängigen 
Krankheitsprozessen.  
Neben PARP-1 sind einige andere Koaktivatoren wie zum Beispiel die 
Koaktivator assoziierte Arginin Methyltransferase-1 (CARM-1) ebenfalls essentiell für 
die NF-κB abhängige transkriptionelle Aktivierung von Genen. 
Ziel dieser Studie war NF-κB abhängige Gene in Abhängigkeit von PARP-1 und 
CARM-1 zu identifizieren und darüber hinaus solche, die von der proteolytischen 
Spaltung von PARP-1 durch Caspasen abhängig sind. Zu diesem Zweck wurden die 
Expressionsstärken von Wildtyp Zellen (embryonale Mausfibroblasten, respektive 
Lungenfibroblasten und Raw264) mit den entsprechenden Knock-out oder Knock-in 
Zellen nach Stimulation verglichen. Es wurden 16 Gene von den über 500 von NF-κB 
abhängigen Genen untersucht. Die Resultate zeigten, dass immer nur ein Teil von 
den NF-κB abhängigen Genen durch die untersuchten Koaktivatoren aktiviert wird. 
Weiter konnte gezeigt werden, dass die Expression von NF-κB abhängigen Genen 
durch PARP Hemmer unter den getesteten Konditionen nicht beeinflusst wird. 
Andererseits scheinen einige Gene durch Caspase Aktivität, z.B. Spaltung von 
PARP-1, reguliert zu werden. 
All diese Resultate sprechen für einen starken Beweis, dass PARP-1 und CARM-
1 eine essentielle Rolle in NF-κB abhängiger transkriptioneller Aktivierung von Genen 
spielt. 
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2. Abbreviations 
 
-/- knock-out 
+/+ wild-type 
ADP adenosine diphosphate 
AGE advanced glycated end product 
ART (ADP-ribosyl) transferase 
ATP adenosine triphosphate 
Bcl-3 B-cell lymphoma protein/gene 3 
BER base excision repair 
BRCT BRCA1 carboxyl-terminal 
cAMP circular adenosine monophosphate 
CARM-1 Coactivator-associated arginine methyltransferase 
CBP CREB binding protein 
CREB cAMP response element binding protein 
cDNA circular deoxyribonucleic acid 
CIA Collagen-induced arthritis 
CIA genes constitutively and immediately accessible genes 
CNS central nervous system 
COX Cyclooxygenase 
DBD DNA binding domain 
DEPC diethyl pyrocarbonate 
DEVD214 Caspase 3, and 7 recognition/cleavage motif 
DNA deoxyribonucleic acid 
EBV Epstein-Barr Virus 
eNOS Endothelial nitric oxide synthetase 
GAPDH glyceraldehydes-3-phosphate dehydrogenase 
Glut-2 Glucose transporter 2 
GM-CSF granulocyte macrophage colony stimulating factor 
GRIP-1 glucocorticoid receptor-interacting protein-1 
GRR glycine-rich region 
HIV human immunodeficiency virus 
HPRT hypoxanthine ribosyltransferase 
HTH helix-turn-helix domain 
ICAM-1 intercellular adhesion molecule-1 
IFN Interferon 
IgG immunoglobulin G 
IKK IκB kinase 
iNOS inducible nitrite oxide synthetase 
IP-10 interferon-inducible protein-10 or immune protein-10 
IRAK IL-1 receptor-associated kinase 
IκB Inhibitor of nuclear factor kappa B 
KC keratinocyte derived chemokine 
kDa kilo Dalton 
KI/KI knock-in 
LPS Lipopolysaccharide 
LZ leucine zipper 
MAPKK Mitogen activated kinase kinase 
MCP-1 monocyte chemoattractant protein-1 
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MEF mouse embryonic fibroblast 
Mg Magnesium 
MgCl2 Magnesium chloride 
MHC major histocompatibility complex 
MIP macrophage inflammatory protein  
MLF mouse lung fibroblast 
MOF Multiple organ failure 
mRNA messenger ribonucleic acid 
NF-κB  nuclear factor kappa B 
NAD nicotinamide adenine dinucleotide 
NEO gene neomycin resistance gene 
NIK NF-κB-inducing kinase 
NK-cell Natural killer cell 
NLS nuclear localization signal 
nNOS neuronal nitric oxide synthetase 
NO nitrite oxide 
NSAID non-steroidal anti-inflammatory drug 
PAF platelet activating factor 
PARP poly(ADP-ribose) polymerase 
PCR polymerase chain reaction 
PDGF Platelet derived growth factor 
PF platelet factor 
PGN Peptidoglycan 
PJ-34 N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-
dimethylacetamide 
PKA protein kinase A 
PMA phorbol myristate acid 
PMN polymorphonuclear neutrophil 
RANTES regulated upon activation, normal T-cell expressed, 
and presumably secreted 
ReI reticuloendotheliosis linked 
RHD ReI homology domain 
RIP receptor-interacting protein 
RT reverse transcription 
RT-PCR reverse transcription-PCR 
Ser Serine 
SZT Streptozotocin 
TAK TGF-associated kinase 
TANK Tankyrase 
T-BP tumor necrosis factor binding protein 
TGF transforming growth factor 
TIR Toll-IL-1 receptor 
TLR Toll-like receptor 
TNF tumor necrosis factor 
TRADD TNF receptor-associated death domain 
TRAF TNE receptor-associated factor 
TRF1 telomer regulatory factor 
ZF zinc finger 
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3. Introduction 
 
3.1. Transcriptional factor nuclear factor kappa B (NF-κB) 
 
Nuclear factor kappa B (NF-κB) is a widely expressed, inducible 
transcription factor of particular importance to cells of the immune system 
[reviewed in ref. 1]. The active NF-κB transcription factor promoted the 
expression of over 500 target genes [2]. It played a crucial role in the 
regulation of gene expression of many genes involved in mammalian immune 
and inflammatory responses, including cytokines, cell adhesion molecules, 
complement factors, and a variety of immune receptors [reviewed in ref. 3]. 
NF-κB also mediated the transcriptional activation of anti-apoptotic genes and 
was therefore essential for the survival of cells under certain conditions [4]. 
Moreover, it was active in tumor cells and required for rapid growth of these 
cells [5]. In addition, some viruses were shown to hijack the NF-κB 
signaling/transcriptional system for the activation of their own genes [6] or 
even influence the expression of host genes by manipulation of the NF-κB 
activity [7-9]. 
Abnormalities in the regulation of NF-κB activity were tightly linked to the 
pathogenesis of inflammatory disorders including septic shock, radiation 
damage, myocardial infarction, acute-phase reactions, and diabetes, as well 
as chronic inflammatory diseases such as asthma, rheumatoid arthritis, and 
inflammatory bowel disease [4].  
 
3.1.1. Family of NF-κB/ReI- and IκB-proteins 
 
3.1.1.1. NF-κB/ReI-proteins 
NF-κB is expressed in most cell types. The ReI family members include 
p65 (ReIA), ReIB, c-ReI, p50/p105 (NF-κB1), and p52/p100 (NF-κB2), which 
form homo- and heterodimers (see Figure 1).  
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Figure 1. Members of the mammalian ReI/NF-κB and IκB protein family: The number of 
amino acids in each protein was shown on the right. The arrows point to the endoproteolytic 
cleavage sites of p52/p100 and p50/p105. RHD, ReI homology domain; N, nuclear 
localization signal; P, PKA phosphorylation motif; TD, transactivation domain; LZ, leucine-
zipper domain of ReI B; G, glycine-rich region; ANK, ankyrin repeats [modified 1]. 
 
The prototypical and most studied form, NF-κB, is the ‘classical’ 
heterodimer consisting of the two subunits p50 (NF-κB1) and p65 (ReIA) [10]. 
When these two subunits are coexpressed at comparable levels in the cell, 
they are preferentially forming the ‘classical’ NF-κB p65/p50 heterodimer, 
generally considered to be the predominant, inducible form of NF-κB in most 
cells [reviewed in ref. 1]. This heterodimer had a high affinity for the 
consensus NF-κB DNA sequence 5’-GGGRNNYYCC-3’ (where R was purine 
and Y was pyrimidine).  
All proteins of the ReI family shares a conserved 300-amino acid region 
within their amino termini, termed the ReI homology domain (RHD) [11]. The 
 8 
RHD is responsible for dimerization, DNA-binding, translocation to the 
nucleus and interactions with heterologous transcription factors. 
The active DNA-binding form of NF-κB is a dimer. Almost all combinations 
of ReI/NF-κB homo- or heterodimers had been identified in many different cell 
types [1]. One exception is ReIB, which only forms heterodimers with p50 or 
p52 [12, 13]. Not all dimers of ReI/NF-κB proteins are transcriptionally active, 
and the members of this family are divided into two groups based on their 
transactivation potential. The first group, including ReIA, c-ReI and ReIB 
contains a strong transactivation domain within the C-terminal sequence [12, 
14-18]. In addition to its C-terminal transactivation domain, ReIB also contains 
an N-terminal leucine zipper-like transactivation domain. Both N- and C-
terminal domains of RelB were required for full transcriptional activity [19]. In 
contrast, the second group composing of p50 and p52, does not contain any 
transactivation domains, and thus, generally does not act as transcriptional 
activators. Indeed, homo- or heterodimers of p50 and p52 could repress NF-
κB-dependent transcription [15, 20-23]. The mechanism by which p50 or p52 
homodimers inhibit transcription is not completely understood. One interesting 
property of p50 and p52 homodimers is their ability to specifically associate 
with the protooncoprotein Bcl-3, a member of the IκB family, through the 
interactions between the RHD of p50 or p52 and the ankyrin repeats of Bcl-3 
[24-29]. This protor complex was shown to either activate or repress NF-κB-
dependent transcription.  
In contrast to the other ReI/NF-κB members, p50 and p52 are synthesized 
as precursor molecules of 105kDa (p105) and 100kDa (p100), respectively 
[30]. The N-terminal regions of p105 and p100 constitute the RHD of p50 and 
p52. Directly adjacent to the RHD is a glycine-rich region (GRR) followed by 
the IκB homologous C terminus [31]. The C-terminal sequences of p105 and 
p100 contain multiple copies of the ankyrin repeat motifs, which were also 
described in all IκB family members. Indeed, p105 and p100 could both inhibit 
upon dimerization the nuclear localization and transcriptional activity of 
ReI/NF-κB proteins. Generation of p50 and p52 from p105 and p100 occurs 
by a proteolytical processing mechanism [32].  
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3.1.1.2. Structure of NF-κB  
The geometry of NF-κB dimers, when bound to DNA, resembles that of a 
butterfly with the cylinder of DNA trapped within its wings (see Figure 2) [1]. 
 
 
 
Figure 2. The structure of the heterodimer bound on DNA. a, Ribbon drawing of the entire 
complex, viewed down the DNA helical axis. The p50 subunit is in green and the p65 subunit 
is in red. The top strand of DNA is in pind, and the bottom strand is in yellow. b, The 
hydrophobic core of the dimer interface between p50 (green) and p65 (red) consists of an 
array of nonpolar hydrocarbons, aromatic rings and uncharged polar residues pointing from 
the β-sheets in towards the interface [33]. 
 
The RHD consists of two domains of anti-parallel β-sheets packed into a 
sandwich structure that resembles the structure of the immunoglobulin [34]. 
Dimerization of two ReI/NF-κB molecules is mediated by an extensive 
hydrophobic surface formed between two β-sheets of the C-terminal globular 
domain in the RHD [35, 36]. The interaction of such a complex with DNA 
involves 10 loops of α-strands at the N-terminal domain of the RHD. This 
extensive contact with DNA explains the high affinity for DNA observed for the 
different NF-κB members. Although loops from both the N- and C-terminal 
sequences of the RHD contact DNA, the majority of the contacts are confined 
to the N-terminal sequences. The advantage of using loops to contact DNA 
might lies in the inherent flexibility of the loops, which could allow NF-κB to 
interact with a greater variety of DNA sequences [30]. A further component of 
the RHD of all ReI/NF-κB proteins is a short stretch of basic amino acids that 
forms the nuclear localization signal. The NLS is located close to the C-
terminal end of the RHD and mutational analysis confirmed the importance of 
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this region for the transport of ReI/NF-κB complexes from the cytoplasm to the 
nucleus [1]. 
 
3.1.2. IκB-proteins 
 
In unstimulated cells, NF-κB is sequestered in the cytoplasm as an 
inactive transcription factor complex by its physical association with one of the 
several inhibitors of NF-κB (IκBs). These proteins also comprise a structurally 
and functionally related family of molecules, which include IκBα (37kDa), IκBβ 
(43kDa), IκBγ, IκBε, p105/p50 (C terminus), p100/p52 (C terminus), IκB-R, 
and Bcl-3 [reviewed in refs. 37, 38]. 
All known IκB proteins contain multiple copies of a 30-33 amino acid 
sequence originally discovered in the SW16 protein of Saccharomyces 
cerevisiae and named SW16/ankyrin repeats. As described above, the p50 
and p52 precursor molecules p105 and p100 also contain ankyrin repeats in 
their C-terminal regions and are capable of inhibiting NF-κB activity [31]. All 
members of the IκB family express between three and seven ankyrin repeats.  
A number of studies reveled that separate IκB molecules preferentially 
inhibited distinct ReI/NF-κB protein dimers. For example, IκBα and IκBβ 
preferentially interacted with dimers containing p65 and had been shown to be 
the main functional modulators of the ‘classical’ NF-κB p65/p50 heterodimer 
[reviewed in refs. 37, 38]. Both IκBα and IκBβ did not only sequester NF-κB in 
the cytoplasm, but also inhibited the DNA binding activity of NF-κB [39]. 
Interestingly, the only IκB molecules, which could associate with ReIB are 
p100, p105, and the 46kDa C-terminal portion of p100 (tentatively named 
IκBε), which all could effectively inhibit p52/ReIB heterodimers [40]. The 
subunit composition of a given NF-κB complex therefore influences its 
subcellular localization, transactivation potential and mode of regulation. For 
example, the prototypical NF-κB complex, composed of p50/p65 
heterodimers, was primarily cytoplasmic. In contrary, homodimers of p50/NF-
κB1 were preferentially shown to be nuclear proteins [41].  
Inhibition of ReI/NF-κB proteins by IκB molecules occurs via protein-
protein interactions between the ankyrin repeats of IκB and regions of the 
RHD. With the exception of Bcl-3 and an unphosphorylated form of IκBβ, this 
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interaction enables the IκB proteins to mask the nuclear localization signal 
(NLS) and prevents nuclear translocation of ReI/NF-κB dimers. Although 
ankyrin repeats are crucial for IκB to bind to ReI complexes, not all ankyrin 
repeats are required, since mutation of the third ankyrin repeat of IκBα had no 
effect on its ability to inhibit NF-κB. In addition to the centrally located ankyrin 
repeats of IκB proteins, the N- and C-terminal domains of each IκB exhibit 
important structural and functional characteristics. Within their C-termini, most 
IκB proteins contain an acidic and Thr-rich sequence, which was thought to 
play a role in stabilization of the molecule and in the prevention of NF-κB 
DNA-binding activity. The N-terminal domain contains sites of serine 
phosphorylation and ubiquitination, which are important for signal-induced 
degradation, at least for IκBα and IκBβ [1] (see also section 3.1.4). Signals 
that induced NF-κB activity cause the dissociation and subsequent 
degradation of IκB proteins, allowing NF-κB dimers to enter the nucleus and 
induce gene expression.  
 
3.1.3. Activators and inhibitors of NF-κB-dependent gene expression 
 
In most cell types, nuclear NF-κB activity is induced by exposure to a wide 
variety of viruses, bacteria or bacterial products. It seems likely that a virus 
would gain a selective advantage from the acquisition of κB binding site in its 
promoter. Indeed, many viruses also harbor NF-κB binding sites in their viral 
promoters. If the transcription factor is induced either directly through viral 
infection or indirectly by the ensuing immune response, the κB sites-
containing viral promoter would be transactivated, resulting in enhanced viral 
transcription [3]. Gram-positive and gram-negative bacteria and their cell wall 
components activate the innate immune system of the host and induce 
secretion of proinflammatory molecules, mainly chemokines and cytokines. 
Chemokines are the main proinflammatory mediators induced in monocytes 
by bacteria through peptidoglycan (PGN) and lipopolysaccharide (LPS), the 
main cell wall components of gram-positive and gram-negative bacteria. 
Gram-positive bacteria, PGN and LPS activate pathways through pattern 
recognition receptors, which result in the activation of NF-κB [42]. The 
observations that distinct eukaryotic parasites (e.g. Theileria parva) could 
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activate NF-κB [43] are of great veterinary interest. NF-κB activity is also 
induced during various physiological stress conditions such as 
ischemia/reperfusion, liver regeneration and hemorrhagic shock [2]. Besides 
physiological stress situations, the human body is exposed to environmental 
hazards and therapeutic drugs, which could also exert a stress. Indeed, NF-
κB was reported to be activated both by environmental stresses, such as 
heavy metals or cigarette smoke, and by therapeutic drugs, including various 
chemotherapeutic agents [2].  
The NF-κB activity could also be negatively regulated by different 
cytokines, such as IL-4, IL-10, IL-11, IL-13, antioxidants, such as glutathione, 
vitamin E or thioredoxin, as well as anti-inflammatory drugs such as 
glucocorticoids, acetylsalicylic acid or cyclosporine A [44-51]. 
 
Bacteria Mycobacterium tuberculosis, Helicobacter pylori, Lactobacilli, 
Listeria monocytogenes, Salmonella dublin, Salmonella 
typhimurium, Staphylococcus aureus 
Bacterial products Exotoxin B, Lipopolysaccharide (LPS), Staphylococcus 
enterotoxin A and B, Toxic Shock Syndrome Toxin I 
Viruses Epstein-Barr Virus (EBV), Hepatitis B Virus, HIV-1, Herpes 
Simplex Virus-1, Influenza Virus, Newcastle disease virus, Bovine 
papillomavirus, Bovine leukemia, Cowpox virus, Adenovirus 
Eukaryotic parasite Theileria parva 
Cytokines IL-1, IL-2, IL-12, IL-15, IL-17, IL-18, TNF-α 
Physiological (stress) 
conditions 
Adhesion, Depolarization, Hemorrhage, Hyperglycemia, 
Hyperosmotic Shock, Hypoxia, Ischemia (transient, focal), Liver 
regeneration, Reoxygenation, T-cell Selection 
Physical stress Ultraviolet irradiation (UV-A, B, C), γ Radiation 
Oxidative stress Hydrogen Peroxide, Ozone, Reoxygenation 
Environmental hazards Chromium, Cigarette Smoke, Cobalt, Nickel, Silica Particles 
Therapeutic used drug Cisplatin, Phenobarbital 
Modified proteins Advanced glycated end products (AGEs) 
Overexpressed 
proteins 
Ig heavy chain, MHC Class I 
Mitogens, growth 
factors and hormones 
Follicle stimulating hormone, Insulin, M-CSF, Serum 
Physiological 
mediators 
Angiotensin II, Bradikinin, Collagen Type I, Hemoglobin, 
Leukotriene B4, PAF (platelet activating factor), Thrombin 
Chemical agents Phorbol ester 
 
Table 1. Partial list of NF-κB activators [3]. 
 
3.1.4. Signal cascade of NF-κB 
 
The pathways of how cytokines and pathogens activate NF-κB have been 
extensively investigated. Cytokine receptors and pathogen pattern recognition 
receptors, such as Toll-like receptors (TLRs) are single-pass, transmembrane 
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receptors lacking intrinsic kinase activity. Upon binding of the corresponding 
ligands, the receptors form dimeric, trimeric or tetrameric structures, resulting 
in intracellular aggregation of the cytoplasmic signaling domains. This results 
in the recruitment and activation of a submembranous IκB-kinase (IKK) 
signalosom. The cytosolic multiprotein IκB-kinase complex of 700 kDa is 
composed of catalytic basic helix-loop-helix-containing kinases, IKKα, IKKβ 
and a regulatory subunit, IKKγ, required for coupling IKK to upstream 
activating kinases [10]. In the IKK complex, the catalytic IKKβ subunit is 
largely thought to be responsible for site-specific serine phosphorylation of 
IκBα in its N-terminal regulatory domain, representing in the first rate limiting 
process of NF-κB activation. 
The composition of receptor and signalosome complexes varies and is 
dependent on the signaling pathway. For instance, in the case of IL-1, the 
signal adapters include MyD88, IL-1 receptor-associate kinase (IRAK), and 
the TNF-α receptor-associated factor 6 (TRAF6) [52]. TRAF6 was required for 
the coupling of activated IL-1 receptors to IKK. TRAF6 was also required to 
activate the downstream MAPKK kinases, TGFβ-associated kinase (TAK1) 
[52]. TAK1, in turn, phosphorylated the NF-κB-inducing kinase (NIK), resulting 
in IKKβ phosphorylation and IKK activation [52]. In the case of the TNF 
signaling, TNF receptor-associated death domain (TRADD), TRAF2, and 
receptor-interacting protein (RIP) constitute the submembranous signaling 
complex. The RIP kinase plays an indispensable role in IKK activation, as 
targeted disruption of RIP abolished NF-κB activation. RIP recruits the IKK 
signalosome to the TNF receptor I by binding IKKβ, thus directly recruiting the 
cytosolic IKK to the receptor. IKKα and IKKβ are subsequently 
phosphorylated, which results in the release of activated IKK complex back 
into the cytosolic fraction [52] (see Figure 3).  
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Figure 3. This diagram portrays the signal transduction pathway in simplified terms. 
Abbreviations: CD40L, CD40 ligand; IKKα/IKKβ, IκB-kinase α- and β-subunits; IL-1, 
interleukin-1, IL-1R, IL-1 type 1 receptor; IL-1βRAcP, IL-1 accessory protein; IRAK, IL-1 
receptor associated kinase; LPS, lipopolysaccharide; LT-βR, lymphotoxin β receptor; MEKK-
1, mitogen-activated protein kinase/extracellular signal-regulated kinase 1; NID, NF-κB-
inducing kinase; p90-RSK, p90-ribosomal S6 protein kinase; p, phosphate; PKAc, protein 
kinase A catalytic subunit; PKCζ, protein kinase Cζ; TNF, tumor necrosis factor; TNFR, TNF 
receptor; TRAF, TNFR-associated factor; UV, ultraviolet [53]. 
 
In most cases, extracellular and intracellular NF-κB activating signals 
converge on the multiprotein IKK complex, which phosphorylates IκBα on two 
serine residues (Ser in position 32 and 36). Phosphorylated-IκB dissociated 
from NF-κB and is specifically bound to a complex initiating IκB ubiquitination 
and proteolysis [10]. A very unusual pathway that induces IκB degradation 
through cytoplasmic calpains also has been identified during infection with 
certain viruses [41]. Following IκB proteolysis, liberates cytoplasmic NF-κB to 
rapidly enter the nucleus and to bind to specific response elements in the 
regulatory regions of its target promoters/enhancers. 
Promoter/enhancers-bound NF-κB activates transcription through the 
assembly of larger nucleoprotein complexes termed enhanceosomes. 
Transcriptional activation is the primary mechanism controlling gene 
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expression in response to tissue specific-, developmental- and hormonal-
induced cellular signaling [52]. Inducible transcriptional regulation is a 
multistep process involving the cooperative assembly of architectural, 
sequence-specific transcription factors, and coactivator/bridging factors on a 
target promoter/enhancer. Formation of the promoter assembly complexes 
/enhanceosomes also regulates in the recruitment and cooperative binding of 
chromatin-remodeling proteins [52]. The presence of chromatin-remodeling 
factors activates the preinitiation complex that, in turn, controls RNA 
polymerase II activity and subsequent gene expression. The phenomenon of 
binding cooperativity allowed highly inducible genes to be expressed in the 
setting of limiting concentrations of transcription factors [52]. 
Although the basic biochemistry of preinitiation complex formation and the 
mechanisms of how signaling molecules control transcription factors had been 
extensively investigated, the spectrum of genes controlled by specific 
signaling pathways within the context of complex biological stimuli remains to 
be explored systematically [52]. 
 
3.1.5. Coactivators of NF-κB 
 
Activator dependent upregulation of class II gene transcription in vivo, 
required a multiply of activities and physical interactions between chromatin 
remodeling factors, RNA-polymerase II (Pol II) and its associated general 
transcription factors (GTFs; TFIIA, B, D, E, F and H), mediator complexes, 
TATA binding protein (TBP) associated factors (TAFs), and other less 
characterized cofactor/coactivator complexes including the USA derived 
positive cofactor [reviewed in ref. 4]. 
Enhanceosome formation involves coactivator recruitment, proteins 
required for the control of core promoter activity at a distance. Coactivators do 
not bind DNA themselves but allowed transcription factors to interact with the 
basal transcriptional apparatus and induce chromatin remodeling [4, 54-56].  
A growing number of coactivators were described to be required for full 
NF-κB-dependent gene expression. The specific sets/combinations of 
coactivators used at a given gene promoter varies and is dependent on the 
cell type and stimulus. It was recently shown that poly(ADP-ribose) 
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polymerase 1 (PARP-1) acts as a coactivator of NF-κB in concert with the 
classical NF-κB coactivator p300/CBP [56]. PARP-1 could directly bind to both 
subunits of NF-κB, p50 and p65, by protein-protein interaction.  
Once in the nucleus NF-κB will activate genes dependent on the 
availability of coactivator sets in the cell. It is conceivable that not only the 
simultaneous activation of other transcription factors such as AP-1, ETS, 
C/EBPβ, STAT-1 and p53 might influence the spectrum of induced NF-κB-
dependent genes but also the availability of different coactivators and 
cofactors of NF-κB, thereby determining whether activation of NF-κB leads to 
cell survival, necrotic cell death or apoptosis [56]. Previous reports have 
shown that NF-κB-dependent transcriptional complexes do not only require 
the presence of the transcriptional coactivator p300 or its structural 
homologue, CBP, but also the p300/CBP-associated factor (P/CAF) and the 
p160 family of steroid receptor coactivators [4].  
It was thought that the critical role of p300/CBP and its associated 
coactivators is to promote the rapid formation of the pre-initiation and re-
initiation complexes which facilitate multiple rounds of transcription by 
modifying the amino-terminal tails of nucleosomal histones and bridging NF-
κB to the general transcriptional machinery. Since other sequence specific 
transcription factors also bind to p300/CBP and their associated coactivators 
and the expression levels and localization of these coactivators varies 
between different cell types, these coactivators are generally limiting in vivo. 
Additional components might be required to stabilize the association of 
distinct NF-κB coactivator complexes. Although the recruitment of p300 or 
CBP to NF-κB-dependent enhanceosomes was required for synergistic 
activation, tethering p300/CBP alone to the promoter through NF-κB might not 
to be sufficient for full activity of NF-κB in the context of chromatin. Several 
reports indicated that the combined actions and interactions of distinct 
transcriptional coactivator complexes and cofactors seemed to be attributable 
to the strong transcriptional activity of NF-κB, depending on the stimuli and 
the cell type [reviewed in ref. 4].  
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3.2. PARP-1 
 
PARP-1 plays an essential and central function in the activation of NF-κB-
dependent target genes during the inflammation processes in classical 
inflammatory diseases as well as cardiovascular and neurodegenerative 
disorders. Remarkably, the fact that PARP knockout (-/-) mice did not show 
any developmental defects, especially regarding the immune system, 
indicated that a multitude of NF-κB-dependent genes could be activated also 
in the absence of PARP-1 under normal physiological conditions [57]. 
Mammalian PARP-1, an abundant 114-kDa nuclear chromatin-associated 
protein, belongs to a large family of enzymes that catalyzes the transfer of 
ADP-ribose units from β-nicotinamide adenine dinucleotide (NAD+) onto 
glutamic acid residues of nuclear protein acceptors [4]. 
Activation of PARP-1 was proposed to be one of the earliest responses of 
mammalian cells to genotoxic stress [reviewed in refs. 58, 59]. The enzymatic 
activity of PARP-1 was strongly stimulated in the presence of nicks and 
double strand breaks in DNA [reviewed in ref. 60]. These observation had 
contributed to the idea that PARP-1 might act as a ‘molecular nick sensor’, 
thereby mediating stress-induced signaling in the presence of DNA lesions in 
an NAD+-dependent manner to downstream effectors involved in coordinating 
the cellular response to DNA damage [reviewed in refs. 60-63]. PARP-1 
recognizes and rapidly binds to DNA strand breaks through its zinc fingers. 
The catalytic domain of PARP-1 is allosterically activated and starts to 
synthesize complex branched poly(ADP-ribose) chains, resulting in 
automodifications of PARP-1 and probably extensive modification of histones 
at sites of DNA strand breaks. Modification of chromatin proteins and PARP-1 
itself might subsequently function as a strong signal that might rapidly recruit 
other DNA damage-signaling molecules [63]. Reported modified proteins 
included topoisomerase I and II, histones, p53, and high-mobility group 
proteins [64-66 and reviewed in ref. 67]. In intact organisms, PARP-1 itself is 
the predominant acceptor of poly(ADP-ribose) [reviewed in ref. 60]. Only a 
few of the proposed substrates of PARP-1, such as p53, topoisomerase I, and 
histone I, have been shown to directly interact with PARP-1 [68-70]. 
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It was suggested that PARP-1 plays a crucial role in DNA replication, DNA 
base excision repair (BER), V(D)J recombination and as regulation of 
telomere length [reviewed in refs. 60, 71]. Other functions proposed for 
PARP-1 include gene expression, chromatin organization, proliferation and 
differentiation, cellular NAD+ metabolism, and apoptosis [reviewed in refs. 71, 
72]. Additionally, PARP-1 was thought to serve also as a marker for apoptosis 
[73, 74]. However, the physiological function of PARP-1 is still under heavy 
debate. 
 
3.2.1. The PARP family  
 
In addition to the ‘classical’ 113-kDa PARP-1, more than 16 novel PARP 
like genes existed in mammalians. These new PARPs were structurally 
distinct from the PARP-1 and could be classified together with PARP-1 
according to their structures and sizes into at least 7 subgroups [4,75,76] (see 
Figure 4). The novel PARP family members seemed to be involved in specific 
functions requiring limited levels of poly(ADP-ribosyl)ation [77]. PARP 
members of class II and III beared the strongest resemblance to PARP-1 [75, 
76, 78, 79]. PARP-2 seems to play an important role in the response to DNA 
damage [78]. Interestingly, in contrast to PARP-1 and PARP-2, the PARP 
activities of these new members seemed not to be dependent on DNA strand 
breaks [80]. 
Tankyrase-1 and 2/3 (TANK-1 and -2), two mammalian proteins with 
PARP activity, were identified as components of the telomere complex [81-
83]. These two proteins of class III were proposed to regulate the length of 
telomeres by modulating the activity of TRF1, a negative regulator of telomere 
length [81-83]. Over-expression of TANK-2/3, in contrast to TANK-1, caused 
rapid necrotic cell death in the absence of DNA damage [82]. 
The functions of the other PARP family members of classes IV-VII are not 
yet known. 
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Figure 4. The structures of the PARP family members [76].  
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3.2.2. Structure of PARP-1 
 
PARP-1 is a highly conserved enzyme found in all multicellular lower and 
higher eukaryotes [60] and consists of three domains [reviewed in refs. 60, 
84]: 
• a DNA binding domain (DBD) containing a bipartite nuclear localization 
signal (NLS) which is interrupted by a caspase cleavage site 
• an automodification domain 
• a catalytic domain which is the most highly conserved region of the 
PARP molecule 
The DNA binding domain contains two zinc fingers (FI and FII) and two 
helix-turn-helix (HTH) motifs [85, 86] (see Figure 5).  
 
     DNA binding domain             Auto-modification                        Catalytic domain 
                                                          domain 
 
 
Figure 5. The structure of PARP-1; Abbreviations: ZF, zinc finger; NLS, nuclear localization 
signal; HTH, helix-turn-helix domain; LZ, leucine zipper; BRCT, BRCA-C-terminal domain; 
PRD, PARP regulatory domain [4]. 
 
These two zinc fingers are the main structures responsible for binding to 
double-strand breaks or single-strand breaks and for the activation of PARP-1 
enzyme activity [85, 86]. A moderate non-specific association of PARP-1 with 
non-damaged DNA had been proposed to depend most probably on the HTH 
motifs [87]. Moreover, the zinc fingers could also act as an interface with 
various protein partners [reviewed in ref. 71]. 
The automodification domain contains a leucine zipper (LZ) motif in the N-
terminal part and a BRCA1 carboxyl-terminal (BRCT) protein interaction 
domain in the C-terminal part [88]. The LZ and BRCT domains are involved in 
protein-protein interactions [89, 90]. The LZs might be responsible for 
homodimerization of PARP-1 [88, 91]. The automodification domain contains 
possible auto-poly(ADP-ribosyl)ation sites implicated in the negative 
regulation of interactions between PARP-1 and DNA [92-94]. 
The catalytic domain of PARP-1 was located in the C-terminal part of the 
enzyme. The N-terminal domain of the catalytic domain, which comprises the 
highly conserved PARP regulatory domain, consists five α-helices and one 
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310-helix [95]. The C-terminal domain of the catalytic domain shares several 
structural features with mono(ADP-ribosyl) transferases including an 
evolutionarily conserved region, called the ‘PARP signature’ [96]. 
PARP-1 was thought to be a special member of the (ADP-ribosyl) 
transferase (ARTase) superfamily since it was suggested to mono(ADP-
ribosyl)ate a protein, comparable to other ARTases, and subsequently to 
elongate this modification to polymers. 
The 15-kDa region between the automodification and the minimal catalytic 
domain has not yet been extensively characterized and its function is still 
unknown [61]. 
 
3.2.3. Localization of PARP-1 
 
The PARP-1 gene is constitutively expressed in testis, spleen, brain, 
thymus, intestine, colon, and nasal cavities [97, 98]. Very high levels of 
PARP-1 were found in lymphoid organs, especially thymus, in the germinal 
centers of the spleen, and in the Peyer’s patches in the ileum, while only very 
low levels of PARP-1 expression were found in organs such as liver, kidney, 
and heart [97-99]. In the central nervous system (CNS), PARP-1 was highly 
expressed in regions with a high neuronal cell density such as hypocampal 
neurons, granule cells of the dentate gyrus, Purkinje cells of the cerebrellar 
cortex, as well as microglia and astrocytes in several regions [99, 100]. For 
non-neuronal cell types, a direct correlation could be observed between cell 
proliferation and high expression levels of PARP-1. 
An increase in PARP-1 mRNA levels was observed during thymocyte 
proliferation and upon activation of lymphocytes and peripheral blood 
mononuclear cells [101, 102]. The tissue-, cell- and cell cycle-specific 
expression pattern of PARP-1 strongly suggests that PARP-1 is not only 
critical to major cellular functions but that its expression is also modulated 
through complex transcriptional regulation [4]. 
PARP-1 exclusively localizes to the nucleus, where it is not 
homogeneously distributed [103]. The exact localization in the nucleus is still 
under debate. It was shown that PARP-1 associates with nuclear matrix 
regions and localizes to centromers during metaphase [104], while other 
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studies indicated that PARP-1 is preferentially found in nucleoli and defined 
nuclear bodies [103, 105]. 
Treatment of cells with RNA synthesis inhibitors caused PARP-1 to 
become evenly distributed throughout the nucleus [105]. The association of 
PARP-1 with actively transcribed regions in the chromatin strongly implies a 
role for PARP-1 in transcription [4]. Surprisingly, treatment with DNA 
synthesis inhibitors did not change the distribution of PARP-1 in the nucleus 
[105]. 
 
3.2.4. Enzymatic activity of PARP-1 
 
Genetic approaches clearly showed that poly(ADP-ribosyl)ation was 
neither affecting the DNA binding activity of NF-κB nor required for NF-κB-
dependent gene expression [4, 56, 106,107]. This seemed on the first hand 
not to be compatible with reports describing an inhibitory effect (15 to 40%) of 
inhibitors of poly(ADP-ribose)polymerases and mono(ADP-ribosyl) 
transferases on the expression of inflammatory mediators in mice [108-114, 
and reviewed in refs. 4, 115]. However these observations might be explained 
in three ways: First, it was known that 3-AB and nicotinamide as well as novel 
types of PARP-inhibitors not only inhibit the enzyme activity of PARP-1 but 
also of other poly(ADP-ribose) polymerases such as PARP-2 or TANK-2 [4, 
82], or even mono(ADP-ribosyl) transferases [116-118], which were also 
described to play a crucial role in inflammatory response pathways [116-118]. 
Indeed, poly(ADP-ribose) formation was drastically reduced only in PARP-1    
-/- brain, pancreas, liver, small intestine, colon, and testis, whereas still 
moderate levels of residual poly(ADP-ribose) formation could be observed in 
PARP-1 -/- stomach, bladder, thymus, heart, lung, kidney and spleen [4, 115, 
119]. Secondly, based on recent reports, one could not exclude the possibility 
that the novel types of PARP-inhibitors might even inhibit non PARP-like 
targets such as Akt/PKB or MMP’s [4, 120]. Third, the enzymatic activity of 
PARP-1 might be required for transcriptional activity of other transcription 
factors involved in these inflammatory processes. Several groups had shown 
that co-operative activities between transcription factors such as AP-1, STAT-
1 or IRF-1 in the enhanceosomes of NF-κB-dependent genes including iNOS, 
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ICAM, COX and IFNβ and IFNγ, were required for full synergistic activation of 
these genes [121-124]. Indeed, in human endothelial cells, the PARP inhibitor 
3-AB reduced oxidant-induced binding activity of the transcription factor 
activator protein 1 (AP-1) to the promoter of ICAM-1 [125]. Finally, a very 
recent report indicated that PARP inhibitors, DHIQ and 3-AB, possess free 
radical scavenging properties [126]. Since inflammation or stroke were related 
to oxidative stress it is quite possible that PARP inhibitors with antioxidative 
potency contribute indirectly and non-specifically to decreased NF-κB-
dependent transcriptional activity by reducing free radicals. Together, it is 
rather unlikely that poly(ADP-ribosyl)ation is directly required for repression or 
stimulation of the transcriptional activity of NF-κB under physiological 
conditions in vivo. 
Although the proximal events and cellular inflammatory networks in 
several inflammatory diseases were quite different, they all had some 
common features characterized by the activation of NF-κB, the production of 
pro-inflammatory mediators and oxygen free radicals as well as subsequent 
culmination in activation of the PARP-1-“suicide-pathway” [reviewed in refs. 4, 
71, 106, 127-131]. Thus, PARP-1 might function in these pathophysiological 
processes at two different levels, firstly through its coactivator function for NF-
κB and secondly by depleting the intracellular NAD+ and ATP levels which 
result in necrotic cell death and tissue damage. Pharmacological inhibition of 
PARP-1 improved the adverse clinical effects in different pathologies 
associated with inflammation after cell death [108-114, 134]. Since the 
enzymatic and DNA binding activity was not required for NF-κB-dependent 
transcriptional activation after treatment of cells with pro-inflammatory or 
genotoxic substances, our lab proposed that the observed anti-inflammatory 
effects of the PARP inhibitors did not influence PARP-1 coactivator function 
but only inhibited the NAD+ and ATP depletion and subsequently also necrotic 
cell death and tissue damage. 
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3.2.5. PARP cleavage by caspase  
 
A very recent study presented evidence that PARP-1 was cleaved during 
inflammation by unknown caspase-like proteases [135]. For this study, a 
PARP-1 knock-in (PARP-1 KI/KI) mice model was generated, expressing a 
PARP-1-DEVD(214) mutant protein, which was resistant to cleavage by 
caspases. While PARP-1 KI/KI mice developed normally, they were highly 
resistant to endotoxic shock and to intestinal and renal ischemia-reperfusions, 
which were associated with reduced inflammatory responses in the target 
tissues and cells due to the compromised production of specific inflammatory 
mediators [135]. Despite normal binding of NF-κB to DNA, NF-κB-mediated 
transcription activity was impaired in the presence of caspase-resistant 
PARP-1 [55]. This study indicated that cleavage of PARP-1 might be required 
for the late NF-κB-dependent inflammatory response.  
Caspase-8 was the most proximal caspase in the caspase cascade and 
had been known for its role in the mediation of cell death by various death 
receptors belonging to the TNFR family but also for its non-apoptotic function 
in T-cell development and differentiation [135]. 
 
3.2.6. PARP-1 and disorders 
 
3.2.6.1. PARP-1 and necrotic cell death 
Some studies showed that several cell types derived from PARP-1 -/- mice 
were protected against necrotic cell death [136-138 and reviewed in ref. 115]. 
These studies clearly suggested that PARP-1 plays an important role in 
necrotic cell death, which was in sharp contrast to its putative and negligible 
functions in apoptosis. The induction of PARP-1 enzyme activity by DNA 
strand breaks or by other stimuli resulted in synthesis of poly(ADP-
ribose)polymers by consuming NAD+ as a substrate. The enzyme activity of 
PARP-1 is thus expected to affect cellular energy levels. Together, PARP-1 
was suggested to play a key role in the processes of cellular energy dynamics 
and necrotic cell death [136]. 
According to the ‘PARP-1 suicide’ model, massive levels of DNA damage  
led to over-activation of PARP-1 which might rapidly deplete intracellular 
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NAD+ levels, thereby reducing the rate of glycolysis and electron transport in 
the mitochondria and abolishing ATP formation, which results in cellular 
dysfunction and, finally, in necrotic cell death. Inhibition of PARP-1 enzyme 
activity or complete absence of PARP-1 significantly improved cellular 
energetics and cell viability after exposure to necrosis-inducing agents [129, 
130, 137, 139, 140, and reviewed in refs. 115, 141].  
 
3.2.6.2. PARP-1 and cancer 
Initial analysis of cells isolated from PARP-1 -/- mice revealed a 
measurable genomic instability, although without consequences for the mice, 
since PARP-1 -/- mice did not show any particular predisposition to develop 
spontaneous tumors [142-144]. Other studies showed that PARP-1 might 
have an indirect role in tumorigenesis [145-148]. It was suggested that the 
elevated tumorigenicity observed in PARP-1 -/- mice under non-physiological 
conditions might be at least in part due to the transcriptional down regulation 
of genes involved in cell differentiation or maintenance of genomic integrity 
and up regulation of the expression of extracellular matrix or cytoskeletal 
proteins which were implicated in cancer initiation or progression [149]. The 
exact role of PARP-1 in tumorgenesis is still under debate. It seems to be 
dependent on the tumor type and genetic background. 
 
3.2.6.3. PARP-1 and inflammatory disorders 
The regulation of immune and inflammatory responses is a complex 
physiological process that is of profound importance to both homeostasis and 
ultimate survival of an organism. The inflammatory response is composed of 
an elaborate cascade of inflammatory mediators. It is important to activate 
both pro- and anti-inflammatory mechanisms in a balanced manner to survive 
in presence of environmental [4]. 
A pathophysiological role for PARP-1 had been demonstrated in a number 
of diseases and animal models, including streptozotocin-induced diabetes 
[112, 140, 150], zymosan-induced vascular failure, a non-septic model of 
multiple organ dysfunction [151], LPS-induced septic shock, and carrageen-
induced pleurisy [108, 111, 152-153], as well as collagen-induced arthritis 
(CIA), a model for chronic inflammation [111, 131] (see also Table 2).  
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Type of disease Common phenotype of PARP-1 -/- mice 
LPS-induced septic shock full resistance to endotoxic shock 
Acute respiratory distress 
syndrome 
reduction of high-permeability pulmonary edema and 
flooding of alveolar spaces by neutrophilic leukocytes, due 
to reduced recruitment of polymorphonuclear neutrophils 
2,4,6-trinitro-benzene-sulfonic 
acid-induced mucosal injury in 
murine colitis 
reduction of mucosal injury due to resolution of colonic 
damage and reduction of neutrophil infiltration; reduction of 
necrosis in endothelial cells of intestine 
Streptozotocin (STZ)-induced 
diabetes 
normoglycemic, reduced sensitivity to SZT and normal 
function of endothelial and pancreatic β cells 
Myocardial postischemic injury reduction of myocardial infarct size 
Hemorrhagic shock increased survival advantage due to protection from 
cardiovascular decompensation, vascular hypocontractility, 
gut barrier failure, and lung neutrophil recruitment 
Zymosan-induced 
inflammation and multiple 
organ failure (MOF) 
resistance against zymosan-induced inflammation and 
MOF due to reduced neutrophil recruitment and organ 
injury. 
 
Table 2. Partial list of disease models in which PARP-1 is involved [4]. 
 
3.2.6.4. PARP-1 and type I diabetes 
Type 1 diabetes is an autoimmune disease characterized by the selective 
T lymphocyte-mediated destruction of insulin-secreting β cells in the 
pancreatic islets of Langerhans, which is thought to be the determining event 
in the pathogenesis of type 1 diabetes [reviewed in refs. 154, 155]. 
Environmental factors (pathogens, drugs, and diet) and the genetic 
background (major histocompatibility complex and non-MHC genes) are 
critical for the initiation of the autoimmune response against the pancreatic β 
cells [156].  
There are two streptozotocin-induced animal models which mimicked at 
least in part several biochemical and pathological hallmarks of type 1 diabetes 
in non-human animals [157, 158]. Streptozotocin is a specific β cell toxin 
which is taken up by β cells through the glucose transporter Glut-2 [159]. 
Streptozotocin-induced and human autoimmune type 1 diabetes are both 
characterized by a progressive hyperglycemia and insulitis, associated with 
drastic up-regulation of the inducible isoform of nitrite oxide (NO) synthase 
(iNOS) in β cells and islet-infiltrating immune cells [131, 160, 161]. 
Stimulation of β cells by polymorphonuclear neutrophil (PMN)/ 
macrophage/T cell-generated cytokines induces the expression of 
inflammatory mediators, such as iNOS and subsequent massive production of 
NO and related free radical species such as peroxynitrite. The formation of 
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free radical species in β cells inhibits insulin secretion, leads to extensive DNA 
damage and thereby activates the PARP-1 ‘suicide pathway’ which finally 
results in cellular energy depletion and necrotic β cell death [112, 140, 162, 
163]. 
Type 1 diabetes is also associated with an increase in formation of 
advanced glycation end product (AGE) in diabetic retinal vessels and renal 
glomeruli [reviewed in ref. 154]. The activity of AGEs influences two different 
events: first, they modify extracellular matrix components and intracellular 
proteins thereby altering their function and, second, certain of these modified 
plasma proteins bind to AGE receptors on endothelial cells, mesangial cells or 
macrophages, thereby inducing the activation of the NF-κB [reviewed in refs. 
154, 164] causing pathological changes in gene expression of pro-
inflammatory mediators [165]. In the last decade, several independent groups 
have shown that novel inhibitors of PARP enzyme activity not only do provide 
a significant protection but also PARP-1 -/- mice of different genetic 
background were nearly completely protected from streptozotocin-induced 
diabetes [134, 140, 160, 166, 167]. Upon treatment with streptozotocin, 
PARP-1 -/- mice remained normoglycemic and their β cells showed preserved 
structure and function concomitant with a drastic reduction in peroxynitrite 
formation, neutrophil recruitment, and endothelial dysfunction [134, 140, 160, 
166, 167]. 
 
3.2.6.5. PARP-1 and septic shock 
Septic shock is the most common cause of death in intensive care units, 
with a high mortality rate, often as a result of a systemic gram-negative 
bacterial infection. It is defined as an acute circulatory failure of dysfunction of 
a number of organ systems associated with severe sepsis, persisting despite 
adequate fluid resuscitation, causing a shock-like state and leading go death 
[4]. 
Septic shock can be mimicked by intravenous injection of microbial 
products such as bacterial LPS. LPS activate a complex signaling cascade, 
enabling the expression of many crucial genes involved in the pathogenesis of 
septic shock, such as cytokines, adhesion molecules, and iNOS [168]. One of 
the striking features of septic shock is the increased production of 
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peroxynitrite which can also induce massive levels of DNA SSBs and 
activation of the PARP-1 ‘suicide-pathway’ resulting in necrotic cell death and 
endothelial dysfunction [169-171]. 
PARP inhibitors could strongly reduce tissue damage caused by high 
doses of endotoxin [170]. Moreover, PARP-1 -/- mice were extremely resistant 
to LPS-induced lethality [152, 153]. The production of peroxynitrite and 
neutrophil recruitment during endotoxic shock as well as local and systemic 
inflammation were drastically reduced in the absence of PARP-1 [152, 153]. 
 
3.3. CARM-1 
 
3.3.1. CARM-1 
 
Coactivator-associated arginine methyltransferase (CARM-1/PRMT-4) was 
identified as SRC-2/TIF2/GRIP1-binding protein and belongs to a family of 
arginine-specific protein methyltransferases, which includes at least eight 
members (PRMT1-8) [55]. 
CARM-1 had been shown to synergistically enhance transcription by 
nuclear receptors in combination with the p160 family of coactivators and to 
form a ternary complex with p300/CBP and SRC-2/TIF2/GRIP1. After 
recruitment to the promoters of estrogen-responsive genes, CARM-1 
methylated specific arginine residues (Arg 17 and Arg26) in the N-terminal tail 
of histone H3 as part of the transcriptional activation process. Recent studies 
broadened the targets of the transcriptional coactivator function of CARM-1: 
CARM-1 coactivated p53-dependent transcription and cooperated with β-
catenin to enhance transcriptional activation by the lymphoid enhancer 
factor/T-cell factor (LEF1/TCF4). Mice with a targeted disruption of CARM-1 
die during late embryonic development or immediately after birth, supporting 
the idea that CARM-1 is a crucial coactivator for gene expression during late 
embryonic development. Aberrant T-cell development in CARM-1 deficient 
embryos was due to a partial developmental arrest in the earliest thymocyte 
progenitor subset, indicating that CARM-1 plays a significant role in promoting 
the differentiation of early thymocyte progenitors [55]. 
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3.3.2. CARM-1 und NF-κB 
 
The assembly of a higher order NF-κB transcriptional initiation complex is 
an important stage in NF-κB-dependent transcription, involving multiple 
coactivator/cofactor-NF-κB-DNA interactions. During this thesis work, 
coactivator-associated arginine methyltransferase CARM-1/PRMT-4 was 
described to function as a novel transcriptional coactivator of NF-κB. CARM-1 
formed a complex with p300 and NF-κB in vivo and interacted directly with the 
NF-κB subunit p65 in vitro. Moreover, CARM-1 synergistically coactivated NF-
κB-mediated transactivation, in concert with the transcriptional coactivators 
p300/CREB-binding protein and the p160 family of steroid receptor 
coactivators. For at least a subset of NF-κB target genes, the enzymatic 
activities of both CARM-1 and p300 were necessary for the synergistic 
activities of CARM-1 and p300 [55]. 
 
3.4. Target genes of NF-κB 
 
The induced NF-κB transcription factor promotes the expression of over 
500 target genes. The majority of proteins encoded by NF-κB target genes 
participated in the host immune response [2]. The web page 
http://people.bu.edu/gilmore/nf-kb/target/index.html shows one possible 
classification also presented in a simplified manner in Annex A. 
 
3.4.1. Short description of the genes used in these studies 
 
3.4.1.1. House keeping genes 
These genes are constitutively expressed in the investigated cells. They 
were included in the analysis as controls or internal standards for 
interpretation of the qualitative/semi-quantitative gene expression data (i.e. 
differences in cellular input, RNA quality, and RT efficiency between samples) 
[171].   
 
β-Actin 
Actin is a protein of the cytoskeleton.  
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GAPDH 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acts as an 
enzyme in the glycolysis pathway. 
 
HPRT 
Hypoxanthine ribosyltransferase HPRT is a crucial enzyme involved in the 
nucleotide metabolism. 
 
3.4.1.2. Cytokines 
Cytokines are proteins that regulated cellular interactions, cell growth and 
secretion. As a result, they regulated many aspects of the immune system. 
 
IL-6 
Interleukin-6 (IL-6) is a crucial inflammatory cytokine of 185 amino acids 
glycosylated at positions 73 and 172. It is synthesized as a precursor protein 
of 212 amino acids. It exists in different molecular forms. They mainly differ by 
post-translational alterations such as glycosylation and phosphorylation. In 
serum IL-6 is complexed with α-2-Macroglobulin, which protected IL-6 from 
cleavage by proteases. IL-6 is a pleiotropic cytokine influencing antigen-
specific immune responses and inflammatory reactions. It is one of the major 
physiological mediators of acute phase reactions. IL-6 induced B-cell 
differentiation and activation of T-cells. For instance, in the presence of IL-2, 
IL-6 induced the differentiation of mature and immature T-cells into cytotoxic 
T-cells. IL-6 is capable of inducing the final maturation of B-cells into 
immunoglobulin-secreting plasma cells if the cells had been pre-activated by 
IL-4. In B-cells IL-6 stimulated the secretion of antibodies to such a degree 
that serum IgG1 levels could raise 120-400-fold [174].  
IL-6 is produced by many different cell types mainly monocytes, 
fibroblasts, and endothelial cells upon stimulation in vivo. Macrophages, T-
cells and B-lymphocytes, granulocytes, smooth muscle cells, eosinophils, 
chondrocytes, osteoblasts, mast cells, glial cells, and keratinocytes can also 
produce IL-6 upon stimulation [174].  
The human IL-6 gene promoter contains many different regulatory 
elements allowing the induction of expression by various stimuli. Physiological 
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and pathophysiological stimuli for the synthesis of IL-6 are PDGF, Ocostatin 
M, IL-1, bacterial endotoxins, and TNF-α. For instance, in fibroblasts the 
synthesis of IL-6 is stimulated by IFNβ, TNF-α, PDGF, and viral infections. IL-
6 also stimulates or inhibits its own synthesis, depending on the cell type. 
Macrolide antibiotics spiramycin and erythromycin stimulated the synthesis of 
IL-6 in human monocytes following cell activation by bacterial 
lipopolysaccharides. Glucocorticoids or TGF-β inhibit the synthesis of IL-6 
depending on the cell type and stimuli [174]. 
The NF-κB binding site is responsible for the induction of the IL-6 gene 
expression by IL-1 or TNF-α in non-lymphoid cells. In lymphoid cells, a factor 
related to the Rel oncogene functioned as a repressor that prevented the 
interaction of transcription factors with the IL-6-κB binding site [174].  
 
TNF-α 
Human tumor necrosis factor alpha (TNF-α) is a non-glycosylated protein 
of 17 kDa with a length of 157 amino acids. Interestingly, murine TNF-α is N-
glycosylated. TNF-α forms dimers and trimers. The 17 kDa form is produced 
through processing of a precursor protein of 233 amino acids by the TNF-α 
converting enzyme. TNF-α contains a single disulfide bond that can be 
destroyed without altering the biological activity of the factor.  
TNF-α is secreted by macrophages, monocytes, neutrophils, neutrophilic 
granulocytes, T-cells and NK-cells following stimulation i.e. bacterial LPS in 
vivo and ex vivo. In addition, a number of transformed cell lines, astrocytes, 
microglial, smooth muscle cells, and fibroblasts can also secrete TNF-α ex 
vivo [174].  
The synthesis of TNF-α is induced by many different stimuli including 
bacterial toxins, interferons, IL-2, GM-CSF, Bradykinin, immune complexes, 
inhibitors of cyclooxygenase and PAF. The production of TNF-α can be 
inhibited by IL-6, TGF-β, vitamin D3, prostaglandin E2, dexamethasone, 
Cyclosporine A and antagonists of PAF [174].  
TNF-α causes cytolysis of many cell types including tumor cells [174]. 
Sensitive cells die within hours after exposure to picomolar concentrations of 
TNF-α ex vivo. The cytotoxic mechanism was shown to involve mitochondria-
derived second messenger molecules serving as common mediators of TNF-
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α cytotoxic and gene-regulatory signaling pathways [174]. TNF-α induces 
hemorrhagic necrosis of transplanted tumors in vivo. Within hours after 
injection TNF-α led to the destruction of small blood vessels within malignant 
tumors. The factor also enhanced phagocytosis and cytotoxicity in neutrophilic 
granulocytes and modulates the expression of many other proteins, including 
IL-1 and IL-6. TNF-α induces the synthesis of a number of chemoattractant 
cytokines, including IP-10, KC, in a cell-type and tissue-specific manner. In 
addition, TNF-α is a growth factor for normal human diploid fibroblasts. It 
promotes the synthesis of collagenase and prostaglandin E2 in fibroblasts. In 
resting macrophages TNF-α induces the synthesis of IL-1 and prostaglandin 
E2. It also stimulates phagocytosis and the synthesis of superoxide dismutase 
in macrophages. TNF-α activates osteoclasts and thus induces bone 
resorption. TNF-α inhibits the synthesis of lipoprotein lipase and thus 
suppressed lipogenic metabolism in adipocytes. The different activities of 
TNF-α on various cell types, i.e. growth-promoting and growth-inhibiting 
activities, were probably mediated by the specific expression pattern and/or 
regulation of multiple receptors in combination with other distinct receptor-
associated proteins [174]. 
Regarding its role in inflammatory disorders, TNF-α is responsible for 
some of the severe effects during gram-negative sepsis. On the other hand, 
TNF-α is required for the B- and T- cell mediated immunity against obligate 
and facultative bacteria and parasites. It conferres protection against infection 
with Listeria monocytogenes, and antibodies against TNF-α weaken the ability 
of mice to cope with these infections. Apart from the membrane-bound 
receptors several soluble proteins that bind TNF-α has been described. These 
proteins of approximately 30 kDa, called tumor necrosis factor binding protein 
1 and 2 (T-BP1 and T-BP2), are similar to the TNF-α-binding domain of the 
membrane receptor. They can be isolated from urine and serum and probably 
function as physiological regulators of TNF-α activities by inhibiting binding of 
TNF-α to its receptor [174].  
 
 33 
3.4.1.3. Chemokines 
Chemokines are a family of pro-inflammatory and chemotactic cytokines 
with a characteristic sequence of four cysteine residues. They regulate the 
migration of leukocytes from blood into tissues. 
 
IP-10 
Interferon-inducible protein-10 (IP-10) has a length of 98 amino acids and 
shows homology to platelet factor-4 (PF4). 
The expression of IP-10 is induced by LPS, IFNγ and/or TNF-α in a variety 
of cells including monocytes, endothelial cells, keratinocytes and fibroblasts. 
Human neutrophils produce IP-10 in response to IFNγ in combination with 
either TNF-α or LPS and this response is blocked by IL-10 and IL-4. IFNγ 
alone or in association with agonists such as IL-8 and GM-CSF has no effect. 
However, IFNγ in combination with TNF-α, LPS, or IL-1β, resulted in a 
considerable induction of IP-10 release by neutrophils, ex vivo [174].  
IP-10 had been detected in keratinocytes, lymphocytes, monocytes, and 
endothelial cells in immunologically mediated processes. Keratinocytes in 
normal epidermis did not produce IP-10. Murine IP-10 is synthesized 
predominantly in the liver and kidney after intravenous injection of 
inflammatory agents, and in particular after injection of IFNγ, and thus, might 
play an important role in the response of liver and kidney to systemic 
inflammation. IP-10 mRNA expression was more sensitive to suppression by 
IL-4 when stimulated by bacterial LPS than by IFNγ/IL-2 [174]. 
IP-10 probably also plays a role in regulation of the growth of immature 
hematopoietic progenitor cells and has been shown to be a potent 
endogenous inhibitor of angiogenesis [174].  
 
KC 
Keratinocyte derived chemokine (KC) was initially identified by its 
overexpression in murine monocytes and macrophages in response to PDGF 
and M-CSF treatment. KC was an early response gene. Its synthesis was also 
induced by TNF-α. KC was involved in neutrophil chemotaxis and activation 
[174].  
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M-CSF 
Macrophage chemotactic colony stimulating factor (M-CSF) was a 
homodimeric glycoprotein linked by disulfide bonds. The sugar moiety is not 
required for the full spectrum of  biological activities. Different molecular forms 
of M-CSF with lengths between 256 and 438 amino acids have been 
described. They arise by translation of alternatively spliced mRNAs. M-CSF-β 
is a secreted form that occurs not in a membrane-bound form. M-CSF-α is 
expressed as an integral membrane protein that is slowly released by 
proteolytic cleavage. The membrane-bound form of M-CSF interacts with 
receptors on near-by cells and therefore mediates specific cell-to-cell 
contacts. Additionally, some high-molecular weight forms of murine M-CSF 
have been described. These forms are complexed with proteoglycan of the 
intracellular matrix [174]. 
M-CSF is produced ex vivo and in vivo by monocytes, granulocytes, 
endothelial cells and fibroblasts. After cell activation, B-cells, T-cells and also 
a number of tumor cell lines are also capable of synthesizing this factor. 
Moreover, M-CSF had been found to be synthesized by uterine epithelial cells 
in vivo. The factor was found also in human urine [174].  
M-CSF was initially isolated as a factor stimulating the growth of 
macrophage/granulocyte-containing colonies in soft agar cultures. M-CSF 
influences the proliferation and differentiation of hematopoietic stem cells into 
macrophages. In combination with another colony stimulating factor, GM-
CSF, the phenomenon of synergistic suppression could be observed. M-CSF 
is highly specific colony stimulating factor and more or less restricted to the 
macrophage lineage. In human macrophages M-CSF induced antibody-
dependent cellular cytotoxicity [174].  
IL-1, TNF-α, IFNγ, GM-CSF and PDGF could induce the synthesis of M-
CSF. Prostaglandins, glucocorticoids and substances that raise intracellular 
levels of cAMP inhibit the synthesis of M-CSF. In monocytes and 
macrophages M-CSF induces the synthesis of IL-1, G-CSF, IFNγ, TNF-α, 
plasminogen activator, thromboplastin, prostaglandins and thromboxanes and 
also oxidative metabolism. M-CSF could act synergistically with IL-1, IL-3 and 
IL-6 in the stimulation of proliferation and the differentiation of primitive 
hematopoietic cells into macrophages [174]. 
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MIP (MIP-1 and MIP-2) 
Macrophage inflammatory proteins 1 and 2 (MIP-1 and MIP-2) are the 
major factors produced by macrophages following their stimulation with 
bacterial endotoxins [174].  
MIP-1α and MIP-1β are acidic proteins with a length of 69 amino acids that 
corresponded to 7.8kDa. Their cDNAs share a homology of 57 percent and at 
the protein level a homology of 60 percent. Both proteins are involved in the 
cellular activation of human granulocytes (neutrophils, eosinophils and 
basophils) and appear to be involved in acute neutrophilic inflammation. Both 
MIP-1α and MIP-1β stimulate the production of reactive oxygen species in 
neutrophils and the release of lysosomal enzymes. They also induce the 
synthesis of other proinflammatory cytokines such as IL-1, IL-6 and TNF-α in 
fibroblasts and macrophages [152]. MIP-1α is a potent basophil agonist, 
inducing a rapid change of cytostolic free calcium, the release of histamine 
and sulfido-leukotrienes, and chemotaxis. Murine MIP-1α is the primary 
stimulator of TNF-α secretion by macrophages, whereas MIP-1β antagonizes 
the inductive effects of MIP-1α. In human monocytes the production of MIP-1β 
is induced by bacterial lipopolysaccharides and IL-7. MIP-1α and MIP-1β can 
also act synergistically with hematopoietic growth factors. Both MIP-1α and 
MIP-1β enhance the activities of GM-CSF and promoted the growth of more 
matur hematopoietic progenitor cells. MIP-1α (but not MIP-1β) also acts as an 
inhibitor of the proliferation of immature hematopoietic stem cells. MIP-1α 
have been shown to be capable of protecting hematopoietic progenitor cells 
from the cytotoxic effects of the cell cycle-specific drug hydroxyurea in vivo 
and might also be of clinical significance [174]. 
MIP-2 is a basic protein of approximately 6 kDa. It is extremely 
chemotactic for segmented neutrophilic granulocytes and acts also 
synergistically with GM-CSF and M-CSF. In contrast to MIP-1, MIP-2 induces 
also the degranulation of human neutrophils but did not enhance oxidative 
metabolism [174].  
 
MCP-1 
Monocyte chemoattractant protein-1 (MCP-1) is produced ex vivo by 
monocytes, vascular endothelial cells, smooth muscle cells, glomerular 
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mesangial cell, osteoblastic cells and human pulmonary type-2-like epithelial 
cells. Its expression is induced by LPS but not by TNF-α. In addition, IgG 
complexes could rapidly induce the synthesis and release of MCP-1 in 
mesangial cells [174]. 
MCP-1 is chemotactic for monocytes but not neutrophils. It regulates the 
expression of cell surface antigens and the expression of cytokines such as 
IL-1 and IL-6. MCP-1 is a potent activator of basophils, inducing the 
degranulation and the release of histamines. In basophils activates MPC-1 
enhanced the synthesis of leukotriene C4. MCP-1 has also been shown to 
exhibit biological activities other than Chemotaxis. It could induce the 
proliferation and activation of killer cells [174].  
 
RANTES 
RANTES is the abbreviation of regulated upon activation, normal T-cell 
expressed, and presumably secreted. RANTES is an early response gene 
and its synthesis was induced by LPS, TNF-α, but not by IL-6 [174].  
RANTES is preferentially highly expressed in T-cells but also moderately 
in other cell types. RANTES is chemotactic for T-cells, human eosinophils and 
basophils and plays an active role in recruiting leukocytes into inflammatory 
sites. It changes the density of eosinophils and makes them hypodense, 
which is thought to represent a state of cell activation. RANTES was also a 
potent eosinophil-specific activator of oxidative metabolism. RANTES could 
increase the adherence of monocytes to endothelial cells. It selectively 
supported the migration of monocytes and T-lymphocytes expressing the cell 
surface markers CD4 [174].  
 
3.4.1.4. Adhesion molecules 
 
ICAM-1 
Intercellular adhesion molecule-1 (ICAM-1) is a member of the 
immunoglobulin gene superfamily, which bound to several surface molecules 
and was involved in the initiation of the immune reaction [174]. 
ICAM-1 is induced by cytokines and various stress stimuli, such as 
hypoxia, ultraviolet, and ionizing radiation [174]. 
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3.4.1.5. Enzymes 
 
COX-2 
Cyclooxygenase-2 (COX-2) is a member of the COX family and catalyses 
the first committed step in the synthesis of prostanoids, which represents a 
large family of arachidonic acid metabolites comprising prostaglandins, 
prostacyclin, and thromboxanes [174].  
The Cyclooxygenase family is a major target of non-steroidal anti-
inflammatory drugs (NSAIDs). COX exists as constitutive (COX-1 and COX-3) 
expressed gene products and as an inducible protein (COX-2). COX-2 is 
rapidly expressed in several cell types in response to growth factors, 
cytokines, and pro-inflammatory molecules. Since its discovery in the early 
1990s, COX-2 had emerged as a major player in inflammatory reactions in 
peripheral tissues [174].  
 
iNOS 
Inducible nitric oxide synthase (iNOS) is a member of the NOS family 
including endothelial NOS (eNOS), neuronal NOS (nNOS) and iNOS. The 
NOS family of enzymes catalyzes the conversion of L arginine to the 
cytostatic molecule nitric oxide (NO). eNOS and nNOS are constitutively 
expressed and are regulated by posttranslational modification [174]. 
The inducible NOS (iNOS) is an early response gene induced by an acute 
inflammatory insult or mechanical perturbation. Once expressed, the iNOS 
activity is generally limited only by the substrate availability [174]. 
 
3.4.1.6. Receptors of the immune system and NF-κB signaling cascade 
 
TLR (TLR-2 and TLR-4) 
Toll-like receptors (TLRs) belong to a large family (TLR1-15). TLRs are 
transmembrane receptors mainly involved in the pathogen pattern recognition 
but also partially involved in developmental processes. TLR proteins are 
characterized by an extracellular leucine-rich repeat domain and a 
cytoplasmic IL-1 receptor-like region known as the TIR domain (Toll-IL-1 
receptor domain) [174].  
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The receptors highly specifically recognize the invasion of distinct 
microorganisms and play the key role in innate immune responses. Distinct 
TLR receptors bind bacterial cell wall components, viral and bacterial 
oligonucleotides (RNA & DNA), thereby activating innate immune responses 
and subsequently at least in part adaptive immunity. Engagement of these 
receptors activates transcription factor NF-κB, which initiates the transcription 
of genes encoding pro-inflammatory cytokines [174]. 
TLR-2 and TLR-4 are the 2 major TLRs in mammals. TLR-2 is highly 
expressed in peripheral blood leukocytes but also moderately in heart, brain, 
and muscle. Signaling through TLR-2 in mammalian cells involves activation 
of NF-κB. In contrast to TLR-4, TLR-2 expression is upregulated by bacterial 
LPS only in granulocytes but not in monocytes. This expression is not affected 
by IL-10. -/- mice lacking TLR-2 are highly susceptible to infection with 
Staphylococcus aureus compared to wild type (+/+) mice. Macrophages from 
such mice produced only low levels of TNF-α and IL-6. TLR-2 appears to be a 
molecular link between microbial products, apoptosis, and host defense 
mechanisms since induction of IL-12 production by microbial lipoproteins in 
human macrophages is also mediated by other TLRs. Microbial lipoprotein-
mediated apoptosis however is only signaled through human TLR-2 in these 
cells [174]. 
Signaling through TLR-4 involves also the activation of NF-κB in 
mammalian cells. TLR-4 expression is induced by bacterial 
lipopolysaccharides and predisposes animals to the development of gram-
negative sepsis. -/- mice lacking TLR-4 were described to be highly resistant 
to LPS-induced septic shock [174].  
 
IRAK-4 
IL-1 receptor-associated kinase-4 (IRAK-4) is a mediator of signaling 
through the IL-1 receptor and TLRs. The protein has an N-terminal death 
domain and a central kinase domain. An IRAK-4 isoform lacking the kinase 
domain inhibits activation of NF-κB and IRAK-1 by IL-1, but not by TNF-α. 
IRAK-4 plays an essential role in pathogen pattern recognition signaling 
cascades [174].  
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IκBα 
see the chapter 3.1.2. 
 
3.5. Aim of the thesis 
 
Aim of this thesis was to investigate NF-κB-dependent genes in regard to 
their depending on PARP-1 or CARM-1, respectively. Additional the particular 
contribution of the enzymatic PARP activity and caspase-mediated cleavage 
of PARP-1 on NF-κB-dependent gene expression was analyzed. For this 
purpose, wild-type (+/+) cells, untreated or treated with the corresponding 
inhibitors, were compared with the corresponding knock-out (-/-) or knock-in 
(KI/KI) cells. 16 genes were chosen from over 500 target genes of NF-κB. PJ-
34 and zVAD-fmk were used as inhibitors of PARP-1 and caspases, 
respectively. 
Several time points were included in this study to obtain semi-quantitative 
kinetics of NF-κB-dependent gene expression. The project of this thesis was 
divided in three parts: 
1. Established of RT-PCR conditions for each single pair of RT-PCR 
primers (described in the Method and Material part). 
2. Identification of PARP-1 and CARM-1 dependent target genes of NF-κB 
3. Identification of PARP-1 dependent target genes of NF-κB, which are 
also regulated by enzymatic activities either of PARPs or caspases. 
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4. Results 
 
4.1. Target genes of PARP-1 
 
In order to test which subsets of NF-κB-dependent genes are impaired in 
primary PARP-1 -/- cells primary mouse lung fibroblasts freshly isolated from 
PARP-1 +/1 and -/- mice were treated with LPS as indicated and the 
expression of NF-κB-dependent genes was assessed by reverse 
transcription-PCR (see Figure 6).  
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 Impaired expression of iNOS, MIP-1α, MIP-2, KC, IP-10 and RANTES in PARP -/- Figure 6.
he experiments revealed that LPS-induced levels of iNOS, MIP-1α,    
MIP
 
cells in response to proinflammatory stimuli. PARP-1 +/+ and PARP-1 -/- MLFs were treated 
with 1μg/ml LPS and RNA isolated at the indicated time points, followed by RT−PCR 
determination of HPRT, GAPDH, IκBα, TLR-4, iNOS, MIP-1α, MIP-2, KC, IP-10, RANTES, 
MCP-1, TNF-α, IL-6 and COX-2 mRNA. mRNA levels were normalized to the HPRT and 
GAPDH mRNAs.  
 
T
-2 and KC were strongly reduced in PARP-1 -/- cells whereas the levels of 
IP-10 and RANTES were only moderately reduced in these cells. Additionally, 
the expression of IκBα, TNF-α, IL-6 and COX-2 was not impaired in PARP-1  
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-/- cells. The mRNAs of IL-6 and COX-2 were even slightly upregulated in 
PARP-1 -/- cells.  
 
4.2. Target genes of non-cleaved and cleaved PARP-1 
 order to test whether cleavage of PARP-1 might be required for early 
NF-
PARP-1 +/+ PARP-1 KI/KI 
 
In
κB-dependent transcription, primary mouse lung fibroblasts freshly 
isolated from PARP-1 +/+ and DEVD(214)-KI/KI mice were treated with LPS 
as indicated and the expression of NF-κB-dependent genes was assessed by 
reverse transcription-PCR (see Figure 7).  
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Figure 7. PARP-1 +/+ and PARP-1 KI/KI MLFs were treated with 1μg/ml LPS and RNA 
isolated at the indicated time points, followed by RT−PCR determination of HPRT, GAPDH, 
IκBα, TLR-4, iNOS, MIP-1α, MIP-2, KC, IP-10, RANTES, MCP-1, TNF-α, IL-6 and COX-2 
downregulated in PARP-1 KI/KI cells at early time points of the inflammatory 
res
mRNA. mRNA levels were normalized to the HPRT and GAPDH mRNAs.  
 
The experiments revealed that no tested NF-κB-dependent genes were 
ponse, indicating that cleavage of PARP-1 might be only required for the 
second wave of NF-κB-dependent inflammatory response.  
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It was recently shown by several independent groups that Caspase-8 
could activate the NF-κB pathway independent of its activity as a pro-
apo
ctivities, macrophage-like Raw264 cells were 
trea
 strongly reduced in presence of 
zVA
ptotic protease. Caspase-8 was identified as an essential component in 
the activation of the IKK complex, linking IKK to the upstream Bcl10-MALT1 
complex. Intriguingly, one study suggested that it was not only the physical 
presence of caspase-8, but rather its enzymatic activity was required for the 
activation of NF-κB. It was previously shown that PARP-1 could be cleaved in 
vitro by caspase-8 [175-177].  
To confirm these data and to test whether NF-κB-dependent inflammatory 
response required caspase a
ted with LPS in presence or absence of the caspase inhibitor zVAD-fmk 
as indicated, and the expression of NF-κB-dependent genes was assessed by 
reverse transcription-PCR (see Figure 8).  
Remarkably, this experiment revealed that expression levels of iNOS, KC, 
MIP-2, MIP-1α, RANTES and IP-10 were
D-fmk, during the second wave of the NF-κB-dependent inflammatory 
response, indicating that a subset of NF-κB target genes were dependent on 
caspase activities. Interestingly, all genes affected by the caspase inhibitor 
zVAD-fmk were also dependent on PARP-1. 
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Figure 8. Impaired expression of iNOS, KC, MIP-2, MIP-1α, RANTES and IP-10 in Raw264 
PARP-1 Inhibitor 
Initial reports using either PARP inhibitors or genetic approaches 
dem
cells in presence of the caspase inhibitor zVAD-fmk. Raw264 cells were treated with 0.1μg/ml 
LPS in presence and absence of 20μM zVAD-fmk and RNA isolated at the indicated time 
points, followed by RT−PCR determination of β-Actin, GAPDH, IκBα, ICAM-1, iNOS, MIP-1α, 
MIP-2, KC, IP-10, RANTES, MCP-1, TNF-α, IL-6 and COX-2 mRNA. mRNA were normalized 
to the HPRT and GAPDH mRNAs.  
 
4.3.  
 
onstrated that the enzymatic activity of PARP-1 was not required for NF-
κB-dependent transcription. However, other studies recently suggested that 
drug-mediated PARP inhibition could affect NF-κB-dependent transcription in 
vivo, most likely in a cell type-specific manner [reviewed in ref. 4]. For 
instance, PARP inhibition with the phenanthridinone-based PARP inhibitor PJ-
34 suppressed inflammatory cell migration of macrophages [108]. These 
effects were associated with down regulation of the CC chemokine MIP-1α, 
but not the CXC chemokine MIP-2. The production of TNF-α and IL-12, but 
not IL-5 or IL-13, was also suppressed by PARP inhibition in macrophages 
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[108].  
In order to test whether inhibition of the PARP enzymatic activity affected 
NF-
 LPS  LPS and PJ-34 
κB-dependent transcription in macrophages Raw264 cells were treated 
with LPS in presence or absence of the PARP inhibitor PJ-34 (as indicated), 
and the expression of NF-κB-dependent genes was assessed by reverse 
transcription-PCR (see Figure 9).  
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Figure 9. The enzymatic activity of PARP-1 was not required for NF-κB-dependent 
d with 0.1μg/ml LPS in presence and absence of 50μM transcription. Raw264 cells were treate
J-34 and RNA isolated at the indicated time points, followed by RT−PCR determination of β-
one of tested NF-κB-dependent genes required the enzymatic activity of 
PA
P
Actin, GAPDH, IκBα, ICAM-1, iNOS, MIP-1α, MIP-2, KC, IP-10, RANTES, MCP-1, TNF-α, IL-
6 and COX-2 mRNA. mRNA levels were normalized to the HPRT and GAPDH mRNAs.  
 
Strikingly, this experiment clearly demonstrated that except for COX-2, 
n
RP-1. A significant reduction was observed only for COX-2 in presence of 
PJ-34 during the second wave of NF-κB-dependent transcription.  
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4.4. Target genes of CARM-1 
 
Experimental data obtained in our lab strongly indicated that CARM-1 
could act as novel coactivator of NF-κB. CARM-1 directly bound to the NF-κB 
subunit p65 and synergistically coactivated NF-κB-mediated transactivation, in 
concert with the transcriptional coactivators p300/CBP and the p160 family of 
steroid receptor coactivators [56].  
To investigate which subset of NF-κB-dependent genes was influenced by 
CARM-1, mouse embryonic fibroblasts (MEFs) isolated from CARM-1 +/+ or 
CARM-1 −/− mice were treated with LPS (see Figure 10) or TNF-α (see 
Figure 11 as indicated) and the expression of NF-κB-dependent genes 
assessed by RT−PCR. These experiments revealed that LPS-induced 
expression levels of G-CSF, MIP-2, MCP-1, IP-10 and ICAM-1 were impaired 
in CARM-1 −/− cells during the first wave. But, the same genes were not 
impaired during the second wave of NF-κB-dependent gene expression (see 
Figure 10A and B). The slight reduction observed for IP-10 and MCP-1 during 
the second wave seemed not to be significant enough.  
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Figure 10A. 
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Figure 10B. 
 
Figure 10. Impaired NF-κB-dependent gene expression in CARM-1 -/- cells in response to 
LPS. CARM-1 +/+ and CARM-1 -/- MEF cells were treated with LPS (10μg/ml) and RNA 
isolated at the indicated time points, followed by RT−PCR determination (A; first wave only) of 
IRAK-4, IκBα, MIP-2, IL-6, KC, COX-2, HPRT and β-Actin mRNA or (B; first and second 
wave) of MCP-1, G-CSF, ICAM1, IP-10, PARP-1 and HPRT mRNA. mRNA levels were 
normalized to the HPRT and/or β-Actin mRNAs.  
 
Similar results were obtained when cells were stimulated with TNF-α (see 
Figure 11). However, the expression of IκBα, IRAK-4, TLR-2, TLR-4, IL-6, KC 
and COX-2 was not reduced, indicating that only a subset of NF-κB-
dependent genes require CARM-1 for induction. The expression of COX-2 
 cells.  and IL-6 was even slightly upregulated in CARM-1 −/−
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Figure 11. Im
TNF α. CARM
paired NF-κB-dependent gene expression in CARM-1 -/- cells in response to 
-1 +/+ and CARM-1 -/- MEF cells were treated with TNF-α (10ng/ml) and RNA 
isolated at the indicated time points, followed by RT−PCR determination of MIP-2, IP-10, 
ICAM-1, TLR-2 TLR-4, HPRT and β-Actin mRNA. mRNA levels were normalized to the HPRT 
and/or β-Actin mRNAs. 
 
-
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Taken together, these experiments suggested that CARM-1 was required 
 target genes of NF-
first wave of NF-κB-dependent g
 
Some of the data of this the
dean (see Annex B). 
for the expression of a subset of κB upon stimulation with 
TNF-α or LPS. Interestingly, CARM-1 seemed to act preferentially during the 
ene expression.  
4.3. Original publications 
 
sis were published with the permission of the 
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5. 
, the existence of at least 12 
different NF-κB dimers, the interaction of these dimers with specific IκBs and 
ttranslational modification of these dimers in 
the
er, differential binding to κB’s response elements due to 
ifferent affinities, and cell type and stimuli specific interaction with a 
combination of coactivators. Aim of this thesis was to investigate the 
dependence of defined NF-κB-dependent genes on PARP-1 or CARM-1, 
respectively. Additionally, the potential contribution of the enzymatic activities 
of PARPs and caspase-mediated cleavage of PARP-1 on NF-κB-dependent 
gene expression were investigated.  
 
5.1. PARP-1 and CARM-1 act as promoter-specific 
coactivators of NF-κB 
 
Several NF-κB-dependent genes has been identified that were strongly 
dependent on PARP-1, CARM-1 or caspase induced cleavage of PARP-1. 
Interestingly, most of the identified target genes were dependent either by 
PARP-1 or CARM-1. Only two NF-κB-dependent genes, namely MIP-2 and 
IP-10 seemed to require the presence of both PARP-1 and CARM-1. 
However, one could not exclude the possibility that the particular requirement 
was cell type-specific. Table 3 summarizes the identified down or upregulated 
NF-κB-dependent genes in the corresponding -/- cells. 
 
 
 
 
 
 
 
 
Discussion 
 
Virtually all cell types induce NF-κB responses. The activity of NF-κB is 
regulated at multiple levels: the level of translation
their subcellular localization, pos
 cytoplasm and the nucleus, differential accessibility of κB sites in various 
promoter and enhanc
d
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 PARP-1 -/-,  
LPS stimulated 
CARM-1 -/-,  
LPS stimulated 
CARM-1 -/-,  
TNF-α stimulated 
down-regulated MIP-2 
IP-10 
MIP-2 
IP-10 
MIP-2 
IP-10 
KC 
MIP-1α 
RANTES 
iNOS 
MCP-1 
G-CSF 
ICAM-1 
 
MCP-1 
slightly up-regulated COX-2 
IL-6 
TNF-α 
 
COX-2 
IL-6 
IκBα 
KC 
IκBα 
 
 
Table 3. A summary of identified PARP-1 and CARM-1 target genes 
 
The exact molecular mechanism underlying the promoter-specific activities 
of PARP-1 and CARM-1 had yet to be investigated. CARM-1 is a classical 
histone modifier and might therefore modulate NF-κB-dependent gene 
expression through its enzymatic activity and specific association with NF-κB-
dependent promoters. Remarkably, experiments preformed in parallel to this 
thesis study in the same lab revealed that CARM-1 acted in a gene-specific 
anner mainly by enhancing NF-κB/p65 recruitment to its cognate sites in the 
Moreover, CARM-1 formed h p300 and NF-κB in vivo and 
inte
ethyltransferases and 
protein lysine acetyltransferases regulates NF-κB-dependent gene activation 
 vivo [55].  
A slightly different situation might be the case for PARP-1. Although it was 
reviously shown that PARP-1 could directly bind to both subunits of NF-κB 
50 and p65) and could act as a coactivator of NF-κB in concert with the 
lassical NF-κB coactivator p300/CBP its not yet cleared whether PARP-1 
cilitates the recruitment of p65 or p50 to its cognate sites in the promoter or 
nhancer region of a corresponding NF-κB target gene. Moreover, unlike 
m
promoter or enhancer region of the corresponding NF-κB target gene. 
a complex wit
racted directly with the NF-κB subunit p65 in vitro. CARM-1 synergistically 
coactivated NF-κB-mediated transactivation, in concert with the transcriptional 
coactivators p300/CREB-binding protein and the p160 family of steroid 
receptor coactivators. Interestingly, for at least a subset of CARM-1-
dependent NF-κB target genes, the enzymatic activities of both CARM-1 and 
p300 were necessary for the observed synergy between CARM-1 and p300. 
Given these additional observations, the results of the thesis suggested that 
the cooperative action between protein arginine m
in
p
(p
c
fa
e
 50 
C RM-1, PARP-1 is ctura nd n cal histone 
modifier. PARP-1 was initially iden as an act mponent of an 
upstream stimulatory fraction from He ar extrac d USA cofactor 
complex. Earlier stu ed tha SA complex is essential in the 
presence of a complete set of general transcription factors for transcriptional 
activity of transcription factors such as NF-κB, including p50 homodimers, 
SP1, Oct-1 and USF reviewed in ref. Subsequent fractionation studies of 
 the discovery of at 
least 6 independent subfractions of positive cofactors: PC-1/PARP-1, PC-2 
("M
dependent genes in PARP-1 -/- mice, only a slight inhibition (15 
to 4
A  an archite l cofactor a ot a classi
tified ive co
la nucle ts terme
dies show t the U
 [  4]. 
the crude precursor USA fraction in the last decade, led to
ediator" like complex), PC-3 (Dr2/topoisomerase I), PC4 (ssDNA binding 
protein), PC-5 and PC-6. Several previous studies showed that the 
cofactor/coactivator function of PARP-1 was not dependent on damaged DNA 
or on the enzyme activity of PARP-1. Since PARP-1 is a component of the 
USA derived positive cofactor complex PC-1, PARP-1 might therefore not 
only function in concert with p300/CBP and potentially CARM-1 (i.e. on MIP-2 
and IP-10 promoter) but also synergistically with other USA-derived positive 
cofactor complexes in stabilizing the interaction between NF-κB and the basal 
transcription machinery, thereby facilitating the formation and subsequent 
activation of the preinitiation complex (PIC) in vivo [reviewed in ref. 4]. 
 
5.1.2. Caspase activities but not the enzymatic activity of PARP are 
required for NF-κB-dependent gene expression. 
 
Another interesting aspect is the possible involvement of possible 
poly(ADP-ribosyl)ation activity in NF-κB-dependent gene expression. Several 
reports had described an inhibitory effect of PARP inhibitors on the 
expression of other κB-dependent genes in mice [reviewed in ref. 4]. 
However, while the complete absence of PARP-1 abolished the induction of 
these NF-κB 
0%) was observed when PARP-1 +/+ mice or cells were treated with high 
doses of nonspecific PARP inhibitors. Moreover, the production of cytokines 
was not affected in a MDML model of diabetes by PARP inhibitors. 
Nevertheless, it was suggested that the partial reduction was due to inhibition 
of the putative chromatin modifying and remodeling activity of PARP-1 
[reviewed in ref. 4]. It had been proposed that polynucleosomes could be 
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completely decondensed upon poly(ADP-ribosyl)ation by PARP-1 in vivo, and 
this in turn might result in full activation of NF-κB-dependent genes. Indeed, 
the modulation of chromatin structure through histone modification is a very 
important process during DNA transcription. Histones are dynamically 
modified during activation of gene expression. Modifications include 
acetylation, phosphorylation, ubiquitination, methylation, and potentially ADP-
ribosylation [reviewed in ref. 178].  
However, the data of this thesis, obtained with the broad range non-
specific PARP inhibitor PJ-34, do not confirm that the enzymatic activity of 
PARP-1 is required for NF-κB-dependent gene expression, ex vivo. With the 
potential exception of MIP-1α and COX-2, which were slightly down regulated 
in presence of PJ-34, no other gene tested was affected by PJ-34. Therefore 
the slight but still significant inhibitory effect observed in vivo, using different 
mice models could be explained by the observation that certain “messenger 
molecules” released from necrotic cells, such as HSP70 or HMGs, often 
induce the activation of NF-κB-dependent gene expression in surrounding 
healthy cells, as a kind of secondary inflammatory response. Since the 
enzymatic activity of PARPs seemed to be crucial for the execution of cell 
death, inhibition of PARPs would not only block necrosis or related cell death 
processes but also block the secondary inflammatory response.  
trea m ad range caspase 
inh
On the other hand a very interesting observation had been made upon 
ent of macrophages with LPS in presence of the brot
ibitor zVAD-fmk. These experiments revealed that the second gene 
expression waves of iNOS, KC, MIP-2, RANTES, MIP-1α (only slightly) and 
IP-10 seemed to be dependent on the enzymatic activity of caspases  
It had been recently discovered that Caspase-8 could activate the NF-κB-
pathway either dependent or independent of its activity as a pro-apoptotic 
protease [154-156]. Caspase-10 and MRIT, two human homologs of 
Caspase-8, could similarly activate the NF-κB-pathway. Dominant-negative 
mutants of the Caspase-8 prodomain could block NF-κB-induced by Caspase-
8, FADD and several death receptors belong to the TNFR family. Caspase-8 
interacts with multiple proteins known to be involved in the activation of the 
NF-κB-pathway, including the serine-threonine kinases RIP, NIK, IKK1 and 
IKK2 [176, 177]. Moreover c-FLIP(L) was recently shown to influence effector 
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T-cell function through its activation of caspase-8, which in turn cleaves c-
FLIP(L) to allow RIP1 recruitment and NF-κB-activation. This mechanism was 
suggested to be partially required to initiate proliferation of resting T-cells 
[158]. Since PARP-1 is also a substrate for Caspase-8 and Caspase-10, the 
observed down regulation of NF-κB-dependent genes during the second wave 
of expression might directly depend on PARP-1 cleavage. Indeed, it was 
previously found that NF-κB-transcriptional activity was impaired in PARP-1 
(D2
nal activity, 
esp
. 
14N-KI/KI) mice in response to inflammatory stress [135]. Interestingly, 
since PARP-1 was fully enzymatic active in PARP-1 KI/KI mice and enzyme 
inactive PARP-1 could restore NF-κB-activity in PARP-1 –/– macrophages, 
the enzymatic activity of PARP-1 seems to be dispensable for NF-κB-
dependent gene expression. Finally, consistent with the observation that the 
activation of caspases could occur rapidly in vivo, it was reported that 
caspase inhibitor Z-VAD-fmk and noncleavable PARP-1 showed a protective 
effect in ischemia/reperfusion (I/R) models [174]. These findings were 
reminiscent of previous studies showing that caspase inhibitors attenuated the 
mouse response to septic shock, focal and renal I/R, and allergic airway 
inflammation in the asthma model. Taken together, our RT-PCR data and 
published data from others provide strong evidence that caspase-mediated 
PARP-1 cleavage might be required for NF-κB-transcriptio
ecially for the second wave of NF-κB-dependent gene expression. Since 
PARP-1 fragments could costimulate NF-κB-activity, it is reasonable to 
speculate that the cleaved fragments of PARP-1 might modulate the 
interaction of p300 and NF-κB with the basal transcription machinery. 
However, the exact molecular mechanisms have yet to be investigated
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5.2. Cautionary notes 
 
5.2.1. Do cell culture systems reflect the real situation in vivo? 
 
All data observed in this thesis as well as most of the published data were 
obtained with ex vivo experiments using isolated cells. There are only few 
studies published that investigated these aspects in vivo using animal models. 
Moreover, most if not all of these ex vivo cell culture studies were performed 
with a single cell type. Additionally, it was known that the phenotypes of 
primary cells (i.e. PARP-1 +/+ and -/-) are different from those of immortalized 
cells (i.e. Raw264.1 or CARM-1 +/+ and -/-). It is obvious that the situation is 
more complex and might be even completely different in vivo. Different types 
of cells in certain tissue were embedded in a special microenvironment, 
communicated with and influenced each other and therefore might have 
reacted differentially upon stimulation with distinct sets of stimuli. The 
transcriptional activity of NF-κB is in a living organism not only dependent on 
the availabilities, combined actions and interactions of distinct transcriptional 
coactivator complexes and cofactors but also depends on the interplay of 
different combinations of stimuli and the signaling between distinct cell types. 
To obtain the most accurate profile of gene expression patterns in vivo, it is 
absolutely essential to use animal models for genome wide RT-PCR or micro 
array analysis and immediately isolated distinct types of tissues or even cells 
after treatment of the animal with the corresponding stimuli.  
 
5.2.2. Comparison between pharmaceutical and genetic approaches 
 
An additional cautionary note has to be made concerning data obtained 
with inhibitors. It is well known that many if not most pharmaceutical 
compounds have side effects. For some of them, off-target effects were minor 
or even negligible whereas for others, the off-target effects were even more 
pronounced then the specific on-target effects. For instance, concerning 
PARP-1 and Caspase-8 or 10, the novel types of PARP and Caspase 
inhibitors still inhibit the enzyme activity of all PARP or caspase family 
members [reviewed in ref. 4]. Finally, very recent reports indicate that certain 
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PARP as well as caspase inhibitors, possess free radical scavenging 
properties [159]. Since inflammation or stroke are both related to oxidative 
tioxidative 
potency contribute indirectly
NF-
erface might be 
obvious targets for new types of specific drugs which could interrupt specific 
ken 
tog
stress, it is quite possible that PARP or caspase inhibitors with an
 and non-specifically to a decreased or increased 
κB-dependent transcriptional activity by the reduction of free radicals. 
Thus, the exact role and contribution of the enzymatic activities of PARPs and 
caspases on NF-κB-dependent gene expression in vivo can only be 
addressed by profound genetic analyses using single or combinations of 
double and triple knock-in mice of enzymatic mutants of distinct PARP and 
caspase members.  
 
5.3. Conclusions 
 
A better understanding of the regulatory network modulating the 
interaction between NF-κB and PARP-1 or CARM-1 respectively, could 
provide new explanations for the aberrant T-cell development in CARM-1 
deficient embryos and why PARP-1 -/- animals are protected against NF-κB 
regulated diseases such as septic shock, stroke and diabetes type 1. 
Deciphering the PARP-1 and CARM-1 dependent gene expression patterns, 
using genome wide approach, would provide us with the opportunities to 
develop new treatments to inhibit the undesired activity of NF-κB and thus, to 
block the inflammatory response in instances where this process became 
chronic. Indeed, the NF-κB PARP-1 or NF-κB CARM-1 int
protein-protein interactions and thus bearing much less side effects. Ta
ether, future investigation of the various roles of PARP-1 and CARM-1 in 
gene-specific regulation of transcription under normal physiological and 
pathophysiological conditions in vivo, would certainly represent an intense 
and exciting new field of research on its own. 
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6. Methods and materials 
 
6.1. Cell culture 
 
Primary mouse macrophage and lung fibroblast (MLF) cells were isolated 
from fresh littermates of 129S/EV-PARP-1 +/+ and 129S/EV-PARP-1 -/- mice 
according to an isolation procedure described in [135]. Primary mouse 
macrophages and the macrophage/monocyte-like murine Raw264 cells were 
grown in Hepes-buffered RPMI-Glutamax-I (Invitrogen) containing 10% FCS 
US/certified (Invitrogen) and supplemented with 50U/ml penicillin, 50µg/ml 
streptomycin (Invitrogen), 1mM sodium pyruvate, 0.05mM β-mercaptoethanol 
mary mouse fibroblast cells were grown in Hepes-
buffered DMEM-Glutamax-I (Invitrogen) containing 4.5g/L glucose, 10% FCS 
US
. For some experiments cells 
were additionally pretreated with 50μM PJ-34, 20μM zVAD-fmk or 1% DMSO 
for 1h prior LPS treatment. 
 
and MEM-NEAA. Pri
/certified (Invitrogen) and supplemented with 50U/ml penicillin, 50µg/ml 
streptomycin (Invitrogen), 1mM sodium pyruvate, 0.05mM β-mercaptoethanol 
and MEM-NEAA. CARM-1 +/+ or CARM-1 –/– mouse embryonic fibroblasts 
(MEFs) were grown in Hepes-buffered DMEM-Glutamax-I (Invitrogen) 
containing 4.5g/L glucose and 10% FCS US/certified (Invitrogen) and 
supplemented with 50U/ml penicillin, 50µg/ml streptomycin (Invitrogen) and 
MEM-NEAA. Only cell passages 2 to 4 were used for all experiments. 
 
6.1.1. Stimulation of the cells 
 
For primary macrophages and macrophage/monocyte-like murine Raw264 
cells, treatment with LPS was performed at a concentration of 0.1μg/ml where 
as for MLFs and MEFs a concentration of 1μg/ml LPS was used. Concerning 
the treatment with TNF-α, a concentration of 10ng/ml was used for all cell 
types. MEFs and MLFs were grown for 12 h in DMEM containing 2% fetal calf 
serum before stimulation with TNF-α or LPS
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6.2. Preparation of RNA 
 
RNA isolation from Primary mouse macrophage, mouse lung fibroblasts 
(MLFs) and mouse embryonic fibroblasts (MEFs) was performed using the 
Trizol procedure KIT from Invitrogen according to manufacturers protocols 
(Invitrogen). 
 
6.3. RT-PCR 
 
Reverse Transcription and PCR procedures were experimentally 
optimized based on original procedures from Promega (optimized parameters: 
length of random hexamer primers, annealing temperatures, annealing time 
and PCR elongation time for each gene specific primer pair, MgCl2 
concentration and number of Units/enzymes). The optimized procedures are 
shortly described below (see Table 4, 5, 6).  
 
per RT reaction (total volume 50μl) 
1. 33.2μl RNA (app. 300-500ng RNA in DEPC treated water) 
2. denaturation at 70°C for 5 min  
3. on ice for 10 min 
4. 2μl of random hexamer primer (500μg/ml stock in DEPC treated water)  
5. incubation at 70°C for 5 min 
6. on ice 
7. (no mastermix) 
8. 10μl of 5x RT Buffer 
9. μl of dNTP (10mM stock in DEPC treated water) 5
10. 0.3μl of 40U/μl RNasin (40U/μl stock) 
11. 1.5μl of AMV Reverse Transcriptase (9U/μl stock) 
12. cubation at 42°C for 60 min in
13. on ice 
14. inactivation at 95°C for 5 min 
15. short centrifugation step 
16. stored at -20°C. 
 
Table 4. Optimized standard reverse transcription reaction procedure 
 
per PCR-reaction (total volume 50μl) 
1.  1μl cDNA (appr. 5-10ng) 
2. 2μl of Fwd Primer (100μM stock) 
3. 2μl of Rev Primer (100μM stock) 
4. 44.6μl mastermix: 
 - 34.8μl of water 
 - 5μl of 10x Dynazyme Buffer with 15mM MgCl2
 - 3μl of 25mM MgCl  (final co2 ncentration 3mM) 
 - 1.8μl of 10mM dNTP Stock 
5. 0.4μl Dynazyme (3U/μl stock) 
6. PCR with optimum conditions for the certain primer (see table 6) 
 
Table 5. Optimized standard PCR reaction procedure  
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gene elongation time annealing temperature  
β-Actin 42 sec 50° C 
COX-2 30 sec 55° C 
GAPDH 45 sec 55° C 
HPRT 60 sec 50° C 
IκBα 50 sec 50° C 
ICAM-1 45 sec 55° C 
IL-6 50 sec 50° C 
iNOS 60 sec 50° C 
IP-10 45 sec 55° C 
IRAK-4 60 sec 50° C 
KC 45 sec 55° C  
MCP-1 45 sec 55° C 
M-CSF 45 sec 55° C 
MIP-1α 60 sec 50° C 
MIP-2 60 sec 50° C 
PARP-1 60 sec 50° C 
RANTES 60 sec 50° C 
TLR-2 45 sec 50° C 
TLR-4 45 sec 50° C 
TNF-α 60 sec 50° C 
 
Table 6. Optimized conditions for each gene-specific primer pair  
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6.3.1. Primer seque
Length in 
bp 
Fo rimer w-Primer 
nces 
 
Gene rward-P Revie
β-Actin 569 5’ A TGA CGA TAT 
CG
T GAG GTA GTC TGT 
-3’ 
-CAT GG
C-3’ 
5’-CA
CAG G
COX-2  5’ T CCT TGC TGT 
TCC AAT C-3’ 
A GAA GGC TTC CCA 
TT G-3’ 
-GCA AA 5’-GG
GCT T
GAPDH 983 5’ G TCG GAG TCA 
ACG GAT TTG G-3’ 
T GRG GGC CAT GAG 
AC CAC-3’ 
-TGA AG 5’-CA
GTC C
HPRT  5’ A TAC AGG CCA 
GAC TTT GTT G-3’ 
T TCA ACT TGC GCT 
TT AGG C-3’ 
-GTT GG 5’-GA
CAT C
IκBα  5’ C CTC AAC TTC 
CAG AAC AAC-3’ 
G ACG CTG GCC TCC 
AC ACA G-3’ 
-GCC TT 5’-CA
AAA C
ICAM-1 432 5’ G GAT CAC AAA 
CGA AGC-3’ 
 ATA AGA GGC TGC 
AC-3’ 
-TCG GA 5’-AAC
CAT C
IL-6  5’ A GCC AGA GTC 
CT AGA G-3’ 
 GGT TTG CCG AGT 
CT C-3’ 
-GAC AA
T CAG 
5’-CTA
AGA T
iNOS  5’-CCC TTC CGA AGT TTC 
TGG CAG CAG C-3’ 
C TGT CAG AGC CTC 
CT TTG G-3’ 
5’-GG
GTG G
IP-10  5’-C C CTG CCC ACG  ACC TCC ACA TAG 
 ACA G-3’ 
CT AT
TGT TGA G-3’ CTT
5’-CAC
IRAK-4  5’-GAT CCT CAA GAA GGG 5’-GCA AGC CCA AAG 
TGG AA-3’ 
TCA 
GAT AT-3’ 
KC 530 5’-AAC GGA GAA AGA AGA 
CAG ACT GC-3’ 
5’-GAC GAG ACC AGG AGA 
AAC AGG G-3’ 
MCP-1  5’-TCT CTT CCT CCA CCA 
CCA TGC AG-3’ 
5’-GGA AAA ATG CAT CCA 
CAC CTT GC-3’ 
M-CSF 726 5’-AGT GAG GGA TTT TTG 
ACC CAG G-3’ 
5’-CTA TAC TGG CAG TTC 
CAC CTG TC-3’ 
MIP-1α 294 5’-AAC ATC ATG AAG GTC 
TCC AC-3’ 
5’-CCA AGA CTC TCA GGC 
ATT CA-3’ 
MIP-2 468 5’-ACT TCA GCC TAG CGC 
CAT GG-3’ 
5’-AGG TCA GTT AGC CTT 
GCC TT-3’ 
PARP-1  5’-GCA GAG TAT GCC AAG 
TCC AAC AG-3’ 
5’-ATC CAC CTC GTC GCC 
TTT TC-3’ 
RANTES 293 5’-GGT ACC ATG AAG ATC 
TCT GCA-3’ 
5’-AAA CCT TCT ATC CTA 
GCT CAT-3’ 
TLR-2 390 5’-CAG ACG TAG TGA GCG 
AGC TG-3’ 
5’-GGC ATC GGA TGA AAA 
GTG TT-3’ 
TLR-4 406 5’-CGA ATG TCT CTG GCA 
GGT GTA-3’ 
5’-CAA GGG ATA AGA ACG 
CTG AGA-3’ 
TNF-α  5’-ATG AGC ACA GAA AGC 
ATG ATC CGC-3’ 
5’-CCA AAG TAG ACC TGC 
CCG GAC TC-3’ 
 
Table 7. The sequences of each primer pair used in this study 
 
6.3.2. Electrophoresis 
 
All PCR products were resolved by 1-2% agarose gel electrophoresis and 
DNA visualized by staining with ethidium bromide according to Sambrook, 
Maniatis and Russell “Molecular Cloning (Third Edition). The electrophoresis 
running time was usually 30min (at 100V). 
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Arginine methyltransferase CARM1 is a promoter-
specific regulator of NF-jB-dependent gene
expression
Marcela Covic1,4, Paul O Hassa1,4,
Simona Saccani2, Christine Buerki1,
Nadja I Meier1, Cornelia Lombardi1,
Ralph Imhof1, Mark T Bedford3,
Gioacchino Natoli2 and Michael O Hottiger1,*
1Institute of Veterinary Biochemistry and Molecular Biology, University
of Zurich, Zurich, Switzerland, 2Institute for Research in Biomedicine,
Bellinzona, Switzerland and 3Department of Carcinogenesis, University
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Nuclear factor kappaB (NF-jB) plays an important role in
the transcriptional regulation of genes involved in inflam-
mation and cell survival. Here, we show that coactivator-
associated arginine methyltransferase CARM1/PRMT4 is a
novel transcriptional coactivator of NF-jB and functions as
a promoter-specific regulator of NF-jB recruitment to
chromatin. Carm1 knockout cells showed impaired ex-
pression of a subset of NF-jB-dependent genes upon
TNFa or LPS stimulation. CARM1 forms a complex with
p300 and NF-jB in vivo and interacts directly with the
NF-jB subunit p65 in vitro. CARM1 seems to act in a gene-
specific manner mainly by enhancing NF-jB recruitment
to cognate sites. Moreover, CARM1 synergistically coacti-
vates NF-jB-mediated transactivation, in concert with the
transcriptional coactivators p300/CREB-binding protein
and the p160 family of steroid receptor coactivators. For
at least a subset of CARM1-dependent NF-jB target genes,
the enzymatic activities of both CARM1 and p300 are
necessary for the observed synergy between CARM1 and
p300. Our results suggest that the cooperative action
between protein arginine methyltransferases and protein
lysine acetyltransferases regulates NF-jB-dependent gene
activation in vivo.
The EMBO Journal (2005) 24, 85–96. doi:10.1038/
sj.emboj.7600500; Published online 16 December 2004
Subject Categories: chromatin & transcription
Keywords: CARM1; ChIP; p300; p65/RelA; methylation
Introduction
Nuclear factor kappaB (NF-kB) is a widely expressed, indu-
cible transcription factor, which plays a key role in the
transcriptional regulation of a variety of genes involved in
mammalian immune and inflammatory responses (Ghosh
et al, 1998). NF-kB has additionally been implicated as an
important regulator of cellular events such as apoptosis, cell
proliferation and differentiation (Baldwin, 1996). NF-kB is
composed of members of the Rel family, which in eukaryotes
includes p50/p105 (NF-kB1), p52/p100 (NF-kB2), Rel (c-Rel),
p65 (RelA) and RelB (Ghosh et al, 1998). These proteins share
a conserved 300 amino-acid region within their amino-termi-
ni, known as the Rel-homology domain (RHD), which med-
iates dimerization, nuclear translocation, DNA-binding and
interaction with heterologous transcription factors and NF-kB
inhibitors (Ghosh et al, 1998). The specificity of NF-kB-
dependent transcription is thought to be at least partially
due to differential homo- and heterodimerization of its family
members, leading to a range of DNA-binding and activation
potential (Karin, 1998). The most abundant and best-studied
form of NF-kB in cells is a ‘classical’ heterodimer consisting
of the two subunits p50 (NF-kB1) and p65 (RelA). Although
all Rel family members bind to DNA, only p65 (RelA), Rel
(c-Rel) and RelB contain a transactivation domain. In most
differentiated unstimulated cells, NF-kB is sequestered in
the cytoplasm as an inactive transcription factor complex
by its physical association with one of the several inhibitors
of NF-kB (IkB) (Baeuerle and Baltimore, 1988; Whiteside and
Israel, 1997). Treatment of cells with extracellular stimuli
such as cytokines, bacterial lipopolysaccharides (LPS) or
potent oxidants leads to the rapid phosphorylation of the
IkBs, which results in their ubiquitination and subsequent
degradation by the 26S-proteasome pathway (Karin, 1998;
Karin and Ben-Neriah, 2000). Consequently, NF-kB accumu-
lates in the nucleus, binds to specific kB consensus sequences
in the chromatin and activates specific subsets of genes.
The assembly of a higher order NF-kB transcription com-
plex is an important stage in NF-kB-dependent transcription,
involving multiple coactivator/cofactor–NF-kB–DNA interac-
tions (Merika et al, 1998; Agalioti et al, 2000; Merika and
Thanos, 2001). The two key coactivators of NF-kB, histone-
acetyltransferases p300 and its homolog, the CREB-binding
protein (CBP), directly associate with the NF-kB subunits p50
and p65 (Gerritsen et al, 1997; Perkins et al, 1997; Hassa et al,
2003). These coactivators are thought to promote the rapid
formation of the pre-initiation and re-initiation complexes by
bridging the sequence-specific activators (like NF-kB) to the
basal transcriptional machinery, thereby facilitating multiple
rounds of transcription (Goodman and Smolik, 2000).
Additionally, the histone acetyltransferases p300 and CBP
can modify the amino-terminal tails of nucleosomal histones,
thereby altering the local chromatin structure (Schiltz et al,
1999; Kundu et al, 2000). It was proposed that the coactivator
p300/CBP functions also as a signal integrator by coordinat-
ing diverse signal transduction events at the transcriptional
level (Goodman and Smolik, 2000). Phosphorylation of p65
by protein kinase A (PKA) has been shown to stimulate
NF-kB-dependent gene expression by enhancing p65 association
with p300/CBP (Zhong et al, 1998). Previous reports have
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shown that NF-kB-dependent transcriptional complexes also
require the p300/CBP-associated factor (P/CAF), the p160
family of steroid receptor coactivators and PC1/PARP-1
(Sheppard et al, 1999; Hassa et al, 2001, 2003). Thus, addi-
tional components might be required to stabilize the associa-
tion of distinct NF-kB coactivator complexes.
Coactivator-associated arginine methyltransferase
(CARM1/PRMT4) was identified as SRC-2/TIF2/GRIP1-bind-
ing protein and belongs to a family of arginine-specific
protein methyltransferases, which includes at least seven
members (PRMT1–7) (McBride and Silver, 2001; Miranda
et al, 2004). CARM1 has been shown to synergistically
stimulate transcription by nuclear receptors in combination
with the p160 family of coactivators and forms a ternary
complex with p300/CBP and SRC-2/TIF2/GRIP1 (Koh et al,
2001; Lee et al, 2002). After recruitment to the promoters
of estrogen-responsive genes, CARM1 methylates specific
arginine residues (Arg17 and Arg26) in the N-terminal tail
of histone H3 as part of the transcriptional activation process
(Bauer et al, 2002; Daujat et al, 2002). Recent studies broa-
dened the targets of the transcriptional coactivator function
of CARM1: CARM1 coactivates p53-dependent transcription
and cooperates with b-catenin to enhance transcriptional
activation by the lymphoid enhancer factor/T-cell factor
(LEF1/TCF4) (Koh et al, 2002; An et al, 2004). Mice with a
targeted disruption of Carm1 die during late embryonic
development or immediately after birth, supporting the idea
that CARM1 is a crucial coactivator for gene expression
during late embryonic development (Yadav et al, 2003).
Aberrant T-cell development in Carm1-deficient embryos
was due to a partial developmental arrest in the earliest
thymocyte progenitor subset, indicating that CARM1 plays a
significant role in promoting the differentiation of early
thymocyte progenitors (Kim et al, 2004).
Since the transcriptional coactivator CARM1 is capable of
forming a complex with the known coactivators of NF-kB,
p300/CBP and SRC-2, we tested whether CARM1 participates
in NF-kB-dependent gene activation. Our results show that
CARM1 directly binds to the NF-kB subunit p65 and syner-
gistically coactivates NF-kB-mediated transactivation, in con-
cert with the transcriptional coactivators p300/CBP and the
p160 family of steroid receptor coactivators. CARM1 is re-
sponsible for H3(R17) methylation of NF-kB target genes
in vivo and is required for NF-kB-regulated activation of a subset
of genes. CARM1 functions by enhancing NF-kB recruitment
to kB sites contained in H3(R17)-methylated promoters,
although additional roles downstream of p65 recruitment
mediated by its bridging factor/coactivator activity cannot
be ruled out. These results suggest that the cooperative action
between coactivators with histone arginine methyltransferase
activities and at least two distinct classes of transcription
coactivator molecules with histone acetyltransferase activ-
ities regulates NF-kB-dependent gene activation in vivo.
Results
NF-jB-dependent gene expression is impaired
in Carm1(/) cells
To test whether CARM1 influences NF-kB-dependent gene
expression, Carm1(þ /þ ) or Carm1(–/–) MEFs were treated
with LPS as indicated and the expression of NF-kB-dependent
genes was assessed by RT–PCR (Figure 1A). The experiments
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Figure 1 Impaired NF-kB-dependent gene expression in Carm1(/)
cells in response to proinflammatory stimuli. (A) Impaired
expression of MIP-2, MCP-1, G-CSF, ICAM1 and IP-10 in
Carm1(/) MEF cells in response to LPS. Carm1(þ /þ ) and
Carm1(/) MEF cells were treated with LPS (10 mg/ml) and
RNA isolated at the indicated time points, followed by RT–PCR
determination of MIP-2, MCP-1, G-CSF, ICAM1, IP-10, IL-6, KC,
COX-2, HPRT and b-actin mRNA. (B, C) Impaired NF-kB-dependent
gene expression in Carm1(/) cells in response to TNFa and LPS.
Carm1(þ /þ ) MEF cells (B) and Carm1(/) MEF cells (C) were
cotransfected with HIV-luc or HIVmut-kB-luc (2mg) and pphRSVnt-
b-gal (200 ng) together with CMV-CARM1 (500 ng) or CMV empty
vector as indicated. Cells were subsequently stimulated with TNFa
(10 ng/ml) or LPS (10mg/ml) 24 h after transfection for 8 h. The
indicated activation was determined by the ratio of the relative
luciferase activity measured for the HIV-luc (black bars) or HIVmut-
kB-luc (white bars) reporter gene after stimulation. The ratio
obtained for untreated cells was arbitrarily set to 1. Error bars
indicate s.e. of three independent experiments.
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revealed that LPS-induced levels of G-CSF, MIP-2, MCP-1,
ICAM1 and IP-10 were impaired in Carm1(–/–) cells
(Figure 1A). However, the expression of IkBa, IL-6, KC and
COX-2 was not reduced (Figure 1A), indicating that only a
subset of NF-kB-dependent genes requires CARM1 for induc-
tion. The expression of IkBa and IL-6 was even slightly
upregulated in Carm1(–/–) cells, a result confirmed by quan-
titative real-time PCR (Figure 1A and data not shown).
Similar results were obtained when cells were stimulated
with TNFa (see below). To further investigate the relevance of
CARM1 in NF-kB-dependent gene expression, Carm1(þ /þ )
or Carm1(–/–) cells were transfected with the indicated
NF-kB-dependent luciferase reporter constructs together
with an expression vector for CARM1, and subsequently
treated with the indicated stimuli (TNFa or LPS). Cell lysates
were tested for luciferase activity as a measure of NF-kB
activity (Figure 1B and C). Although TNFa and LPS were able
to induce NF-kB-dependent transcriptional activation in
Carm1(þ /þ ) cells (Figure 1B), the NF-kB-dependent tran-
scriptional activation was severely reduced in Carm1(–/–)
cells upon stimulation with TNFa or LPS (Figure 1C). Re-
expression of CARM1 in Carm1(–/–) cells synergistically
enhanced NF-kB-dependent transcriptional activation five-
fold in response to TNFa or LPS (Figure 1C). No synergistic
activation was observed in Carm1(þ /þ ) cells, indicating
that endogenous CARM1 levels are sufficient to provide
maximal coactivation (Figure 1B). The same transfection
experiments with a reporter gene under the control of mu-
tated kB sites revealed that the observed induction was
NF-kB-specific. Together, these results indicate that CARM1 is
required for NF-kB-dependent transactivation of extra-chro-
mosomal templates upon stimulation with proinflammatory
stimuli.
Normal NF-jB induction in Carm1(/) cells
To analyze whether the activation of the NF-kB-signaling
pathway is affected in Carm1(/) cells upon stimulation
with TNFa or LPS, we assessed the expression levels of
important components of the NF-kB-signaling pathway by
immunoblot and RT–PCR analysis (Figure 2A and B). The
immunoblot analysis of nuclear and cytoplasmic extracts of
Carm1(þ /þ ) and Carm1(/) cells revealed that p65,
c-Rel, RelB, p300 and PARP-1 are equally expressed in
Carm1(þ /þ ) and Carm1(/) cells (Figure 2A, left and
right panels). Additionally, these experiments showed that
there is equivalent nuclear translocation of NF-kB in
Carm1(þ /þ ) and Carm1(/) cells. Moreover, the expres-
sion levels of upstream signaling components, TLR-2, TLR-4
and IRAK4 mRNA, was not impaired in Carm1(/) cells
(Figure 2B, right panel), compared to Carm1(þ /þ ) cells
(Figure 2B, left panel). We then investigated whether the
degradation of IkBa might be affected due to the absence of
CARM1. Carm1(þ /þ ) and Carm1(/) cells were treated
with TNFa or LPS for the indicated time points and the
protein levels of IkBa subsequently tested by immunoblot
analysis (Figure 2C). No differences in degradation and re-
synthesis of IkBa could be observed between Carm1(þ /þ )
and Carm1(/) cells upon stimulation with TNFa
(Figure 2C) or LPS (data not shown). To further investigate
whether the activation of the NF-kB-signaling pathway is
affected in Carm1(/) cells upon stimulation, we analyzed
the kinetics of nuclear translocation of p65 in Carm1(þ /þ )
and Carm1(/) cells by immunofluorescence analysis.
Kinetics of p65 nuclear entry in Carm1(/) cells was
comparable to that observed in Carm1(þ /þ ) cells
(Figure 2D). Finally, we tested whether the DNA-binding
activity of NF-kB on naked templates is affected in
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Figure 2 Expression levels of components of the NF-kB signaling pathway and nuclear–cytoplasmic shuttling of NF-kB is not affected in
Carm1(/) MEFs. (A) Protein expression levels of p65, c-Rel, RelB, p300 and PARP-1 are not affected in Carm1(/) MEF cells. Carm1(þ /þ )
and Carm1(/) MEF cells were treated with TNFa (10 ng/ml) for 20 min and cytoplasmic and nuclear extracts resolved by SDS–PAGE
followed by subsequent immunoblot analysis for p65, c-Rel, RelB, p300 and PARP-1 (A, left and right panels). a-Tubulin was used as an internal
standard. (B) mRNA expression levels of TLR4, TLR2 and IRAK4 are not impaired in Carm1(/) MEF cells. Carm1(þ /þ ) and Carm1(/)
MEF cells were treated with TNFa (10 ng/ml) (B, left and right panels) and RNA isolated at the indicated time points followed by RT–PCR
analysis for TLR4, TLR2, IRAK4 and HPRT (B, left and right panels). (C) Degradation and re-synthesis of IkBa is not affected in Carm1(/)
MEF cells. Carm1(þ /þ ) and Carm1(/) MEF cells were treated with TNFa (10 ng/ml) (C, left and right panels) and whole-cell extracts
isolated at the indicated time points and resolved by SDS–PAGE, followed by subsequent immunoblot analysis for IkBa. a-Tubulin was used as
an internal standard. (D) Nuclear translocation of NF-kB is not delayed in Carm1(/) MEFs. Carm1(þ /þ ) and Carm1(/) MEF cells were
treated with TNFa (10 ng/ml) (D, upper and lower panels) and fixed with paraformaldehyde at the indicated time points followed by
immunostaining for p65 and analysis by immunofluorescent microscopy.
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Carm1(/) cells. EMSA studies with DNA oligos corre-
sponding to the kB sites in IL-6, IP-10 and MIP-2 promoter
revealed no differences between Carm1(þ /þ ) and
Carm1(/) cells in DNA-binding activity of NF-kB (p50/p65)
to nonchromatinized templates (data not shown).
CARM1 forms a complex with NF-jB in vivo and binds
directly to p65 in vitro
To investigate whether CARM1 physically interacts with NF-
kB in vivo, we immunoprecipitated CARM1 complexes from
nuclear extracts upon stimulation of 293T cells with TNFa
and tested the presence of p65 and p300 by immunoblot
analysis using anti-p65, anti-CARM1 or anti-p300 antibodies.
p65 and p300 formed a complex with CARM1 in the nucleus
(Figure 3A). DNA did not mediate the association of p300 and
p65 with CARM1 in the nucleus since the presence of
ethidium bromide or DNAse1 did not affect p300/p65/
CARM1 binding (data not shown). As these results strongly
suggested that CARM1 would directly interact with at least
one subunit of NF-kB, recombinant purified GST-p65 full
length was bound to glutathione beads, followed by incuba-
tion with recombinant purified full-length His-CARM1
(Figure 3B). After extensive washes, bound proteins were
resolved by SDS–PAGE, followed by immunoblot analysis for
CARM1. CARM1 was able to bind directly to the NF-kB
subunit p65 but not to the GST control (Figure 3B). To map
the interaction domains within p65 and CARM1, GST and
GST-fusion proteins expressing either the Rel-homology do-
main of p65 (RHD; aa 1–305), or the transactivation domain
of p65 (aa 441–551), were used in GST pull-down experi-
ments with in vitro translated full-length CARM1 or deletion
mutants corresponding to the N-terminal domain (aa 1–148),
catalytic domain (aa 140–480) or transactivation domain
(aa 462–608), respectively. These experiments revealed that
a region between aa 148 and 462 containing the catalytic
domain but not the N- or C-terminal domain of CARM1 was
able to selectively interact with the RHD of p65 (Figure 3C),
confirming that the interactions described above were direct
and not mediated by other proteins.
CARM1 coactivates NF-jB synergistically
with p300/CBP
CARM1 and p300/CBP were recently shown to form a ternary
complex and to function synergistically to enhance the activ-
ity of nuclear receptors (Lee et al, 2002). Thus, CARM1 in
combination with p300 might also synergistically coactivate
NF-kB-mediated transactivation. In order to directly test this
possibility, we transfected Carm1(þ /þ ) and Carm1(/)
cells with expression vectors for CARM1 and p300 along with
a NF-kB-dependent luciferase reporter; cells were subse-
quently treated with TNFa or LPS (Figure 4A and B). p300
and CARM1 synergistically stimulated NF-kB-mediated tran-
scription in response to TNFa or LPS (Figure 4A and B).
Expression of p300 synergistically enhanced reporter gene
expression (up to three-fold) in Carm1(þ /þ ) cells in re-
sponse to TNFa or LPS (Figure 4A and B, left panel).
However, in Carm1(/) cells, the synergy between p300
and TNFa or LPS was severely impaired (Figure 4A and B,
right panel). Coexpression of CARM1 together with p300
caused a highly synergistic enhancement in Carm1(/)
cells (Figure 4A and B, right panel), indicating that the
presence of CARM1 itself is required for the synergistic
transcriptional activation of NF-kB by p300 (Figure 4A
and B).
To confirm these results, experiments were repeated over-
expressing p65 without exogenous stimulation. The amount
of p65 expression vector strongly influenced the degree of
cooperation among these coactivators; as previously shown
for nuclear receptors (Lee et al, 2002), high synergistic
enhancement of transcriptional coactivation was obtained
only under conditions where limiting levels of p65 were
expressed (data not shown). Therefore, we decided to pro-
ceed with low amounts of p65 expression vectors for all the
following experiments. Carm1(þ /þ ) and Carm1(/) cells
were transfected with expression vectors for CARM1, p65 and
p300 along with a NF-kB-dependent luciferase reporter con-
taining wild-type or mutated kB sites. In the absence of
cotransfected coactivator, the low levels of p65 used pro-
duced only a slight increase (4.5-fold) in luciferase activity in
Carm1(þ /þ ) cells (Figure 4C, left panel). No significant
increase (1.5-fold) in luciferase activity could be observed in
Carm1(/) cells (Figure 4C, right panel). Coexpression of
CARM1 with p65 augmented NF-kB-dependent transcrip-
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WB: anti-p300
WB: anti-p65
WB: anti-CARM1
In
pu
t
Co
nt
ro
l
CA
RM
1
IP
Input GST p65 full length
Input GST RHD TA
CARM1 aa 1−148
CARM1 aa 140−480
CARM1 aa 462−608
CARM1 full length
A
B
C
Figure 3 CARM1 forms a complex with NF-kB in vivo and directly
binds to the NF-kB subunit p65 in vitro. (A) CARM1 and p65 form a
complex in vivo. p65, CARM1 and p300 were coimmunoprecipitated
(IP) in the presence of 120 mM NaCl from nuclear extract of TNFa-
treated 293Tcells (30 min, 10 ng/ml) using control IgGs and an anti-
CARM1 antibody. Bound proteins were resolved by SDS–PAGE and
subsequently detected by immunoblot (IB) analysis for p65, CARM1
and p300. Input lanes represent 10% of the input. (B) CARM1
directly binds to p65. Pull-down assays with purified GST and p65
full-length fused to GST (1mg) and purified recombinant CARM1
full-length (0.1mg) in the presence of 120 mM NaCl. Bound proteins
were resolved by SDS–PAGE and detected by immunoblot analysis
for CARM1. Input lanes represent 1% of the input. (C) The central
domain of CARM1 binds to the RHD domain of p65. Pull-down
assays with GST, the Rel-homology domain of p65 (RHD; aa 1–305)
or the transactivation domain of p65 (TA; aa 441–551) fused to GST
(1mg) and different in vitro-translated CARM1 deletion mutants
(N-terminal domain (aa 1–148), catalytic domain (aa 140–480) or
transactivation domain (aa 462–608), respectively) in the presence
of 120 mM NaCl. Bound proteins were resolved by SDS–PAGE
visualized by autoradiography. Input lanes represent 1% of the
input.
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Figure 4 CARM1 synergistically coactivates the NF-kB-mediated transactivation, in concert with the transcriptional coactivator p300/CBP.
(A, B) CARM1 synergistically activates together with p300 NF-kB-dependent gene expression in response to proinflammatory stimuli.
Carm1(þ /þ ) MEF cells (left panel) and Carm1(/) MEF cells (right panel) were cotransfected with HIV-luc or HIVmut-kB-luc (2mg) and
pphRSVnt-b-gal (200 ng), together with CMV-CARM1 (200 ng) and RSV-p300 (500 ng) or CMV and RSV empty vectors as indicated. Cells were
subsequently stimulated with TNFa (10 ng/ml) (A) or LPS (10mg/ml) (B) 24 h after transfection for 8 h. Cells were harvested 32 h after
transfection and the indicated activation of NF-kB-dependent gene expression determined as described in Figure 1. (C) CARM1 synergistically
activates together with p300 and p65-dependent gene expression. Carm1(þ /þ ) MEF cells (left panel) and Carm1(/) MEF cells (right
panel) were cotransfected with HIV-luc or HIVmut-kB-luc (2 mg) and pphRSVnt-b-gal (200 ng) together with CMV-p65 (80 ng) CMV-CARM1
(200 ng) and RSV-p300 (500 ng) or CMVand RSVempty vectors as indicated. The indicated activation of NF-kB-dependent gene expression was
determined as described in Figure 1.
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tional activation in Carm1(/) cells to a similar extent as
observed in Carm1(þ /þ ) cells with p65 alone (Figure 4C,
left panel). Coexpression of p300 with p65 synergistically
enhanced reporter gene expression (four-fold) in Carm1(þ /þ )
cells (Figure 4C, left and right panels), whereas no
synergistic enhancement could be observed in Carm1(/)
cells (Figure 4C, right panel). However, addition of CARM1
with p300 caused a highly synergistic enhancement in
Carm1(/) cells (Figure 4C, right panel). No synergistic
activation was observed in Carm1(þ /þ ) cells, indicating
that endogenous CARM1 is sufficient to provide maximal
coactivation (Figure 4C, left panel). When p300 was substi-
tuted for CBP, a similar level of synergy was observed (data
not shown).
CARM1 and SRC-2/TIF2/GRIP1 synergistically
coactivate NF-jB-mediated transactivation
Next, we tested whether the combined coexpression of p65
together with CARM1, p300 and p160 family members might
result in even stronger synergistic coactivation of NF-kB.
Coexpression of SRC-2/TIF2/GRIP1 with p65 and p300
resulted in a additional (three-fold) synergistic increase in
NF-kB activity in Carm1(þ /þ ) cells (Figure 5A), compared
to coexpression of p65 and p300. This could not be observed
in Carm1(/) cells (Figure 5B). This synergy between p300
and p160 family members observed in Carm1(þ /þ ) cells is
in agreement with recent reports, showing that NF-kB-depen-
dent transcriptional activity requires p300/CBP but also the
p160 family of steroid receptor coactivators (Sheppard et al,
1999). Remarkably, strong synergistic coactivation of NF-kB
by p300 and SRC-2/TIF2/GRIP1 could be observed in
Carm1(/) cells only when CARM1 was present (Figure 5B),
while additional expression of CARM1 did not enhance NF-
kB-dependent transcriptional activation in Carm1(þ /þ )
cells (Figure 5A). Combined coexpression of p65 together
with CARM1, p300 and other p160 family members
in Carm1(/) cells led to similar results, although the
additional synergistic coactivation of NF-kB by SRC-1/
NCoA-1 or SRC-3/p/CIP/RAC-3 was not as high as observed
for SRC-2/TIF2/GRIP1 (data not shown). To further confirm
the relevance of CARM1 for synergistic coactivation of NF-kB
by p300 and p160 family members, we repeated these experi-
ments in the monkey COS-1 cells (Figure 5C). The results of
these experiments revealed that combined expression of p65
together with all three coactivators in COS-1 cells led to a
similar level of coactivator synergy as observed in Carm1(/)
cells (Figure 5C). Coexpression of CARM1 resulted in a strong
synergistic coactivation, despite endogenous CARM1 expres-
sion in these cells. Thus, the endogenous levels of CARM1
seem to be limiting in these cells. Together, these results
strongly suggest that CARM1 is required for synergistic
coactivation of NF-kB-dependent gene activation by p300/
CBP and p160 family members.
CARM1 is required for H3(R17) methylation and
recruitment of p65 to the MIP-2 and IP-10 promoters
We next tested both CARM1 and p65 recruitment as well as
H3(R17) methylation at NF-kB-dependent genes using quan-
titative chromatin immunoprecipitation (ChIP) assays. First,
we confirmed by real-time PCR the CARM1 dependency of
NF-kB-dependent gene induction in TNFa-stimulated cells.
While MIP-2, IP-10 and MCP-1 mRNA induction in response
to TNFa was nearly completely abrogated in Carm1(/)
cells, IL-6 mRNA expression was not affected or even in-
creased in Carm1(/) cells, thus strengthening the concept
that CARM1 requirement is strictly gene-specific (Figure 6A).
An anti-CARM1 ChIP assay revealed that CARM1 is not only
recruited to the CARM1 dependent MIP-2 and IP-10 promo-
ters but also to the CARM1 independent IL-6 promoter in
Carm1(þ /þ ) cells, upon stimulation (Figure 6B). We next
investigated H3(R17) methylation at all three genes using a
ChIP assay with an antibody recognizing H3(R17) only when
methylated. A strong increase in H3(R17) methylation was
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Figure 5 CARM1 synergistically coactivates NF-kB-dependent tran-
scription in concert with the transcriptional coactivators p300/CBP
and the p160 family of steroid receptor coactivators. (A, B) CARM1
synergistically activates together with p300 and SRC-2 p65-depen-
dent gene expression. Carm1(þ /þ ) MEF cells (A) and Carm1(/)
MEF cells (B) were cotransfected with HIV-luc or HIVmut-kB-luc
(2mg) and pphRSVnt-b-gal (200 ng), together with CMV-p65 (80 ng),
CMV-CARM1 (200 ng), CMV-SRC-2 (300 ng) and RSV-p300 (500 ng)
or CMV and RSV empty vectors as indicated. Cells were harvested
32 h after transfection and the indicated activation of NF-kB-depen-
dent gene expression determined as described in Figure 1.
(C) CARM1 synergistically activates together with p300 and p65
NF-kB-dependent gene expression in COS-1 cells. COS-1 cells were
cotransfected with HIV-luc or HIVmut-kB-luc (2mg) and pphRSVnt-
b-gal (200 ng) together with CMV-p65 (50 ng) CMV-CARM1
(200 ng), CMV-SRC-2 (300 ng) and RSV-p300 (500 ng) or CMV and
RSV empty vectors as indicated. The indicated activation of NF-kB-
dependent gene expression was determined as described in Figure 1.
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Figure 6 CARM1 functions in a gene-specific manner. (A) Quantification of TNFa-stimulated MIP-2, IP-10, MCP-1 and IL-6 transcription
Carm1(þ /þ ) MEF cells (filled circles) and Carm1(/) MEF cells (empty circles) by real-time PCR. (B) Quantitative ChIP assays with anti-
CARM1 antibodies were performed for the indicated genes on TNFa-stimulated Carm1(þ /þ ) (filled circles) and Carm1(/) MEF cells
(empty circles). (C) Anti-methyl-H3(R17) ChIP assay for the indicated genes on TNFa-stimulated Carm1(þ /þ ) (filled circles) and Carm1(/)
MEF cells (empty circles). (D) ChIP assays with anti-p65 antibodies were performed for the indicated genes on TNFa-stimulated Carm1(þ /þ )
(filled circles) and Carm1(/) MEF cells (empty circles).
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found to occur on MIP-2, IP-10 and IL-6 promoters in TNFa
stimulated Carm1(þ /þ ) cells (Figure 6C). No H3(R17)
methylation could be detected on either gene in Carm1(/)
cells, indicating that methylation of H3(R17) is entirely
CARM1-dependent (Figure 6C). Surprisingly, an anti-p65
ChIP assay revealed a major defect in p65 recruitment to
the MIP-2 and IP-10 promoters in Carm1(/) cells
(Figure 6D), whereas no significant differences could be
observed at IL-6 between Carm1(þ /þ ) and Carm1(/)
cells (Figure 6D), thus indicating that the mechanism under-
lying CARM1 requirement for transcriptional induction
differs depending on the gene. While these results implicate
that CARM1 functions in a gene-specific manner by enhan-
cing NF-kB recruitment to regulatory sites, possibly through
an increase in kB site accessibility, they do not rule out the
possibility that further effects downstream of NF-kB recruit-
ment also occur. Moreover, the results obtained with IL-6
indicate that H3(R17) methylation may not be required for
the activity of all promoters at which it occurs.
The enzymatic activities of CARM1 and p300/CBP are
required for full cooperativity and NF-jB-dependent
transcription
Since our ChIP study revealed induced methylation of
H3(R17) upon stimulation, the observed cooperativity be-
tween CARM1 and p300/CBP regarding NF-kB-dependent
gene expression might require their enzymatic activities.
We first tested whether in transient luciferase reporter assays
the IL-6-, MIP-2 and IP-10 promoters are regulated in
Carm1(þ /þ ) and Carm1(/) cells, similarly as their
endogenous counterparts (Figure 7A). These experiments
revealed that all promoters requiring CARM1 for activity were
similarly dependent on CARM1 when taken out of their
natural context and tested in reporter assays. Re-expression
of CARM1 in Carm1(/) cells fully rescued stimulus-in-
duced activation of the MIP-2 and IP-10 promoter in
Carm1(/) cells (Figure 7A). We next transfected
Carm1(/) cells with expression vectors for p65, wild-
type or enzymatic mutants of CARM1 and/or p300 along
with a luciferase reporter under the control of the endogen-
ous MIP-2 or IP-10 promoter (Figure 7B and C). Coexpression
of wild-type CARM1 and p300 together with limiting levels of
p65 in Carm1(/) cells caused a highly synergistic en-
hancement of transcription regulated from both MIP-2 and
IP-10 promoters (Figure 7B and C). However, the cooperativ-
ity/synergy between p300 and CARM1 was severely impaired
when an enzymatic mutant form of either CARM1 or p300
was coexpressed. Coexpression of an enzymatic mutant form
of both CARM1 and p300 caused an even more severe
reduction in p65-dependent activation of the IP-10 and MIP-
2 promoter, indicating that the enzymatic activities of both
CARM1 and p300/CBP are required for full synergistic
enhancement of NF-kB-dependent transcription.
To rule out the possibility that the observed effects were
due to an impaired binding of p65 to the enzymatic mutants
of CARM1 or p300, we performed co-immunoprecipitation
assays with nuclear extracts isolated from TNFa stimulated
293T cells expressing either myc-tagged wild-type or enzy-
matic mutant forms of both, CARM1 or p300, respectively.
Both wild-type and enzymatic mutant forms of CARM1 and
p300 formed a comparable complex with p65 in the nucleus
(Figure 7D left and right panels).
Discussion
The aim of this study was to investigate the role of CARM1, a
coactivator for p53- and nuclear receptor-dependent tran-
scription, in NF-kB-dependent gene (Koh et al, 2001; An
et al, 2004). We provide both biochemical and genetic
evidence that CARM1 is an essential NF-kB coactivator and
a promoter-specific regulator of NF-kB recruitment to chro-
matin.
Impaired NF-jB-dependent transcription
in Carm1-deficient cells
An impaired expression of ICAM-1, G-CSF, MCP-1, IP-10 and
MIP-2 was found in TNFa or LPS stimulated Carm1(/)
fibroblasts. Similarly, NF-kB-dependent reporter gene activity
upon LPS or TNFa stimulation was four- to five-fold lower in
Carm1(/) cells than in wt cells. Interestingly, the expres-
sion of IkBa, IL-6, KC and COX-2 was not reduced in
Carm1(/) fibroblasts upon stimulation, indicating that
only a subset of NF-kB-dependent genes is dependent on
CARM1. It is unlikely that the canonical pathway of NF-kB
transduction cascade is affected by lack of CARM1 since the
upstream signaling transducers tested are equally expressed
and IkBa degradation and re-synthesis as well as nuclear
entry of p65/RelA was similar in Carm1(þ /þ ) and
Carm1(/) cells. Moreover, the DNA-binding activity of
NF-kB(p65/p50) assayed in vitro on naked non-chromati-
nized templates was not impaired in nuclear extracts from
Carm1(/) fibroblasts, irrespective of the kB site tested.
CARM1 forms a complex with p65 in vivo and in vitro
We could detect endogenous CARM1 in a nuclear complex
with p65 and p300, upon TNFa stimulation. Moreover,
CARM1 directly binds to the Rel homology domain p65
in vitro. The interaction is mediated through the central region
Figure 7 Enzymatic activities of CARM1 and p300/CBP are required for full cooperativity between CARM1 and p300. (A) Carm1(þ /þ ) MEF
cells (black bars) and Carm1(/) MEF cells (dashed bars) were cotransfected with pGL3-MIP-2(770), pGL3-IP-10(533) or pOLUC-IL-
6(303/þ 23) (5mg) and pphRSVnt-b-gal (200 ng) alone or together with CMV-CARM1 (200 ng) or CMV empty vectors as indicated. Cells were
subsequently stimulated with TNFa (10 ng/ml) for 6 h. Cells were harvested 32 h after transfection and the indicated activation of NF-kB-
dependent gene expression determined as described in Figure 1. (B, C) Enzymatic activities of CARM1 and p300/CBP are required for full
cooperativity between CARM1 and p300. Carm1(/) MEF cells were cotransfected with pGL3-MIP-2(770) (B) or pGL3-IP-10(533)
(C) (5 mg) and pphRSVnt-b-gal (200 ng), together with CMV-p65 (80 ng) CMV-CARM1-WT or CARM1-E267Q (200 ng), CMV-p300-WT
or p300mutAT2 (750 ng) and CMV empty vectors as indicated. Cells were harvested 32 h after transfection and the indicated activation of
NF-kB-dependent gene expression determined as described in Figure 1. (D) Both wild type and mutant forms of CARM1 and p300 interact to
the same extent with p65 in vivo. 293T cells were transfected with CMV expression vectors, either for wild type or enzymatic mutant forms of
myc tagged p300 (left panel) or CARM1 (right panel) as well as pphCMV-kozak-myc empty vector. p65, CARM1 and p300 were coimmunopre-
cipitated (IP) from nuclear extract of TNFa-treated 293Tcells (30 min, 10 ng/ml) using an anti-myc antibody. Bound proteins were resolved by
SDS–PAGE and subsequently detected by immunoblot (IB) analysis for p65, CARM1 and p300. Input lanes represent 10% of the input.
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of CARM1 containing the methyltransferase domain. Since
this region is very conserved among members of the PRMT
family (Zhang et al, 2000), p65 might also interact with other
members such as PRMT1. The interaction between full-length
p65 and CARM1 was weaker in vitro, when compared to the
interaction in vivo. It is possible that the interaction between
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p65 and CARM1 might be modulated or stabilized by post-
translational modifications of p65. Whether this modification
could be phosphorylation of the Rel homology domain of p65
by protein kinase A (PKA) has yet to be investigated.
Phosphorylation of p65 by PKA was shown to open the p65
structure and increase the efficiency of interaction with p300/
CBP (Zhong et al, 1998). Whether p65, CARM1 and p300
exist in a single complex or different p65/CARM1 and p300/
CARM1 complexes form during the transcriptional activation
process in vivo remains to be elucidated.
Cooperation between CARM1, p300/CBP and p160
family of coactivators in NF-jB-mediated transcription
Depending on the stimulus and the cell type, multiple inter-
actions and the combined actions of distinct transcriptional
coactivators seem to be required for the assembly of NF-kB
transcription complexes and transcriptional activity of NF-kB.
The current study shows that CARM1 synergistically coacti-
vates NF-kB-mediated transactivation, in concert with p300/
CBP and the p160 family members. CARM1 was previously
shown to function as a secondary coactivator for nuclear
receptors (NRs) cooperating with p160 coactivators and
p300/CBP under conditions where limiting levels of the
NRs are expressed (Lee et al, 2002). Similarly, high synergis-
tic enhancement of NF-kB coactivation by CARM1 and pro-
tein acetyltransferases was obtained only under conditions
where limiting levels of p65 were expressed (data not
shown).
Although NRs and NF-kB utilize similar sets of coactiva-
tors, there are qualitative differences in the assembly process
of each coactivator component by NRs and NF-kB. p160
family members are shown to act as primary coactivators
for nuclear receptors and recruit the secondary coactivators
CBP/p300 and CARM1 (Lee et al, 2002). In contrast, p300/
CBP serves as primary coactivator for NF-kB and provides a
platform for the secondary coactivators p/CAF and p160
family members (Sheppard et al, 1999). Moreover, CARM1
directly interacts with the NF-kB subunit p65 in vitro and
might act as a primary coactivator for NF-kB.
CARM1 coactivates NF-jB in a promoter-specific
manner
At the estrogen-responsive promoter pS2 and p53-dependent
promoter GADD45, CARM1 recruitment was shown to follow
ER or p53 recruitment, respectively. Thus, CARM1 seems to
be recruited by ER or p53 to these promoters (Daujat et al,
2002; Metivier et al, 2003; An et al, 2004). Surprisingly, our
ChIP data revealed a major defect in p65 recruitment to the
CARM1-dependent MIP-2 and IP-10 promoters in Carm1(/)
fibroblast upon TNFa stimulation. In contrast, no signifi-
cant differences could be observed at the IL-6 promoter
between Carm1(þ /þ ) and Carm1(/) fibroblasts. Since
NF-kB dimers from Carm1(/) cells retained full DNA-
binding activity in EMSA, it can be assumed that one critical
role of CARM1 in vivo is to promote NF-kB recruitment to
selected target genes that, due to their chromatin configura-
tion, are unable to recruit NF-kB ‘by default’. This does not
rule out the possibility that CARM1 exerts additional essential
activities required for NF-kB to activate transcription after it
is recruited to chromatin. While H3(R17) methylation at the
IL-6 promoter is not important for p65 recruitment, in the
case of the IP-10 and MIP-2 promoters the modification of H3
seems to be required. This might be due to a different histone
positioning on the IL-6 promoter or due to an ‘open’ and
acessible chromatin conformation maintained by other tran-
scription factors. In contrast, at the IP-10 and MIP-2 promo-
ters, Arg methylation and most likely subsequent
modifications of H3 and other histones might enhance kB
site accessibility. The specific determinants dictating CARM1
dependency of NF-kB-regulated genes remain to be defined.
The importance of CARM1 enzymatic activity for NF-kB-
dependent transcription is supported by complementation
experiments in CARM1(/) cells using an enzymatic mu-
tant of CARM1 and p300. Full synergistic enhancement of
transcription regulated from the MIP-2 and IP-10 promoters
was obtained only when wild-type forms of both CARM1 and
p300 were coexpressed in CARM1(/) cells. Thus, for at
least a subset of CARM1-dependent NF-kB target genes, the
enzymatic activities of both CARM1 and p300 are necessary
for NF-kB-dependent transcription. However, transiently
transfected plasmids are thought not to be properly chroma-
tinized, suggesting that nucleosomal histones are unlikely to
represent the only relevant substrates whose Arg methylation
is required for NF-kB-dependent transcription (Smith and
Hager, 1997; Nan et al, 2004). Studies regarding the require-
ment of CARM1-dependent methylation of nonhistone pro-
teins such as p300/CBP (Xu et al, 2001; Chevillard-Briet et al,
2002) in NF-kB-dependent transcription are ongoing. Since
the enzymatic mutant of CARM1 could still partially contri-
bute to NF-kB-dependent transcription, similar to p300/CBP,
CARM1 might also act downstream of NF-kB recruitment as a
bridging factor. In addition to central methyltransferase/p65-
binding domain, the unique N- and C-terminal regions of
CARM1 were recently shown to be also required for enhance-
ment of transcriptional activation by nuclear receptors
(Teyssier et al, 2002). The C-terminal part of CARM1 contains
a transactivation domain, which might interact with not yet
identified cofactors, thereby driving the equilibrium toward
formation of the fully competent NF-kB-dependent coactiva-
tor-complex(es).
Interestingly, CARM1 was recruited in a stimulus-depen-
dent manner to all tested promoters, and recruitment corre-
lated with an increase in H3(R17) methylation. Given our
results, it seems plausible that CARM1 recruitment to the
MIP-2 and IP-10 promoters may be independent of p65 and
precede p65 recruitment. It remains to be investigated
whether other sequence-specific transcription factors known
to cooperate with NF-kB in gene induction, such as STAT1,
IRF3 or AP1, are required for CARM1 recruitment to those
promoters. The IL-6 promoter reflects a complete different
situation, where the TNFa-induced recruitment of CARM1
coincides with p65 recruitment in both Carm1(þ /þ ) and
Carm1(/) fibroblasts. This could imply that p65 itself
might recruit CARM1 to the IL-6 promoter.
It is of great interest to elucidate the relationship of CARM1
to other NF-kB-associated coactivators regarding their rela-
tive contribution to NF-kB-dependent gene activation, with
respect to different promoters and stimuli. A combination of
microarray and genomewide Chip studies using conditional
single, double or triple knockout mice or conditional knockin
mice expressing enzymatic mutants of particular coactivators
could verify their relative contribution and identify the se-
quential order of particular promoter-specific recruitment
cascades in vivo.
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Materials and methods
Plasmids
Expression vectors for p300 and p65 were described in Hassa et al
(2003). pphRSV-nt-bgal and the NF-kB-dependent luciferase repor-
ter constructs HIV-luc and HIV-mutkB-luc are described in Hassa
et al (2001). pGL3-MIP-2(770), pGL3-IP-10(533) and pOLUC-IL-
6(303/þ 23) are described in Han et al (1999), Borgland et al
(2000) and Walpen et al (2001). The different CMV-myc expression
vectors for CARM1 were obtained by cloning the corresponding
PCR products (CARM1 full-length, CARM1—aa 1–148, CARM1—aa
140–480 and CARM1—aa 462–608) in frame into pphCMV-T7-km-3
(Hassa et al, 2003). The enzymatic mutant form (E267Q) of CARM1
was created by site-directed mutagenesis as described in Lee et al
(2002) and verified by sequencing. The CMV-kozak-myc-p300 wild
type and p300mutAT2 (enzymatic mutant) were obtained by
cloning the corresponding PCR products into pphCMV-T7-km-3.
pBKS-p300mutAT2 is described in Kraus et al (1999). GST-fusion
vectors for p65—aa 1–305 and p65—aa 441–551 were obtained by
cloning the corresponding PCR products into pGex6P1.
Cell culture and transient transfection
Carm1(þ /þ ) or Carm1(–/–) MEFs, 293Tand COS-1 were grown in
DMEM (Invitrogen). Cells were transfected as described previously,
except that MEFs were grown for 12 h in DMEM containing 2% fetal
calf serum before stimulation with TNFa or LPS (purchased from
Sigma). The amount of DNA indicated in the figure legends was
calculated for 10 ml of medium. Total amounts of DNA and equal
molar ratios of promoters were kept constant in all setups by using
empty vectors. For MEFs, only cell passages 2–5 were used for
experiments. Owing to differences in transfection efficiencies, an
expression plasmid of b-galactosidase (pph-RSV-nt-b-gal) was
cotransfected as a transfection efficiency control, and luciferase
activities were normalized based on b-galactosidase activity.
Luciferase activity was measured as described in Hottiger et al
(1998).
RNA isolation and RT–PCR analysis
RNA isolation and RT–PCR from Carm1(þ /þ ) or Carm1(–/–)
MEFs was performed according to the manufacturer’s protocols
(Invitrogen). Sequences of primers are available upon request. All
PCR products were resolved by 1–2% agarose gel electrophoresis,
and DNA bands were visualized by staining the gel with ethidium
bromide.
Nuclear extracts, immunoprecipitation and immunoblotting
Nuclear, cytoplasmic and whole-cell extracts were prepared as
described in Hottiger et al (1998) and Hassa et al (2003). All
immunoprecipitation and immunoblotting analysis for CARM1,
PARP-1, p65, c-Rel, RelB and p300 were performed as described
previously (Hottiger et al, 1998; Hassa et al, 2003). Anti-RelA/p65
(C-20, sc-372), anti-p300 (sc-C260), mouse IgG (sc-2025), rabbit IgG
(sc-2027), anti-c-Myc IgG (sc-2027) and anti-a-tubulin (sc-8035)
antibodies were obtained from Santa Cruz Biotechnology; anti-
PARP-1 antibody (clone C-2–10) was from Anawa trading SA
(Switzerland) and anti-p300 antibody (14991A) was from BD
PharMingen. The anti-CARM1 antibodies were either described in
Kim et al (2004) or a generous gift from Dr S Richard (McGill
University, Quebec, Canada) and Dr M Stallcup (University of
Southern California, USA). The anti-dimethyl-H3-Arg17 antibody
(07-214) was from Upstate. The anti-RelB and anti-c-Rel antibodies
were kindly provided by Dr NR Rice (National Cancer Institute at
Frederick, USA).
In vitro interaction and GST pull-down assay
Recombinant His-mCARM1 and GST-p65 full-length proteins were
expressed in Sf21 cells. GST-p65—aa 1–305, -p65—aa 1–441 and
-p65—aa 441–551 proteins were expressed in Escherichia coli and
purified according to the manufacturer’s protocols (Novagen,
Amersham/Pharmacia Biosciences). All purified proteins were
confirmed by Coomassie staining and Western blot analysis using
the corresponding antibodies. Coupled in vitro transcription/
translation reactions were carried out using the TNT T7-Quick
system (Promega) according to the manufacturer’s protocol. GST
pull-down assays were performed in the presence of 120 mM NaCl
as described previously (Hassa et al, 2003).
ChIP assay
ChIP was carried out as described previously (Saccani and Natoli,
2002). Sequences of promoter-specific primers and a detailed
experimental protocol are available upon request.
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Acetylation of Poly(ADP-ribose) Polymerase-1 by
p300/CREB-binding Protein Regulates Coactivation
of NF-B-dependent Transcription*□S
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Poly(ADP-ribose) polymerase-1 (PARP-1) and nuclear factor B
(NF-B) have both been demonstrated to play a pathophysiological
role in a number of inflammatory disorders.We recently presented
evidence that PARP-1 can act as a promoter-specific coactivator of
NF-B in vivo independent of its enzymatic activity. PARP-1
directly interacts with p300 and both subunits of NF-B (p65 and
p50) and synergistically coactivates NF-B-dependent transcrip-
tion. Here we show that PARP-1 is acetylated in vivo at specific
lysine residues by p300/CREB-binding protein upon stimulation.
Furthermore, acetylationofPARP-1 at these residues is required for
the interaction of PARP-1 with p50 and synergistic coactivation of
NF-Bby p300 and theMediator complex in response to inflamma-
tory stimuli. PARP-1 physically interacts with the Mediator. Inter-
estingly, PARP-1 interacts in vivo with histone deacetylases
(HDACs) 1–3 but not with HDACs 4–6 and might be deacety-
lated in vivo by HDACs 1–3. Thus, acetylation of PARP-1 by
p300/CREB-binding protein plays an important regulatory role
in NF-B-dependent gene activation by enhancing its functional
interaction with p300 and the Mediator complex.
Nuclear factor B (NF-B) is a widely expressed transcription factor
of particular importance to the regulation of cells of the immune system
(1). NF-B encompasses a family of inducible transcription factors
including RelA/p65, RelB, c-Rel, p50, and p52 (1). These proteins share
a conserved 300-amino acid region within their amino termini, desig-
nated Rel-homology domain (RHD). This domain is responsible for
dimerization, nuclear translocation, DNA binding, and interaction with
heterologous transcription factors (1). NF-B is composed of homo- or
heterodimers with a range of DNA binding and activation potentials.
The most abundant and best-studied form of NF-B in cells is a het-
erodimer consisting of the two subunits, p50 (NF-B1) and p65 (RelA).
NF-B plays a key role in the regulation of many genes involved in
mammalian immune and inflammatory responses, apoptosis, cell pro-
liferation, and differentiation (1, 2). NF-B has additionally been asso-
ciated with neurodegenerative processes and cancer (3, 4). In unstimu-
lated cells, NF-B is sequestered in the cytoplasm as an inactive
transcription factor complex by its physical association with one of sev-
eral inhibitors ofNF-B (IBs)2 (5). Treatment of cells with extracellular
stimuli including cytokines, bacterial lipopolysaccharides (LPS), phor-
bol esters, or potent oxidants leads to rapid phosphorylation of IB,
which results in ubiquitination of IB and subsequent degradation by
the 26 S proteasome (4, 5). Dissociation of NF-B unmasks the nuclear
localization sequences of p65 and p50 subunits, which leads to nuclear
translocation and binding of NF-B to specific B consensus sequences
in the chromatin and activation of specific subsets of genes (3).
NF-B-dependent gene expression requires growing families of tran-
scriptional coactivators (6, 7). The two key coactivators of NF-B, his-
tone acetyltransferases p300 and its homolog, the cAMP-response ele-
ment-binding protein (CREB)-binding protein (CBP), directly associate
with the NF-B subunits p50 and p65 (8–10). These coactivators are
thought to promote the rapid formation of the pre-initiation and re-ini-
tiation complexes by bridging the sequence-specific activators (like
NF-B) to the basal transcription machinery, thereby facilitating mul-
tiple rounds of transcription (11). Additionally, the histone acetyltrans-
ferases p300 and CBP can modify the amino-terminal tails of nucleoso-
mal histones, thereby altering the local chromatin structure (12–14).
Although the recruitment of p300 or CBP to NF-B-dependent enhan-
ceosomes is required for synergistic activation, tethering p300/CBP
alone to the promoter through NF-B is not sufficient for full activity of
NF-B in the context of chromatin. Several reports indicated that the
combined actions and interactions of distinct transcriptional coactiva-
tor complexes and cofactors seem to be attributable to the strong tran-
scriptional activity of NF-B, depending on the stimuli and the cell type
(6, 8, 15, 16).
Poly(ADP-ribose) poly-merase-1 (PARP-1) is a nuclear chromatin-
associated protein and belongs to a large family of enzymes that can
synthesize polymers of ADP-ribose units by using -nicotinamide ade-
nine dinucleotide (NAD) as substrate (17). PARP-1 and NF-B have
both been suggested to play a pathophysiological role in a number of
inflammatory disorders (17). Several studies showed that PARP-1(/)
mice were protected against myocardial infarction, streptozotocin-in-
duced diabetes, LPS-induced septic shock, zymosan-induced vascular
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failure, a non-septic model of multiple organ dysfunction as well as
collagen-induced arthritis. This indicates that PARP-1 has a vital role in
inflammatory disorders (17). PARP-1 has been suggested to act as a
promoter-specific coactivator of NF-B in these inflammatory disor-
ders (18). Indeed, up-regulation of subsets of inflammatory mediators
such as TNF, IFN, and iNOS was shown to be impaired in PARP-
1(/) mice upon treatment with LPS, zymosan, or streptozotocin (17,
19). We recently presented evidence that PARP-1 can act as a coactiva-
tor of NF-B in vivo (18). Neither the nuclear translocation nor the
DNA binding ability of NF-B was affected in PARP-1(/) cells (18).
However, PARP-1 directly interacted with both subunits of NF-B (p65
and p50) in vitro and in vivo (18, 20). Remarkably, the enzymatic activity
of PARP-1 was not required for full activation of NF-B in response to
various stimuli in vivo (20). In addition, PARP-1 directly interacted with
p300 and synergistically coactivated NF-B-dependent transcription
(8). Tulin and Spradling (21) recently found that Drosophila mutants
lacking normal PARP-1 levels display immune defects similar to mice
lacking the NF-B subunit p50. Their results imply that the role of
PARP-1 in NF-B-dependent gene expression during immune
responses has been conserved during evolution.
Because NF-B-dependent gene expression requires post-transla-
tional modifications (22), we decided to test whether the coactivator
activity of PARP-1 might also be regulated by post-translational modi-
fications. We show here that PARP-1-dependent gene expression not
only requires the enzymatic activity of p300/CBP but also that PARP-1
itself is acetylated in vivo in response to inflammatory stimuli. Acetyla-
tion sites weremapped in vitro and in vivo to Lys-498, Lys-505, Lys-508,
Lys-521, and Lys-524. Furthermore, acetylation of PARP-1 at these
lysines is required for the interaction with p50 and the transcriptional
activation of NF-B in response to inflammatory stimuli. Interestingly,
the synergistic coactivation of PARP-1, p300, and also the Mediator
complex was dependent on acetylation of PARP-1. Moreover, PARP-1
interacted with and is potentially deacetylated in vivo by class I HDACs.
PARP-1-dependent transcriptional activation of NF-B was negatively
regulated by HDACs 1–3 in vivo. Together, these results support the
hypothesis that acetylation of PARP-1 is important for its role as tran-
scriptional coactivator and that the different physiological functions of
PARP-1 might be in general regulated by post-translational modifica-
tions in a stimulus-dependent manner.
MATERIALS ANDMETHODS
Reagents—Recombinant TNF was obtained from R&D Systems.
Phorbol esters andmouse interferon-was purchased from Sigma. LPS
(Escherichia coli, O26:B6) prepared by phenol extractionwas purchased
from Sigma and prepared as dispersed sonicate in endotoxin-free water
before diluting to a final concentration in supplemented media. Nonfat
dry milk was obtained fromMigros (Switzerland). Nitrocellulose mem-
branes were purchased fromOsmonics Inc. Tosyl-activated Dynabeads
were purchased from Dynal Biotech GmbH.
Plasmids—GST-PARP-1 and GST-p50 full-length expression vec-
tors, CMV-PARP-1, and CMV-p300 expression vectors were described
in Hassa et al. (8) and Covic et al. (16). The CMV expression vectors for
the different Mediator subunits were generated by PCR or were a gen-
erous gift from Dr. L. Freedman (Merck Research Laboratories, West
Point, NY). The CMV expression vectors for Myc-tagged HDACs 1–3
were created by PCR. The CMV expression vectors for FLAG or hem-
agglutinin-tagged HDAC 4–6 were kind gifts from Dr. S. L. Schreiber
(Harvard University, Cambridge, MA). The expression vectors for
CDK8/cyclin C and subunits of TFIID and TFIIF were kind gifts from
Dr. M. Otsuka (University of Tokyo, Japan), Dr. Z. F. Burton (Michigan
StateUniversity, East Lansing,MI), andDr.G.Napolitano (University of
Naples “Frederico II,” Naples, Italy). NF-B-dependent luciferase
reporter constructs for MIP-2 (MIP-2 (531/wt and MIP-2 (-531/
mutB)-Luc) and iNOS (iNOS (1485/31wt)-Luc and iNOS(1485/
31-mutB)-Luc) were generous gifts from Dr. H.-J. Kwon, (Yonsei
University, Seoul, Korea) and Dr. M. A. Perrella (Harvard School of
Public Health, Boston, MA) and are described in Perrella et al. (23) and
Kim et al. (24). pphRSV-nt--galactosidase is described in Hassa et al.
(20). The baculovirus for CDK8 and cyclin C was a generous gift from
Dr. R. Pinhero (University of Guelph, Ontario, Canada) (25). The bacu-
lovirus for human p300 and mouse CBP was a generous gift from Dr.
W. L. Kraus (Cornell University, New York) and Dr. D. Thanos (Insti-
tute of Molecular Biology and Genetics, Alexander Fleming Biomedical
Sciences Research Center, Athens, Greece). The baculovirus for
PARP-1 full-length and different domains were created by PCR using
the PAK-8/9 system (BD Biosciences). GST-fusion expression vectors
for different domains of PARP-1 were created by PCR. The PARP-1
mutant constructs were obtained by site-directedmutagenesis and con-
firmed by sequencing.
Mice Breeding Conditions, Cell Culture, and Transient Trans-
fections—129S/EV-PARP-1(/) and 129S/EV-PARP-1(/) mice
were bred under specified pathogen-free conditions. The initial 129S/
EV-PARP-1(/) and 129S/EV-PARP-1(/) mice breeding pairs
were a kind gift from Dr. Z. Q. Wang (26) (International Agency for
Research on Cancer, Lyon, France). Primary macrophage cells were
isolated from fresh littermates of 129S/EV-PARP-1(/) and 129S/
EV-PARP-1(/) mice (20, 26) according to an isolation procedure
described in Petrilli et al. (19), and human monocyte/macrophage-like
THP-1 cells and Jurkat-T cells were grown in Hepes-buffered RPMI-
Glutamax-I (Invitrogen) containing 10% fetal calf serum U. S.-certified
(Invitrogen) and supplemented with 50 units/ml penicillin, 50 g/ml
streptomycin (Invitrogen), 1 mM sodium pyruvate, 0.05 mM -mercap-
toethanol, and minimum Eagle’s medium-nonessential amino acids.
Primary mouse fibroblast cells were grown in Hepes-buffered Dulbec-
co’s modified Eagle’s medium-Glutamax-I (Invitrogen) containing 4.5
g/liter glucose, 10% fetal calf serumU. S.-certified (Invitrogen) and sup-
plemented with 50 units/ml penicillin, 50 g/ml streptomycin (Invitro-
gen), 1 mM sodium pyruvate, 0.05 mM -mercaptoethanol, and mini-
mum Eagle’s medium-nonessential amino acids. HEK293 cells were
grown in Hepes-buffered Dulbecco’s modified Eagle’s medium-Glu-
tamax-I (Invitrogen) containing 4.5 g/liter glucose and 10% fetal calf
serum U. S.-certified (Invitrogen) and supplemented with 50 units/ml
penicillin, 50 g/ml streptomycin (Invitrogen), and minimum Eagle’s
medium-nonessential amino acids. For luciferase reporter assays, cells
were grown in 24- or 48-well dishes. Cells were transfected using cal-
cium phosphate or polyethyleneimine procedures (as described in Refs.
27–30) except that primary cells were grown for 12 h in RPMI medium
containing 2% fetal calf serum before stimulation with TNF or LPS/
IFN. The amount of DNA indicated in the figure legends was calcu-
lated for 10 ml of medium. Total amounts of DNA and equal molar
ratios of promoters were kept constant in all set-ups by using empty
vectors. For primary cells only cell passages 1–4 were used for transfec-
tion experiments. Because of differences in transfection efficiencies, an
expression plasmid of -galactosidase (pph-RSV-nt--Gal) was
co-transfected as a transfection efficiency control, and luciferase activ-
ities were normalized based on -galactosidase activity. Luciferase
activity wasmeasured as previously described in Hottiger et al. (27). For
further experimental procedures see the supplemental material.
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FIGURE 1. PARP-1 is acetylated upon stimulation in vivo and requires the enzymatic activity of p300 for full NF-B-dependent transcriptional activity. A, primary PARP-
1(/) or PARP-1(/) macrophages were treated with LPS (0.1 g/ml) as indicated, and the expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT), glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), andNF-B-dependent genes KC,MIP-2, iNOS, IB and interleukin-6 (IL-6) was assessed by reverse transcription-PCR. B, equal amounts
of total cell extracts fromprimary PARP-1(/) and PARP-1(/) lung fibroblasts or primary PARP-1(/) and PARP-1(/) macrophageswere resolved by SDS-PAGE followed by
immunoblot analysis using anti-p300, anti-PARP-1, anti-PCAF, or anti--tubulin antibodies. C andD, primary PARP-1(/) macrophageswere cotransfectedwith RSV-nt--Gal (300
ng), expression vectors for PARP-1 (2g), andwild type (WT) or an enzymaticmutant (Mut) of p300 (2g) alongwith a luciferase reporter under the control of the endogenousMIP-2
(1g)or iNOS (3g)promoters; cellswere subsequently treated for 4hwithTNF (10ng/ml) or LPS/IFN (0.05g/ml/100units) in the simultaneouspresenceor absenceof lowdoses
of deacetylase inhibitors (10 nM TSA/200MNAM). Cellswere harvested 24h after transfection, andNF-B-dependent gene expressionwas determined. The indicated activationwas
determined by the ratio of the relative luciferase activitymeasured for the promoters containingwild type B sites (black bars) or mutB sites (white bars) after stimulation. The ratio
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RESULTS
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-B-
dependent Transcriptional Activity and Is Acetylated in Vivo by p300/
CBP upon Stimulation—Because the coactivator activity of PARP-1 for
NF-B-dependent gene expression is dependent on the stimuli and cell
type (17), we first tested which NF-B-dependent genes are impaired in
freshly isolated primary PARP-1(/) macrophages. Primary PARP-
1(/) or PARP-1(/) macrophages were treated with LPS as indi-
cated, and the expression of NF-B-dependent genes was assessed by
reverse transcription-PCR (Fig. 1A). The experiments revealed that
LPS-induced levels of KC, MIP-2, and iNOS were impaired in PARP-
1(/) cells (Fig. 1A). The expression of IB and interleukin-6 (IL-6)
was not reduced (Fig. 1A), indicating that only a subset of NF-B-de-
pendent genes requires PARP-1 for gene induction in these cells. Similar
results were obtained when cells were stimulated with TNF (data not
shown). To confirm that the expression levels of histone acetyltrans-
ferases are not reduced in primary PARP-1 (/) cells, we tested the
protein levels of p300 and PCAF by immunoblot analysis using anti-
PARP-1, anti-p300, or anti-PCAF antibodies. The endogenous protein
levels of p300 and PCAF were not impaired in freshly isolated primary
PARP-1(/) lung fibroblast or macrophage cells (Fig. 1B).
PARP-1 and p300/CBP were shown to form a complex and function
synergistically to enhance NF-B-mediated gene expression (8). To test
whether the synergistic coactivation of NF-B-mediated transactiva-
tion by PARP-1 and p300/CBP might require the enzymatic activity of
p300/CBP, we transfected PARP-1(/) cells with expression vectors
for PARP-1 and wild type or an enzymatic mutant of p300 along with a
luciferase reporter under the control of the endogenousMIP-2 or iNOS
promoters, shown to be PARP-1-dependent. Cells were subsequently
treated with TNF or LPS/IFN in the simultaneous presence or
absence of low doses of deacetylase inhibitors (TSA and nicotinamide
(NAM)) (Fig. 1, C andD). Coexpression of wild type p300 with PARP-1
in PARP-1(/) cells resulted in a highly synergistic enhancement of
transcription regulated from both MIP-2 and iNOS promoters upon
stimulation (Fig. 1, C andD). However, the cooperativity between p300
and PARP-1 was severely impaired when an enzymatic mutant of p300
FIGURE 1—continued
obtained for untreated cells was arbitrarily set to 1. Error bars indicate S.E. of three independent experiments. E and F, primary PARP-1(/) and PARP-1(/) macrophages were
repeatedly transfected with scrambled- or p300-siRNA targeting vector DNA (30 g) as indicated and then transfected and treated as indicated and described in D. The indicated
activation was determined as described in D. G, equal amounts of total cell extracts from primary macrophages repeatedly transfected with scrambled- or p300-siRNA targeting
vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti- -tubulin antibodies. H, THP-1 or Jurkat-T cells were treated
as indicated with LPS (0.2g/ml) or phorbol ester (10 nM) and simultaneously with or without deacetylase inhibitors (100 nM TSA/400M NAM) for 30min. PARP-1 was immunopre-
cipitated (IP) under high salt conditions from nuclear extracts, and the presence of acetylated forms of PARP-1 was subsequently tested by immunoblot analysis using anti-AcK or
anti-PARP-1 antibodies. PMA, phorbol 12-myristate 13-acetate. I, left panel, 293 cells were repeatedly transfectedwith scrambled-, p300-, or CBP-siRNA targeting vector DNA (30g)
and treated as indicated. PARP-1was immunoprecipitated under high salt conditions fromnuclear extracts, and the presence of acetylated forms of PARP-1was subsequently tested
by immunoblot analysis using anti-AcK or anti-PARP-1 antibodies. Right panel, equal amounts of total cell extracts from 293 cells repeatedly transfected with scrambled- or
p300-siRNA targeting vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti- -tubulin antibodies.
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was coexpressed. The most striking differences between wild type and
the enzymatic mutant of p300 were observed in the presence of low
doses of deacetylase inhibitors (Fig. 1, C and D). The same transfection
experiments with a reporter gene under the control of mutated B sites
revealed that the observed cooperative effect of p300 and PARP-1 was
mainly NF-B-specific (Fig. 1, C and D). To further confirm these
FIGURE 2.PARP-1 is acetylated in vitroand in vivoat Lys-498, Lys-505, Lys-508, Lys-521, andLys-524byp300/CBPuponstimulation.A, recombinantpurified full-lengthPARP-1was
incubatedwith recombinant purified full-length p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. B, baculo-purified
PARP-1 fragments corresponding to aminoacids (aa) 1–214, 215–372, 373–525, 525–656, or 657–1014were incubatedwith recombinant purified full-lengthp300orCBP in thepresenceof
radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. C, recombinant purified full-length PARP-1 wild type and two mutant forms of PARP-1; mutKTR
(K498R/K521R/K524R)andmutKQR(K498R/K505R/K508R/K521R/K524R)were incubatedwith recombinantpurified full-lengthp300orCBP in thepresenceof radioactive labeledacetyl-CoA
and resolved by SDS-PAGE followed by autoradiography.D, Myc-tagged PARP-1wild type (WT) ormutantmutKQRwere overexpressed in 293 cells and treated as indicatedwith TNF (10
ng/ml) and/or deacetylase inhibitors (100 nM TSA/400MNAM) for 30min. Myc-tagged PARP-1 wild type ormutantmutKQRwas then immunoprecipitated (IP) under high salt conditions
fromnuclear extracts of 293 cells, and thepresenceof acetylated formsof PARP-1was subsequently testedby immunoblot analysis (IB) usinganti-AcKor anti-PARP-1 antibodies. E, the same
experimentswere repeated in the presence of increasing amounts of overexpressed p300. Immunoblot of p300 input is shown in the upper panels
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results, the same experiments were repeated in the presence of different
p300-siRNA targeting vectors (Fig. 1, E and F). These experiments
revealed that the presence of endogenous p300 is required for PARP-1-
dependent coactivation of NF-B-dependent gene expression (Fig. 1, E
and F). Together these results indicate that the enzymatic activity of
p300/CBP is required for NF-B-dependent transactivation of extra-
chromosomal templates upon treatment with inflammatory stimuli.
p300 and CBP are known to modify a variety of proteins, such as
histones and transcription factors (31). To investigate whether endog-
enous PARP-1 itselfmight be acetylated by p300/CBP in vivo, we immu-
noprecipitated endogenous PARP-1 under high salt conditions from
nuclear extracts of THP-1 or Jurkat-T cells upon treatment with the
indicated stimuli (LPS or TNF) in the simultaneous presence or
absence of deacetylase inhibitors (Fig. 1H, left and right panels). Possible
acetylation of PARP-1 was analyzed by immunoblot analysis using an
anti-AcK antibody. Endogenous PARP-1 was acetylated in vivo only in
the presence of deacetylase inhibitors upon stimulation of these cells
(Fig. 1H, left and right panels). Next we tested whether the observed
acetylation of PARP-1 is dependent on p300/CBP. 293 cells were
cotransfected with a control-siRNA vector and/or different siRNA tar-
geting vectors for p300 or CBP. Endogenous PARP-1 was immunopre-
cipitated under high salt conditions from nuclear extracts of 293 cells
upon treatment with TNF in the presence of deacetylase inhibitors
(Fig. 1H, left and right panels). These results revealed that endogenous
PARP-1 was only acetylated in vivo upon stimulation in presence of
endogenous p300 or CBP (Fig. 1I).
PARP-1 Is Acetylated by p300/CBP in Vitro and in Vivo at Lys-498,
Lys-505, Lys-508, Lys-521, and Lys-524—Next, we tested whether
PARP-1 can be acetylated by p300 or CBP in vitro. Recombinant-puri-
fied full-length PARP-1 was incubated with recombinant-purified full-
length p300 or CBP in the presence of radioactive labeled acetyl-CoA
and resolved by SDS-PAGE followed by autoradiography analysis (Fig.
2A). PARP-1 was strongly acetylated in vitro by p300 or CBP (Fig. 2A).
To map the domains within PARP-1 subjected to acetylation by p300
and CBP, the same in vitro acetylation assay was repeated with different
PARP-1 fragments corresponding to amino acids 1–214, 215–372, 373–
525, 525–656, or 657–1014. These experiments revealed that p300 and
CBP strongly acetylated the PARP-1 domain corresponding to amino
acids 373–525 (Fig. 2B, left and right panels). Interestingly, a longer
autoradiography exposure revealed that the domain corresponding to
amino acids 1–214 of PARP-1 and to the small product of caspase
cleaved PARP-1, was weakly acetylated by p300 or CBP (supplemental
information and data not shown). The physiological relevance of this
finding is currently under investigation. To identify the lysines acety-
lated by p300/CBP within PARP-1, recombinant purified full-length
PARP-1 was acetylated in vitro by p300 full-length and analyzed by
microcapillary reverse-phase high performance liquid chromatography
nanoelectrospray tandem mass spectrometry. Lys-498, Lys-505, Lys-
508, Lys-521, andLys-524were identified as strong candidates for acety-
lation. To confirm that these lysines are the main acceptor sites, full-
length PARP-1 wild type or two PARP-1 mutant forms, mutKTR
(K498R/K521R/K524R) and mutKQR (K498R/K505R/K508R/K521R/
K524R) were incubated with p300 or CBP in the presence of radioactive
labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiog-
raphy analysis (Fig. 2C). These experiments confirmed that only the
PARP-1 mutant harboring all five mutated lysines was no longer acety-
lated in vitro by p300 and CBP (Fig. 2C). To investigate whether these
lysines are also themain acceptor sites for acetylation in vivo by p300,we
immunoprecipitated Myc-tagged PARP-1 wild type or mutant mut-
KQR under high salt conditions from nuclear extracts of 293 cells upon
treatment with the indicated stimuli in the presence or absence of
deacetylase inhibitors (Fig. 2D). The presence of acetylated forms of
PARP-1was tested by immunoblot analysis using an anti-AcK antibody.
PARP-1 was acetylated in vivo at Lys-498, Lys-505, Lys-508, Lys-521,
and Lys-524 in the presence of deacetylase inhibitors upon stimulation
(Fig. 2D, also see the supplemental information). The same experiments
performed in the presence of increasing amounts of overexpressed p300
suggested that these lysines are acetylated in vivo by p300 (Fig. 2E).
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Is Required in Vivo for Full NF-B-dependent Transcriptional
Activity—To directly test whether acetylation of PARP-1 is required for
NF-B-dependent transcriptional activity in vivo, we transfected PARP-
1(/) cells with expression vectors for p300 and PARP-1 wild type or
mutant mutKQR along with a luciferase reporter under the control of
the endogenous MIP-2 or iNOS promoters. Cells were subsequently
treated with the indicated stimuli (TNF or LPS/IFN) in the simulta-
neous presence or absence of low doses of deacetylase inhibitors (Fig. 3,
A and B). Coexpression of wild type p300 and wild type PARP-1 in
PARP-1(/) cells caused a highly synergistic enhancement of tran-
scription regulated from both MIP-2 and iNOS promoters upon stim-
ulation (Fig. 3, A and B). However, the cooperativity between p300 and
PARP-1 was severely impaired when the PARP-1 mutant mutKQR was
coexpressed. The most striking differences between PARP-1 wild type
and the mutant mutKQR were observed in the presence of low doses of
deacetylase inhibitors. The same transfection experiments with a
reporter gene under the control of mutated B sites revealed that the
observed induction was mainly NF-B-specific (Fig. 3, A and B; and
supplemental information).
Pavri et al. (32) have very recently shown that PARP-1 can associate in
vivo with the Mediator. Therefore, we repeated the same transfection
experiments in the presence of overexpressed subunits of the Mediator
complex. Coexpression of PARP-1 wild type, p300, and Mediator sub-
units inPARP-1(/) cells causedasynergisticenhancementofNF-B-
dependent transcription, whereas no synergistic enhancement was
observed when the mutant form of PARP-1, mutKQR, was coexpressed
(Fig. 3, C and D), indicating that acetylation of PARP-1 is also required
for the transcriptional cooperativity between p300/CBP, Mediator, and
PARP-1 on these promoters.
PARP-1 Interacts in Vivo with the Mediator Complex and in Vitro
Directly with the Mediator Subunits CDK8 and DRIP150—To further
confirm these data and to investigate whether CDK8 or other subunits
of the Mediator complex might directly interact with PARP-1, we first
coexpressed tagged forms of different Mediator subunits in 293 cells
(Fig. 4A). Immunoprecipitation experiments using an anti-PARP-1
antibody revealed that PARP-1 interacted with the whole Mediator
complex (Fig. 4A). Next, we repeated these experiments with primary
macrophages (Fig. 4B). These experiments revealed that endogenous
PARP-1 could indeed interact with the endogenous Mediator complex
under physiological conditions (Fig. 4B). DNAdid notmediate the asso-
ciation of PARP-1 with the Mediator in the nucleus since the presence
of ethidium bromide or DNase I did not affect PARP-1/Mediator inter-
action (data not shown). Surprisingly, whereas the interaction of
PARP-1 with the core Mediator module was increased upon stimula-
tion, the interaction of PARP-1 with CDK8 was decreased (Fig. 4,A and
B). CDK8 is thought to act mainly as a repressor sub-module of the
Mediator complex (32).
Because these results strongly suggested that PARP-1 would directly
interact with at least one of theseMediator subunits, recombinant puri-
fied GST-PARP-1 full-length was bound to glutathione beads followed
by incubation with in vitro translated and radioactive-labeled Mediator
PARP-1 Is Acetylated by p300/CBP
DECEMBER 9, 2005•VOLUME 280•NUMBER 49 JOURNAL OF BIOLOGICAL CHEMISTRY 40455
subunits as indicated in Fig. 4C. After extensive washes, bound proteins
were resolved by SDS-PAGE followed by autoradiography analysis for
Mediator subunits. PARP-1 directly bound to CDK8 and MED14,
although to a low extent, but not to the other tested subunits (Fig. 4C).
We next tested whether PARP-1 might also directly interact with other
components of the RNA polymerase II machinery. Recombinant puri-
fied HMG(YI), CDK8, cyclin C, TFIIF/RAP74, TFIIF/RAP30, TATA
box-binding protein (TBP), and TBP-associated factors fused to GST
were bound to glutathione beads followed by incubation with recombi-
nant baculo-purified PARP-1 (Fig. 4D, left and right panels). After
extensivewashes, bound proteins were resolved by SDS-PAGE followed
by immunoblot analysis for PARP-1. PARP-1was able to bind directly to
HMG(YI), CDK8, and TFIIF/RAP74 but not to the other factors tested
(Fig. 4D, left and right panels).
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Stabilizes the Interaction of PARP-1 with p50—To investigate
whether acetylation of PARP-1 mechanistically influences protein-pro-
tein interactions, we first tested which of the interaction partners asso-
ciates with the acetylated domain of PARP-1. Different domains of
PARP-1 fused to GST were bound to glutathione beads and incubated
with purified p300, PARP-1, CDK8/cyclin C, p65, p50, TFIIF/RAP74 or
in vitro transcribed/translated and radioactive-labeledMED14 (Fig. 5,A
and B). After extensive washes, bound proteins were resolved by SDS-
PAGE followed by immunoblot analysis with the indicated antibodies
(Fig. 5A) or autoradiography (Fig. 5B). p300, PARP-1, CDK8, p65, p50,
TFIIF/RAP74, and MED14 bound to different domains of PARP-1 as
schematically drawn in Fig. 5C. PARP-1 interacted with a region
between amino acids 1 and 214 as well as between amino acids 465 and
FIGURE3.AcetylationofPARP-1 is required forNF-B-dependent transcriptionand for the transcriptional cooperativitybetweenPARP-1, p300/CBP, andMediator in vivo.
A and B, primary PARP-1(/) macrophageswere cotransfectedwith RSV-nt--Gal (300 ng), expression vectors for p300 (2g), and PARP-1wild type (WT) ormutantmutKQR (2g)
along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (A) or iNOS (3 g) (B) promoters; cells were subsequently treated for 4 h with TNF (10 ng/ml) or
LPS/IFN (0.05g/ml/100units) in the simultaneouspresenceor absenceof lowdoses of deacetylase inhibitors (10nMTSA/200MNAM). Cellswereharvested24hafter transfection,
and NF-B-dependent gene expression determined as described in Fig. 1C. C andD, primary PARP-1(/) macrophages were cotransfected with RSV-nt--Gal (300 ng), expression
vectors for p300 (2 g), MED-1 (2.5 g), MED-7 (0.4 g), MED-14 (2 g), MED-15 (1.1 g), MED-17 (0.75 g), MED-23 (1.5 g), MED-24 (1 g), and PARP-1 wild type or mutant
K498R/K505R/K508R/K521R/K524R ((mutKQR) (2 g) along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (C) or iNOS (3 g) (D) promoters; cells were
subsequently treated for 4 h with TNF (10 ng/ml) or LPS/IFN (0.05 g/ml/100 units) in the simultaneous presence of low doses of deacetylase inhibitors (HDi; 10 nM TSA/200 M
NAM). Cells were harvested 24 h after transfection and NF-B-dependent gene expression was determined as described in Fig. 1C.
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FIGURE 4. PARP-1 interacts with theMediator complex in vivo and directly with theMediator subunits MED14 and CDK8 in vitro. A, Myc- or FLAG-taggedMediator subunits
MED-1, MED-7, MED-14, MED-17, MED-23, and MED-24 were overexpressed in 293 cells and treated as indicated, and PARP-1 complexes were immunoprecipitated (IP) under
physiological salt conditions fromnuclear extracts usingananti-PARP-1 antibodyand tested for PARP-1 andMyc- or FLAG-taggedMediator subunits, p300, andCDK8by immunoblot
analysis using anti-PARP-1, anti-p300, anti-CDK8, anti-Myc, or anti-FLAG antibodies. C, control IgG; P1, anti-PARP-1. B, primary macrophages were treated as indicated with LPS (0.2
g/ml) for 1 h. PARP-1 was immunoprecipitated under physiological salt conditions from nuclear extracts, and the presence of Mediator subunits was subsequently tested by
immunoblot analysis using anti-MED1, anti-MED6 anti-TRAP150, anti-CDK8, or anti-PARP-1 antibodies. C, GST pull down assays under physiological salt conditions with PARP-1
full-length fused to GST (3 g GST fusion protein) and the indicated in vitro transcribed/translated Mediator subunits. Bound proteins were resolved by SDS-PAGE followed by
autoradiography. TheCoomassie control gel is shown in the left panel.D, GSTpull downassaysunderphysiological salt conditionswith the indicatedgeneral transcription factors and
CDK8/cyclin C fused to GST (1–4g of GST fusion protein) and baculo-purified PARP-1 (0.5g input). Bound proteins were resolved by SDS-PAGE followed by immunoblot analysis
using anti-PARP-1 antibodies (upper panel). The corresponding Coomassie control gel is shown in the lower panel. TBP, TATA box-binding protein.
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FIGURE5.AcetylationofPARP-1 stabilizes the interactionofPARP-1withp50butnotp65orPARP-1.A andB,mappingof the interactiondomains inPARP-1. ShownareGSTpull
down assays under high salt conditions with PARP-1 fragments fused to GST (1–3 g of protein) as indicated and recombinant purified p300 (2 g), PARP-1 (0.3 g), RAP74 (1 g),
CDK8 (1 g), cyclin C (0.5 g), p65 (0.5 g), and p50 (0.5 g) (A) or in vitro transcribed/translated MED14 (B). Bound proteins were resolved by SDS-PAGE followed by immunoblot
analysis with the corresponding antibodies (A) or autoradiography (B). The corresponding Coomassie control gel is shown in the lower panels. aa, amino acids. C, schematic picture
of the PARP-1 interactionmap: ZF I and ZFII, zinc finger 1 and 2;NLS, nuclear localization signal;HTH, helix turn helix domain, BRCT, C-terminal domain of a breast cancer susceptibility
protein (BRCA);WGR, central WGR motif-containing domain;PADR1, PARP regulatory domain; CC, catalytic center. D and E, acetylation-dependent interaction of PARP-1 and p50.
PARP-1 (D) or p50 (E) fused to GST (3 g/2 g) were incubated with in vitro acetylated or non-acetylated baculo-purified PARP-1 wild type (WT) or mutant formmutKQR (500 ng) in
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524 (Fig. 5C). MED14 was the only tested protein that bound to the
BRCT (carboxyl-terminal domain of a breast cancer susceptibility pro-
tein (BRCA)) domain of PARP-1. We have previously shown that p50
and p65 interact with a region between amino acids 341 and 531 of
PARP-1 (20). In addition, p50 interacted also with a region between
amino acids 1 and 140 containing the zinc finger I. Our more detailed
interaction analysis suggests that p65 would interact with a region
between amino acids 341 and 383 of PARP-1. p50 would interact with
zinc finger I or zinc finger II and with a region between amino acids 477
and 524 (Fig. 5C). Together, these experiments revealed that only the
interaction of PARP-1 with PARP-1 itself or p50might be influenced by
acetylation of PARP-1.
To test this hypothesis, recombinant purified PARP-1 or p50 fused to
GST were bound to glutathione beads and incubated with non-acety-
lated or in vitro acetylated purified PARP-1 wild type and the mutant
form mutKQR in the presence of increasing concentrations of NaCl as
indicated (Fig. 5,D and E). After extensive washes, bound proteins were
resolved by SDS-PAGE followed by immunoblot analysis for PARP-1
(Fig. 5, D and E). No significant differences between the acetylated or
non-acetylated form of PARP-1 were observed for the dimerization or
potential tetramerization of PARP-1 (Fig. 5D). Surprisingly, in vitro
acetylated PARP-1 bound significantly better to p50 than did the non-
acetylated PARP-1 (Fig. 5E). These results suggest that PARP-1 would
dimerize or potentially tetramerize through the regions between amino
acid 1 and 214 as well as between amino acid 465 and 497, whereas the
region between amino acid 477 and 524 is required for acetylation-de-
pendent interaction with p50 (Fig. 5C).
To confirm these in vitro data and to investigate whether acetylation
would influence the stimuli-dependent complex formation between
subunits of NF-B and PARP-1 in vivo, we coimmunoprecipitated the
NF-B subunits p65 and p50 from nuclear extracts upon treatment of
THP-1 with LPS in the presence or absence of deacetylase or phospha-
tase inhibitors (Fig. 5F, left and right panels) and tested the presence of
PARP-1 by immunoblot analysis using anti-PARP-1 antibodies.
Remarkably, PARP-1 bound significantly better to p65 when cells were
simultaneously treatedwith LPS and phosphatase inhibitors (Fig. 5F, left
panel), whereas p50 bound significantly better to PARP-1 upon simul-
taneous treatment with LPS and deacetylase inhibitors (Fig. 5F, right
panel). No significant differences between deacetylase or phosphatase
inhibitors were observed for the interaction between p50 and p65 (Fig.
5F, left and right panels). Taken together, these results suggest that
phosphorylation might mainly enhance the interaction between p65
and PARP-1, whereas acetylation mainly enhances the interaction
between p50 and PARP-1.
PARP-1 Interacts with Members of HDAC Class I and Is Potentially
Deacetylated by HDACs 1–3 in Vivo—Because acetylation of proteins is
known to be a reversible modification in vivo, we next tested whether
PARP-1 might physically interact with HDACs in vivo. Because of the
low quality of commercially available anti-HDAC antibodies, we
decided to perform these experiments with overexpressed Myc- or
FLAG-tagged HDACs. We coimmunoprecipitated PARP-1 complexes
from nuclear extracts of untreated 293 cells overexpressingMyc-tagged
versions of HDAC-1, HDAC-2, or HDAC-3 (Fig. 6A) and FLAG-tagged
versions of HDAC-4, HDAC-5 or HDAC-6 (Fig. 6B) and tested the
FIGURE 5—continued
presence of increasing concentrations of NaCl (125 mM NaCl, 25 mM potassium acetate to 225 mM NaCl, 25 mM potassium acetate) as indicated. Bound proteins were resolved by
SDS-PAGE followed by immunoblot analysis using a anti-PARP-1 antibody. F, acetylation and stimuli-dependent complex formation of PARP-1 and subunits of NF-B in vivo. NF-B
subunits p65 and p50were coimmunoprecipitated (IP) from nuclear extracts upon treatment of THP-1 with LPS in the presence or absence of deacetylase or phosphatase inhibitors
(left and right panels) and tested for the presence of p50, p65, and PARP-1 by immunoblot analysis using anti-p50, anti-p65, and anti-PARP-1 antibodies. C, control.
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FIGURE 6. PARP-1 interacts with members of HDAC class I and is potentially deacetylated by HDAC-1, HDAC-2, or HDAC-3 in vivo. A and B, FLAG-tagged HDACs were
overexpressed in 293 cells. PARP-1 complexes were co-immunoprecipitated (IP) from nuclear extracts of untreated 293 cells using an anti-PARP-1 (P1) antibody and subsequently
tested for PARP-1 and Myc-tagged HDAC-1, HDAC-2, or HDAC-3 and FLAG-tagged HDAC-4, HDAC-5, or HDAC-6 by immunoblot (WB) analysis using anti-PARP-1, anti-Myc or
anti-FLAGantibodies. c, control IgG.C, GSTpull downassaysunderphysiological salt conditionswithPARP-1 fused toGST (4gofprotein) and in vitro transcribed/translatedHDAC-1,
-2, -3, or -8. Bound proteins were resolved by SDS-PAGE followed by autoradiography (left panel). The corresponding Coomassie control gel is shown in the right panel. D and E,
FLAG-tagged PARP-1 wild type was coexpressed with increasing amounts of Myc-tagged HDAC-1, HDAC-2, or HDAC-3 and hemagglutinin (HA)-tagged HDAC-4 or HDAC-5 in 293
cells. 24 h later cells were simultaneously treated with TNF (10 ng/ml) and NAM (1 mM) for 30 min. FLAG-tagged PARP-1 was subsequently immunoprecipitated under high salt
conditions from nuclear extracts of 293 cells, and the presence of acetylated forms of PARP-1 was tested by immunoblot analysis using anti-AcK or anti-FLAG antibodies.
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FIGURE 7. The coactivator activity of PARP-1 is negatively regulated in vivo byHDAC-1 HDAC-2, or HDAC-3. A–F, primary PARP-1(/) macrophages were cotransfectedwith
expression vectors for RSV-nt--Gal (300 ng), PARP-1wild type (WT) ormutantmutKQR (2g), p300 (2g), HDAC-1, HDAC-2, or HDAC-3 (2.5g each) alongwith a luciferase reporter
under the control of the endogenous MIP-2 (1 g) (A–C) or iNOS promoters (3 g) (D–F); cells were subsequently treated for 4 h with TNF (10 ng/ml) or LPS/IFN (0.05 g/ml/100
units) in the simultaneous presence of low doses of deacetylase inhibitor (500 M NAM). Cells were harvested 24 h after transfection, and NF-B-dependent gene expression was
determined as described in Fig. 1C.
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presence of these HDACs by immunoblot analysis using anti-PARP-1,
anti-Myc, or anti-FLAG antibodies. Interestingly, PARP-1 interacted
with HDAC-1, HDAC-2, and HDAC-3 but not with HDAC-4,
HDAC-5, or HDAC-6 (Fig. 6, A and B). DNA did not mediate the asso-
ciation of PARP-1 withHDACs since the presence of ethidium bromide
orDNase I did not affect the interaction (data not shown). Because these
results suggested that PARP-1 would directly interact with at least one
of these HDACs, GST-PARP-1 full-length was bound to glutathione
beads and incubated with in vitro translated and radioactive-labeled
HDAC class ImembersHDAC-1, HDAC-2, HDAC-3, orHDAC-8 (Fig.
6C). After extensive washes, bound proteins were resolved by SDS-
PAGE followed by autoradiography analysis forHDACs. PARP-1 bound
directly to HDAC-1, HDAC-2, and HDAC-3 but not to HDAC-8
(Fig. 6C).
To investigate whether PARP-1 might be deacetylated by HDAC-1,
HDAC-2, or HDAC-3 in vivo, FLAG-tagged PARP-1 wild type was
coexpressed with increasing amounts of Myc-tagged HDAC-1,
HDAC-2, or HDAC-3 (Fig. 6D) and hemagglutinin-tagged HDAC-4 or
HDAC-5 in 293 cells (Fig. 6E). FLAG-tagged PARP-1 was immunopre-
cipitated from nuclear extracts under high salt conditions upon treat-
ment of cells with TNF andNAM. The presence of acetylated forms of
PARP-1 was tested by immunoblot analysis using anti-AcK or anti-
FLAG antibodies. These experiments revealed that PARP-1 might be
deacetylated in vivo byHDAC-1,HDAC-2, orHDAC-3 (Fig. 6,D andE).
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be
Negatively Regulated by HDACs 1–3 in Vivo—Next, we tested which
HDAChas the strongest influence on the transcriptional coactivator activ-
ity of PARP-1 andmight therefore also act functionally as a deacetylase for
PARP-1 in vivo. PARP-1(/) cells were cotransfected with expression
vectors for PARP-1 wild type or PARP-1 mutant form; that is, mutKQR,
p300, HDAC-1, HDAC-2, or HDAC-3 along with a luciferase reporter
under the control of the endogenousMIP-2 (Fig. 7,A–C) or iNOSpromot-
ers (Fig. 7,D–F). Cellswere simultaneously treatedwith the indicated stim-
uli (TNF or LPS/IFN) and low doses of deacetylase inhibitors (Fig. 7,
A–F). Coexpression of p300 with HDAC-1, HDAC-2, or HDAC-3 in the
absence of PARP-1 resulted in a reduced activation of NF-B-dependent
transcriptional activation (Fig. 7, A–F). No significant differences between
HDAC-1, HDAC-2, or HDAC-3 were observed in the absence of PARP-1
for eitherMIP-2 or iNOSpromoters (Fig. 7,A–F), indicating that the resid-
ual activation of NF-B in PARP-1(/) cells in the absence of PARP-1 is
equally repressed byHDAC-1, HDAC-2, or HDAC-3. Similar results were
obtained in presence of PARP-1 wild type, although the repression by
HDAC-2was weaker when comparedwithHDAC-1 andHDAC-3 (Fig. 7,
A–F). Remarkably, the repression by HDAC-1, HDAC-2, or HDAC-3 was
strongly reduced when HDAC-1 HDAC-2, or HDAC-3 was coexpressed
withPARP-1mutantmutKQR (Fig. 7,A–F). Together these results suggest
that HDAC-1, HDAC-2, and HDAC-3 might repress NF-B-dependent
transcription in part through deacetylation of PARP-1.
DISCUSSION
Growing experimental evidence suggests that PARP-1 can function
as a promoter-specific coactivator (17). PARP-1was also identified as an
interaction partner not only of NF-B but also of several sequence-
specific transcription factors and cofactors including E2F1, Oct-1, and
PC3/topoisomerase-I (17, 33) and has been shown to increase the tran-
scriptional activity of these transcription factors (17). In 1997 Meister-
ernst et al. (34) identified human PARP-1 as one active component of
the upstream stimulatory activity (USA)-derived positive cofactor com-
plex PC-1 (34). The crude precursor human USA fraction consists of
PC1/PARP-1, PC2/Mediator-like complex, PC3/topoisomerase-I, PC4/
single-stranded DNA-binding protein, PC52, PC6, and HMG2 (34, 35).
Earlier studies showed that full activation of transcription by NF-B,
Sp1, and Oct-1 in cell-free systems required a crude precursor USA
coactivator fraction in addition to general transcription factors (36).
Because PC1/PARP-1, PC3, and PC4 are all sequence-unspecific DNA-
binding proteins, it was suggested that PC1/PARP-1 provide together
with the other USA-derived positive cofactors PC3, PC4, PC52, and
HMG2 a mainly structural/architectural role in assembling and stabi-
lizing the pre-initiation complex by affecting the accessibility of RNA
polymerase II to chromatin (17, 34, 35, 37).
The aim of this study was to investigate whether the coactivator activity
of PARP-1 might be regulated by post-translational modifications such as
acetylation. We provide both biochemical and functional evidence that
acetylation of PARP-1 is required for its NF-B coactivator activity.
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-B-
dependent Transcriptional Activity—Several reports demonstrated that
coactivator activity of PARP-1 for NF-B-dependent gene expression
seems to be dependent on the stimuli and cell type (17).We observed an
impaired expression in primary PARP-1(/) macrophages of iNOS,
KC, and MIP-2 genes but not of IB and IL-6 upon stimulation with
TNF or LPS/IFN, indicating that PARP-1 acts in a promoter-specific
manner, similar to other coactivators of NF-B such as CARM1 (16).
PARP-1 and p300/CBP were shown to form a complex and function
synergistically to enhance NF-B-mediated gene expression (8). More-
over, we recently provided evidence that the enzymatic activities of
p300/CBP and protein argininemethyltransferase CARM1 are required
for NF-B-dependent gene expression in vivo (16). NF-B-dependent
reporter gene analysis using the PARP-1-dependent MIP-2 and iNOS
promoters revealed that the cooperativity between p300 and PARP-1
was severely impaired when an enzymatic mutant of p300 was coex-
pressed, indicating that the enzymatic activity of p300/CBP is required
for NF-B-dependent transactivation of PARP-1-dependent promoters
upon treatment with inflammatory stimuli.
PARP-1 Is Acetylated in Vivo at Lys-498, Lys-505, Lys-508, Lys-521,
and Lys-524 by p300/CBP upon Stimulation—Growing experimental
evidence has accumulated that NF-B-dependent gene expression is
also regulated by post-translational modifications such acetylation (22).
This acetylation-dependent regulation was shown to occur at multiple
levels (38). Acetylation of histones regulates theNF-B-dependent gene
accessibility (22). Moreover, direct acetylation of the NF-B subunits
p65 and p50 was shown to regulate transcriptional activation of NF-B
(39–41). Finally, other acetylation eventswere suggested to temporarily
modulate the duration of NF-B presence in the nucleus and DNA
binding activity as well as protein-protein interactions with several
cofactors involved in the transcriptional activity of NF-B (22, 38). It
was recently reported that the USA-derived positive cofactor PC4 is
specifically acetylated by p300, thereby stimulating its double-stranded
DNA binding activity which correlates with its coactivation activity (42,
43). Here we show that PARP-1 is acetylated in vitro and in vivo by p300
and CBP. Combined analysis by microcapillary reverse-phase high per-
formance liquid chromatography nanoelectrospray tandemmass spec-
trometry and coexpression of p300/CBP and PARP-1 wild type or
mutant revealed that PARP-1 is acetylated in vivo at Lys-498, Lys-505,
Lys-508, Lys-521, and Lys-524 by p300/CBP upon stimulation. In vitro
acetylation experiments using purified recombinant PARP-1 wild type
or mutant forms supported these in vivo observations.
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Is Required for NF-B-dependent Transcriptional Activity in
Vivo—The importance of PARP-1 acetylation for NF-B-dependent tran-
scription is supported by complementation experiments in primary PARP-
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1(/)macrophages using the PARP-1mutantmutKQR (K498R/K505R/
K508R/K521R/K524R). Full synergistic enhancement of transcription
regulated from the MIP-2 and iNOS promoters was obtained only when
PARP-1 wild type was coexpressed with p300 in PARP-1(/) macro-
phages. The observed residual cooperative effects in the presence of
mutatedBsites on thepromotermost likely reflect the coactivator activity
of PARP-1 on other sequence-specific transcription factors such as activa-
tor protein-1, Sp-1,Oct-1, interferon regulatory factors, or signal transduc-
ers and activators of transcription (STATs), which are also important for
full activity of NF-B on these promoters (24, 44–46). Several recent
reports provided evidence that PARP-1 might also act as a coactivator of
AP-1 and STATs (47–49). Interestingly, the observed differences between
PARP-1 wild type and mutant mutKQR regarding the co-operativity of
p300 and PARP-1 were less significant in experiments using reporter plas-
midswithmutatedBsites, suggesting that acetylationofPARP-1mightbe
mainly required for the NF-B-dependent promoter activity. However, it
remains to be further investigated whether acetylation of PARP-1 could
also strongly influence other sequence-specific transcription factors or
cofactors under certain conditions. Remarkably, coexpression of PARP-1
wild type or mutant mutKQR with p300 andMediator subunits in PARP-
1(/) macrophages demonstrated that acetylation of PARP-1 is also
required for the transcriptional cooperativity between p300/CBP, Media-
tor, and PARP-1 on these promoters. Recent reports showed that ARC/
Mediator interacts with the transactivation domain of p65 and enhances
chromatin-dependent transcriptional activation by p65 in vitro (50). The
Mediator complex is thought to provide the penultimate step in the activa-
tion process by bridging a given activator to RNA polymerase II and form-
ing a scaffold onto which RNA polymerase II and general transcription
factors can assemble and initiate transcription (51). Based on themultistep
interaction model of transcriptional activation proposed by Roeder and
co-workers (51), it was suggested that PC1/PARP-1 might facilitate
togetherwith other structural/architectural positive cofactors the co-oper-
ative interactions between sequence-specific activators and different coac-
tivator complexes such as p300/CBP and Mediator, thereby providing an
architectural function in stabilizing the pre-initiation complex (17). In our
current studiesweprovidedevidence thatPARP-1 interacts in vivowith the
Mediator complex under physiological conditions. Furthermore, PARP-1
directly interacted in vitrowith the Mediator subunits MED14 and CDK8
aswell as theTFIIF subunit RAP74but notwithTFIIB,TATAbox-binding
protein (TBP) and the testedTBP-associated factors.These results are con-
sistent with the observation ofMeisterernst et al. (34) that in “in vitro tran-
scription” assays, PARP-1 is only required during assembly of RNApolym-
erase II andgeneral transcription factorsonpreformedTFIID-TFIIA-DNA
complexes (34). In these studies PARP-1 was unable to stimulate the for-
mation of a TFIID-promoter complex. In addition, PARP-1 stimulated
transcription only when added before the complete pre-initiation complex
was formed,which implies that PARP-1might only functionduring assem-
bly of the pre-initiation complex (34).
Whether acetylation of PARP-1 might regulate the PARP-1 activity at
this level in the context of chromatin remains to be investigated. However,
it seems unlikely since theMediator subunits DRIP150 and CDK8 did not
bind to the acetylated domain in PARP-1. Surprisingly, acetylation of
PARP-1 regulates the stimuli-dependent interaction of PARP-1 with
NF-B1 subunit p50 but not p65. Because the acetylationmutantmutKQR
of PARP-1 could still partially coactivate NF-B, acetylation of PARP-1
might be mechanistically required for the stabilization of preformed
PARP-1 containing transcriptional coactivator-cofactor complexes.
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be
Negatively Regulated in Vivo by HDACs 1–3—Overexpression of
HDAC-1, HDAC-2, and HDAC-3 was shown to repress NF-B-de-
pendent transcription upon treatment with inflammatory stimuli (22,
38, 41). HDAC-3 was shown to be required for the deacetylation of p65
(52). HDAC-1, HDAC-2, and HDAC-3 interact directly with several
proteins involved in the NF-B signaling pathway, including NF-B
itself (22, 52, 53). Interestingly, PARP-1 formed a complex with
HDAC-1, HDAC-2, or HDAC-3 in the nucleus but not with HDAC-4,
HDAC-5, or HDAC-6. The direct interaction in vitro between PARP-1
and HDACs 1–3 was weak and might be very transient or regulated in
vivo by other unidentified post-translational modifications. Subsequent
in vivo deacetylation experiments with increasing amounts of overex-
pressed HDACs suggested that deacetylation of PARP-1 in vivo might
be mediated by HDAC-1, HDAC-2, or HDAC-3. Transient reporter
assays revealed that the PARP-1-dependent transcriptional activity of
NF-B is negatively regulated in vivo by HDAC-1, HDAC-2, or
HDAC-3. Because transiently transfected plasmids seemnot to be prop-
erly chromatinized, nucleosomal histones are unlikely to represent the
only relevant substrates whose lysine acetylation is required for NF-B-
dependent transcription. Remarkably, when HDAC-1, HDAC-2, or
HDAC-3 was co-expressed with PARP-1 mutant mutKQR, no signifi-
cant additional promoter-specific decrease in NF-B-dependent tran-
scription was obtained. These results suggest that HDAC-1, HDAC-2,
and HDAC-3might deacetylate promoter-bound PARP-1 or other uni-
dentified cofactors or coactivators dependent on acetylation of PARP-1.
Interestingly, several recent reports demonstrated that inhibition of
HDACs could selectively suppress transcription in a gene-specific manner
by inducing an elongational arrest and/or premature termination between
exons 1 and 2 (54–57). Thus, in the context of chromatin, it might be that
for at least a subset of NF-B-dependent genes, deacetylation of NF-B
itself or of coactivators involved in the nuclear activity of NF-B, such as
PARP-1, could be required for transcriptional elongation or re-initiation.
For at least a subset of PARP-1-dependent NF-B target genes, both the
enzymatic activities of p300 and acetylation of PARP-1 are required for
transcriptional activity. However, the exact molecular mechanism by
which acetylationofPARP-1 regulates the coactivator activity of PARP-1 in
the context of chromatin remains to be investigated. In addition,we cannot
exclude the possibility that other histone acetyltransferasesmight acetylate
PARP-1 on other lysine residues and thereby influence its activities.
Whether p65 or other sequence-specific transcription factors known to
cooperate with NF-B in gene induction could regulate the acetylation of
PARP-1 is currently under investigation.
Taken together, these results support the hypothesis that the differ-
ent physiological functions of PARP-1 are regulated by post-transla-
tional modifications such as acetylation in a stimuli-specific manner.
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